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1.1.1 Clinical aspects 
 
1.1.1.1 Introduction, origin and route of spread. Retinoblastoma (Rb) is an aggressive 
and potentially fatal tumor of the eye, rapidly developed from the immature cells of 
retina, which is the specialized light-sensitive inner layer of nerve tissue at the back of 
the eye that detects light and color. The eye is essentially an opaque eyeball filled with a 
water-like fluid. Its structure can be divided into two main parts: the anterior segment, 
that occupies approximately one-third of the volume, includes cornea, conjunctiva, 
aqueous humor, iris, ciliary body and lens; whereas the back of the eye or posterior 
segment is the remaining portion and involves sclera, choroid, retinal pigment 
epithelium, neural retina, optic nerve and vitreous humor[1]. During the early 
development in the womb, the eye cells called retinoblasts divide into new cells until 
they fill the retina. Normally at this point, cells stop dividing and develop into mature 
retinal cells. Rarely however, instead of maturing into special cells that detect light, some 
retinoblasts continue dividing and grow out of control, forming a cancer known as 
retinoblastoma. Rb is a relatively rare cancer, although represents the most frequent 
ocular malignancy of childhood, with different incidences around the world[2]. It can 
occur in heritable and non-heritable (sporadic) forms and its fundamental diversity in the 
pathogenesis represents the basic distinction between two main different clinical 
retinoblastoma phenotypes[3]. 
 
Unilateral retinoblastoma occurs if only one eye is affected and represents the great 
majority of the cases. The term "unilateral" roughly translates to "one side". The tumor is 
usually unifocal and retinoblasts are involved. In many unilateral cases, cancer mass is 
large and it is not possible to determine if a single tumor is present. Some individuals 
have instead multifocal tumors in one eye (unilateral multifocal Rb). In most patients 
with unilateral retinoblastoma without a family history, inactivation of both alleles of the 
Retinoblastoma suppressor gene (RB1) that initiated tumor development is a somatic 
event, and none of them is present in DNA from constitutional cells[4].  
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Unilateral tumors are therefore mostly sporadic and non-hereditary, however about 10-
15% of all occurs in patients who have inherited or de novo germline mutations[5].  
 
Bilateral retinoblastoma occurs if both eyes are affected and represents about 35% of the 
cases[6]. The term "bilateral" equates to "two sides". In many children with this tumor, 
both eyes are affected at the time of initial diagnosis and they usually carry an inherited 
mutation from either affected or unaffected parents[5]. Almost all children with bilateral 
eye involvement have the hereditary form of retinoblastoma, in which the aberrant 
alteration might be inherited via the germ cells from affected parents. Other small 
percentage of patients with bilateral Rb has instead sporadic disease with no familial 
transmission, that arises through de novo mutation of RB1 gene either in the germ line 
(from unaffected parents) or embryo[7]. 
In individuals with bilateral Rb both eyes may show multiple tumors with different 
sizes[8].  
Bilaterality usually happens at the same time, although some children, who are initially 
diagnosed with unilateral Rb, may develop a tumor in the contralateral unaffected eye 
few months or even years later and patients could remain at an increased risk of 
subsequent cancers.  
 
Unilateral cases are more common than bilateral cases in a ratio of 2.7:1. Diagnosed 
patients' age correlated significantly with laterality; young onset is associated with 
bilateral, while increasing age with unilateral cases. Bilateral retinoblastoma in early and 
advanced stages of intraocular diseases also showed significant presence at a younger 
onset[9].  
 
Retinoblastoma arises from primitive unidentified retinal stem cells or cone precursor 
cells in nucleated layers of the eye. Rb can spread through three ways in the body: the 
tumor can extend from where it began by growing into nearby areas in tissue, or by 
getting into the lymph system or into the blood, and then travels through the lymph or the 
blood vessels, respectively, to other parts of the body. Its growth is usually under the 
retina and the tumor can locally spread either posteriorly, seeding the subretinal space, or 
anteriorly, toward the vitreous and aqueous[10 ] (Fig.1.1). Involvement of the ocular coats 
and optic nerve occurs as a sequence of events as the tumor progresses. Invasion of the 
choroid is common, although occurrence of massive invasion is usually limited to 
advanced disease. Following invasion of the choroid, the tumor gains access to systemic 
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circulation via central retinal vessels and creates the potential for distant metastases, such 
as skull, bones and lymph nodes. Further progression through the ocular coats leads to 
invasion of the sclera and the orbital soft tissue. The route of spread through the optic 
nerve and past the lamina cribrosa may lead the subarachnoid space invasion and it 
increases the risk of systemic and central nervous system (CNS) dissemination[11]. 
Anteriorly, Rb can spread to conjunctiva, eyelids and extraocular tissue and the diffusion 
of tumor seeding in the area of the vitreous base and anterior chamber may gain access to 




Fig. 1.1: Healthy eye (left) vs intraocular retinoblastoma (right)[2]. 
 
1.1.1.2 Historical perspectives. The first description of a tumor resembling 
retinoblastoma was provided on 1597 by Pieter Pawius, who described a malignancy 
invading the orbit, the temporal region, and the cranium, filled with a "substance similar 
to brain tissue mixed with thick blood and like crushed stone"[13-14]. After these 
observations, only in 1767 other cases bearing true resemblance to Rb were found in the 
literature and Hayes described the tumor like a soft cancer, publishing a description of a 
neuroepiblastic tumor of the retina[14-15]. In 1805, William Hey coined the term fungus 
haematodes to describe a fungating mass affecting the eye and destroying its internal 
organization. However, Hey thought that this tumor might affect other regions of the 
body, including the limbs and breast[16]. In 1809, James Wardrop, a Scottish surgeon, 
provided the first description of retinoblastoma as a clinical entity. He stated that the 
tumor arose from the retina, based on gross morphologic studies. Wardrop documented 
extension of the tumor to the optic nerve and brain and later he described metastasis of 
this tumor to different parts of the body. He also concluded that because the ocular form 
of this disease so often involved children, it must be distinguished from the general 
classification of fungus haematodes or soft cancer. Furthermore, he was the first to 
suggest that enucleation should be the primary mode of management for 
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retinoblastoma[17]. In 1836, Langenbech, Robin and Nystin confirmed by microscopic 
studies that the tumor definitely arose from retina[18]. Hermann Von Helmholtz invented 
the ophthalmoscope in 1851 and facilitated the recognition of clinical features of Rb, 
with an earlier diagnosis before extraocular extension occurred. In 1864, Virchow 
described the tumor as glioma retinae, supporting glial cell origin within the retina[19]. 
Both Flexner and Wintersteiner, in 1891 and 1897 respectively, histologically described 
the rods and cones of the classical rosettes found in many retinoblastomas and they 
indicated the tumor as a neuroephitelioma, suggesting the photoreceptor cell-layer 
origin[20-21]. In 1922, Verhoeff believed that the tumor arose from retinoblasts and 
proposed the name "retinoblastoma", the term that was officially adopted by the 
American Ophthalmological Society in 1926 as a general term of this entity[22]. In 1956, 
Steward found in literature fifteen cases of spontaneous remission of retinoblastomas, in 
which the evidence both for the diagnosis and for the regression appeared satisfactory[23]. 
In 1970, Ts'o and colleagues established that retinoblastoma arises by way of 
photoreceptor differentiation, the most advanced degree of retinal differentiation[24-25]. 
Most notably, in 1971, Alfred Knudson, by reviewing a series of clinical cases, 
formulated what is now known as his "two-hit" hypothesis, a mechanism that explains 
the subsequent genetic events that are believed to give rise to tumorigenesis in 
retinoblastoma. For the first time, he hypothesized that Rb may be determined by the loss 
(or inactivation) of both copies of a single gene. This view opened the field of 
investigation for the study of genetic and /or epigenetic pathogenesis in Rb and several 
other cancers.  
Most interestingly, some authors reported the occurrence of spontaneously regressed 
retinoblastomas that seemed to undergo a new malignant transformation[26]. In 1982, 
Gallie and coworkers suggested that non-progressive retinal lesions observed in patients 
known to carry genetic impairments, and previously thought to represent all examples of 
spontaneous regression, were indeed benign manifestations of the disease and they 
proposed to call them as retinoma[27]. One year later, Margo reported analogous benign 
retinal tumor composed entirely of photoreceptor differentiation, which was called 
retinocytoma, before assuming lesions were the same. These benign variants are highly 
differentiated tumors with basically no growth potential[28]. In 1984, Kyritsis described 
Rb is a cancer stemming from the overproduction of immature retinal cells resulting in a 
heterogeneous tumor cell population[29].  
More recently, both Gallie and Dimaras suggested that retinoma/retinocytoma is a 
precursor of retinoblastoma, a pre-cancerous lesion, and there are well-documented cases 
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of malignant transformation of benign lesions into Rb[30]. 
 
1.1.1.3 Epidemiology. Retinoblastoma is a relatively rare cancer, although it accounts 
for about 3% of all pediatric malignancies from birth to 14 years old[31], with the average 
age at diagnosis at 18 months[32] and with 90% diagnosed before five years of age. 
Affected patients will develop Rb before they are born or very early in life because it 
originates from cells that differentiate. Only few cases have been reported in adults[32], 
when Rb is thought to arise from previously existing retinoma/retinocytoma. Rb is the 
second most common solid pediatric tumor after brain/nervous system tumors and 
lymphomas in several countries[33].  
Prior to the 20th century, retinoblastoma was a uniformly fatal disease. If left untreated, 
the mortality rate of retinoblastoma is still about 99%[34]. The major risk of fatality factor 
is whether the tumor is confined to the eye. If retinoblastoma spreads beyond the orbit or 
reaches the cut end of the optic nerve, the mortality rate increases markedly. Fatalities 
from retinoblastoma are also increased in trilateral cases[35], second malignant neoplasms 
such as sarcomas and especially in systemic metastasis[36]. 
In the early 1900s, the positive prognosis for children with retinoblastoma was a mere 
5%[37]. Major advances, such as the understanding of the tumor molecular biology and 
the development of targeted therapy, have dramatically improved the survival rates of 
patients with retinoblastoma over the last three decades and today it is higher than 90% in 
industrialized countries[38]. However, late presentation and delayed diagnosis are still a 
drawback to positive prognosis in the developing world, resulting in lower survival 
rates[39]. In fact, only approximately 50% of affected children survive worldwide[40]. This 
evident discrepancy is largely due to efficient earlier detection in medically developed 
nations when the tumor is confined to the eye, whereas in underdeveloped regions 
retinoblastoma is often noticed after it has invaded the orbit or brain. The high mortality 
is thus associated with late presentation and poor facilities for detection and 
treatments[41].  
Retinoblastoma has a worldwide incidence of one case per 15-20k live births, which 
corresponds to about 9000 new cases every year. The disorder has no validated 
geographic hotspots, both males and females are equally affected[42] and there is no 
predilection for any race[43]. However, a higher incidence is noted in developing 
countries and this has been implicated to lower socio-economic status[7]. Rb has not been 
related to smoking, alcohol assumption or any maternal problem during pregnancy. 
Nevertheless, it has been shown that a poor diet and infectious diseases are presently 
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considered risk factors for Rb development in less affluent populations throughout the 
world, demonstrating the crucial role of environmental factors in the tumorigenesis of 
retinoblastoma[44]. Moreover, a low folate intake may play a role in the risk of 
occurrence[45].  
Retinoblastoma can develop in a healthy child despite a normal or premature birth[46]. 
The overall incidence of childhood cancer has been slowly increasing since 1975[47] and a 
rise in number of Rb cases also been detected, partly due to the environmental 
pollution[48] and the exposure to chemical and physical agents [3]. 
Survival and the chance of saving vision depend on severity of disease at presentation 
and the mortality from retinoblastoma is about 70% in countries of low and middle 
income, where most of the affected children live[49]. 
However, the overall incidence of retinoblastoma decreases with advancing age. About 
70-80% of patients have only one impaired eye, with a mean age of diagnosis of 24 
months, while the remaining 20-30% of affected children with multifocal retinoblastoma 
that affects both eyes is presented at mean age 15 months[50]. Finally, the diffuse anterior 
retinoblastoma represents a rare variant of retinoblastoma and affected patients are older 
than those with the classical types, with the mean age being 6.1 years[12].  
 
1.1.1.4 Clinical presentation. The clinical presentation of retinoblastoma varies 
according to several aspects, like its presence within or spread beyond the affected eye, 
the cell morphology and the type of tumor growth and duration, degree of vascularization 
and the presence of calcifications, vitreous seeding, retinal detachment or hemorrhage. 
 
Doctors divide the extended tumors into two main groups, according to the fact if the 
cancer is still within or it has spread beyond the eye. This distinction is made for practical 
purposes mostly to decide on the best treatment options. 
 
Intraocular retinoblastoma occurs in one or both eyes and may be confined to the retina 
or may also be found in other parts of the eye such as the choroid, ciliary body, or part of 
the optic nerve, but it has not distributed into surrounding tissues around the outside the 
eye.  
 
Extraocular retinoblastoma has instead spread to tissues beyond the eye or to other parts 
of the body: orbital retinoblastoma may be found in tissues around the eye; however, 
extraocular Rb may have spread to the CNS (brain and spinal cord) or to the liver, bones, 
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bone marrow, or lymph nodes. When retinoblastoma remains confined to the eye, it has 
one of the best survival rates of all the childhood cancers, but once the spread outside the 
globe, the prognosis is dismal[51]. The clinical scenario of a patient being treated for 
intraocular disease, where survival is not in significant jeopardy, is completely different 
from the cases with metastatic disease for which there is a life-threatening occurrence[52]. 
 
Retinoblastoma cells are small and when stained with hematoxylin and eosin (H&E) 
staining they acquire a characteristic color blue. In fact, tumor is composed of small 
basophilic cells (retinoblasts) with large hyperchromatin nuclei and scanty cytoplasm. In 
many retinoblastoma specimens from patients, most of the cells appear undifferentiated; 
however, a sort of differentiated feature could be characterized by the formation of 
rosettes: round assemblage of cells consisting in a spoke circle, a halo collection 
surrounding a central or acellular lumen. Most of the rosettes are found in tumors of the 
nervous system and their detection help in the diagnosis of different cancers[53]. Different 
rosette formations such as Flexner-Wintersteiner (FW) rosettes, Homer Wright (HW) 
rosettes and pseudorosettes have been described in retinoblastoma[54].  
FW rosette is a feature of retinoblastoma and represents early attempt at retinal 
differentiation. These rosettes consist of a ring of cuboidal tumor cells neighboring the 
central empty lumen, which corresponds to subretinal space and it stains with alcian blue 
containing cytoplasmic extensions from the tumor cells. The cells surrounding the lumen 
are joined near the apices by intracellular connections (zonulae adherents), which is 
analogous to the external limiting membrane of retina. FW rosettes are not 
pathognomonic because they also occur in malignant medulloepitheliomas and some 
pineal tumors. On electron microscopy, they resemble primordial photoreceptor cells. 
HW rosettes are typically seen in neuroblastoma, medulloblastoma, primitive neuro-
ectodermal tumors and retinoblastoma. They lack a central lumen and their constituent 
cells encompass a central tangle of neural filaments. Their presence indicates 
neuroblastic differentiation[55]. 
Both these rosettes are characteristic but not sufficient to make a diagnosis of 
retinoblastoma and they are more common in eyes removed from younger patients.  
Pseudorosettes, a ring of cells with an eosinophilic fibrillary center, are also commonly 
present in retinoblastomas. 
About 15-20% of retinoblastomas harbor very well differentiated foci of actual 
photoreceptor differentiation that might be derived from retinoma precursor lesions. Such 
areas contain aggregates of neoplastic photoreceptors called fleurettes, which have 
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undergone photoreceptor differentiation. They are typically found in retinoblastomas on 
low magnification microscopy of H&E stained sections and are paucicellular compared 
to adjacent undifferentiated areas of viable tumors that appear relatively eosinophilic[55]. 
Recent studies reported of a new type of rosettes in retinoblastoma, consisting of clear 
lumens and collections of basophilic cells inside. This type of new rosette is larger than 
the FW or HW ones[56]. It needs to be stressed that histological assays can only be 
performed after the eye has been surgical removed at late stage of cancer development 
and after the therapies have begun. This investigation lays fundamentals for the following 
therapeutic steps as certain macroscopic and microscopic features contribute to determine 
tumor stage that leads to the prognosis and future therapeutic outcomes[57]. 
 
Three retinal types are distinguished after the morphological examination of the retina, 
adjacent to the main tumor. Retina type 1 contains a single tumor that is sharply 
demarcated from surrounding normal tissue and it correlated significantly with early 
surgical removal of the whole eye both in hereditary and non-hereditary cases. In retina 
type 2, large parts of the retina are affected and the main tumor mass gradually blended 
with the adjacent pathological retina. The progressing tumor may release growth factors 
in the intraocular space that stimulate the cells of the adjacent retina and lead to multiple 
new primary tumors in the adjacent retinal area. Retina type 3 is characterized by a retina 
almost entirely affected by diffuse tumor growth and it is only present in non-hereditary 
cases with late surgical removal of the whole eye (at 2-5 years)[58]. 
The degree of tumor differentiation is inversely proportional to the age in months when 
the eye is removed and this relationship is statistically significant. On average, 
retinoblastomas taken from older children tend to be poorly differentiated[53].  
 
The initial growth pattern and tumor cell divisions may occur in different internal retinal 
layers; a tumor developing on the retina surface and into the vitreous cavity has an 
endophytic growth, while a tumor developing from the external layers, invading the sub-
retinal space and causing a retinal detachment presents an exophytic growth pattern.  
 
Endophytic retinoblastoma is characterized by a tumor, which bursts through the internal 
limiting membrane and appears as a white-to-cream mass. It presents as one or more 
isolated or coalesced tumors of variable size, round or oval-shaped, yellowish-white 
(calcifications) or pinkish (vascularization) in color with its own, often turgescent and 
tortuous, vascular network. Endophytic Rb tends to increase inward into tissues in finger-
9 
An innovative epigenetic strategy for retinoblastoma treatment 
like projections from a superficial site of origin and it arises from inner layers of retinal 
surface toward the vitreous as a friable mass, frequently associated with fine blood 
vessels on its surface. Vitreous seeding also may be commonly present in endophytic Rb 
and anteriorly it reaches aqueous venous channels and it may permeate through 
lymphatic channels.  
 
Exophytic retinoblastoma develops from outer layers of retina towards the choroid and is 
frequently associated with progressive retinal detachment, that masks to a greater or 
lesser degree the details of the underlying mass or masses and it is caused by subretinal 
fluid accumulation. It spreads outward beyond the surface epithelium from which it 
originates and it may become a multi-lobulated tumor. There is the presence of vitreous 
hemorrhage and a choroidal invasion through Bruch's membrane[59].  
The most common growth pattern is mixed between endophytic and exophytic 
growths[34]. Both forms are distinctively characterized by vitreous and subretinal seeding 
and by the common presence of calcifications, in the form of white patches within the 
tumor mass. Necrosis is also very frequent and occurs when the tumor outgrows its 
vascular supply. Necrotic cells appear pink on H&E staining.  
 
Rarely, the tumor may develop in an insidious manner within the retinal layers and 
subretinal space, with no elevated mass and no calcifications, growing slowly along the 
retinal axis towards the anterior segment where late manifestations of the disease occur in 
the form of pseudoinflammatory complications[59]. This is the diffuse infiltrating or 
plaque-like form retinoblastoma, first suggested by Norman Ashton in 1958 to describe 
the unusual nature of a flat neoplasm that seldom formed tumor masses in retina[60]. It is 
characterized by a relatively flat infiltration of the retina by tumor cells without an 
obvious mass. The diffuse anterior retinoblastoma presents itself as a grayish retinal 
coating with no elevated mass and no calcifications[61].  
 
1.1.1.5 Signs and symptoms. Retinoblastomas nearly always occur in young children. 
They are often found when a parent or doctor notices a child's eye looks unusual, with 
typical signs and symptoms. In industrial countries, patients mainly exhibit signs rather 
than symptoms, presenting intraocular tumors without local extension, meanwhile in 
developing countries the diagnosis is frequently done only after an enlarged eye or gross 
orbital extension occurs. 
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Leukocoria, a white or light pink abnormal reflection from the retina, also known as 
white pupillary reflex or "amaurotic cat's eye", is the most common (60%) initial sign of 
retinoblastoma[8], occurring when the tumor is still contained within the vitreous and it is 
associated with the disease in almost half of all infants presenting with a white pupil[62]. 
The term leukocoria literally means "white pupil" from the Greek "leucos" (white) and 
"korê" (pupil) and is created by the reflection of incident light off the retinal lesion within 
the pupillary area when the fundus is directly illuminated[59]. This life-threatening white 
tumor then reflects light and blocks view of the red retina. Leukocoria is occasionally 
first noticed by close family members or after a flash photograph is taken[63].  
 
Strabismus, also known as lazy eye, is the second most frequent manifestation, occurring 
in about 20% of retinoblastoma cases and it is due to loss of central vision following 
retinal detachment, poor visual tracking, vitreous hemorrhage, glaucoma or optic nerve 
involvement singly or in combination. Both exotropia (eye turned outward, temporal) or 
esotropia (eye turned inward, nasal) can be presenting signs for Rb[64].  
Strabismus usually correlates with macular involvement and it is an invaluable early sign 
carrying an excellent life prognosis and every chance of preserving the globe. It is an 
affection thus not to be taken lightly and requiring immediate ophthalmological 
examination comprising full fundus examination with a dilated pupil, under anesthesia if 
necessary[59]. 
 
Proptosis, the anterior protrusion of the eye from the orbit, is because of tumor growth 
with displacement of normal tissues or seeding into the tissues and consequent 
enlargement of the tissues. It follows orbital invasion and secondary microbial infections 
are often present, with mucopurulent or fungating ocular mass referable to neglect or 
mismanagement. This is indeed a common type of presentation in most developing 
countries[65], due mainly to socioeconomic and cultural limitations resulting in delayed 
presentation[66]. 
 
Atypical signs are seen both in some retinoblastomas and certain pseudoretinoblastomas, 
they are often inflammatory or hypertensive and can cause major problems in 
diagnosis[67]. Atypical changes in eye appearance are very late pathological 
manifestations carrying a far more reserved vital and functional prognosis and they 
include painful red eye, uveitis, and multifocal iris invasion associated with hyphema and 
iris neovascularization, heterochromia, rubeosis iridis, phthisis bulbi, secondary 
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glaucoma. All of them are commonly found in particular as ultimate complications of a 
very advanced and unchecked disease. Decrease in visual acuity (e.g. not fixing or 
following in infants, clumsiness in ambulatory children)[64] and orbital inflammation after 
toxin release from tissue necrosis are also associated with tumor development. 
 
Metastases can be considered as sign of a primary retinoblastoma, and can occur as the 
tumor progresses thought the orbit, the optic nerve and then reaching the brain. Other 
distant spread may involve the abdominal organs (such as liver, spleen, and lung), bones 
(especially skull and long bones), bone marrow and lymph nodes.  
 
1.1.1.6 Diagnosis. There are no widely recommended screening tests to look for 
retinoblastoma in children without symptoms. A comprehensive diagnosis is made from 
history, physical, histological and radiological examinations; blood chemistry, 
cerebrospinal fluid and marrow aspiration analyses are also performed to better diagnose 
patients. 
 
It is strictly recommended that all infants should have a red reflex examination before 
discharge from the neonatal nursery and at all subsequent routine health supervision 
visits[68]. The red reflex test is performed in a dimly lit or dark room with a direct 
ophthalmoscope or a retinoscope and children with an abnormal red reflex need 
immediate referral to an ophthalmologist skilled in pediatric examinations.  
Many tumors are early discovered by parents, relatives, or when a child is brought to a 
doctor because his/her eye does not look normal. Therefore, early detection is key to a 
successful outcome and an immediate referral of children with Rb increases the 
possibility of saving lives and eyes, and preserving useful vision. Late diagnosis rather 
delays treatment, retinoblastoma spreads from the eye, and the chances of survival 
decrease[49].  
 
During a regular physical examination and history, doctors routinely check general signs 
of health and especially both eyes, including possible changes in how they appear and 
move, lumps or anything else that seems unusual. Vision screening in babies and 
children at appropriate ages and intervals may identify tumors at earlier stages, when 
more treatment options are available and the chance of cure is high[69]. Furthermore, 
health care costs are reduced, resources are redirected to high-risk patients, and 
unnecessary clinic visits and worry for unaffected family members are eliminated. Some 
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patients diagnosed initially with possible retinoblastoma prove, on referral to ocular 
oncologists and radiologists, to have one of pseudoretinoblastoma forms[59].  
The ocular oncologist will then collect a complete medical history of the patient's health 
habits, past illnesses and treatments, that is important when deciding if more tests and 
exams are needed, mainly in patients with a family history of the disorder, who may 
continue to develop new tumors for a few years after diagnosis and treatment and, for 
this reason, they need to be examined frequently. Moreover, molecular genetic testing for 
early identification of asymptomatic at-risk children in a family reduces the need for 
costly and invasive screening procedures. Tumor and blood samples can be tested to 
identify possible genetic changes and eventually other family members can be directly 
screened. 
A proportion of children who present with unilateral retinoblastoma will develop disease 
in the opposite eye and periodic examinations of the unaffected eye will be performed for 
future years. 
Unlike as for many other types of cancer, biopsies are not usually done to diagnose Rb 
because trying to collect a tumor specimen from retina can often damage the tissue and it 
would risk of spread cancer cells beyond the eye, endangering the life of patient.  
 
If a child has typical clinical manifestations of retinoblastoma, the ophthalmologist or 
optometrist will then closely perform the eye examination with dilated pupil, that is so 
wide opened with medicated eye drops to allow the doctor to look through the lens and 
pupil to the retina, usually performed under general anesthesia. The inside of the eye is 
then examined with a light. The diagnosis is generally established after the fundoscopy 
with an indirect ophthalmoscopy, using a small magnifying lens and a light[40], and the 
lesion appears as a white tumor with angiomatous dilatation of the vessels. Two other 
types of eye exams with the dilated pupil can be achieved: the slit-lamp biomicroscopy is 
performed to check the retina, optic nerve, and other parts of the eye using a strong beam 
of light and a microscope, whereas fluorescein angiography involves an orange 
fluorescent dye to look at vessels and the blood flow inside the eye.  
The inspection of the ocular fundus is carried out every three to four weeks until age six 
months, then less frequently until age three years[70]. The interval between exams is based 
on the stability of the disease and age of the child (i.e., less frequent visits as the child 
ages). 
Clinical examinations with cooperative children are then performed every three to six 
months until age seven years and yearly and eventually biannually for life. These early 
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surveillance methods are required to visualize, confirm and classify the condition and 
they determine the unilateral or bilateral nature of the lesion, the number of tumors, their 
position in the retina (posterior pole and anterior retina), the tumor size (diameter and 
thickness), the subretinal fluid and tumor seeds, the vitreous seeding, as well the 
anatomical relations with the optic disc and macula[71].  
 
Imaging tests using ultrasound examination of the eye will be first done to determine 
size, location and extent of the tumor. High-energy sound waves are bounced off the 
internal tissues of the eye to make echoes. A small probe that sends and receives sound 
waves is placed gently on the surface of the eye. The echoes make a picture of the inside 
of the eye and the distance from the cornea to the retina is measured. The picture called a 
sonogram, shows on the screen of the ultrasound monitor and can be printed to be looked 
at later.  
Three-dimensional (3D) ultrasonography can be used to perform retinal and tumor 
mapping and to diagnose calcification and retinal detachment. This technique allows for 
new oblique and coronal views of the tumor and optic nerve; however, it is not useful for 
describing the extraocular spread of tumors[72].  
 
A novel handheld spectral-domain optical coherence tomography (HHSD OCT) could 
be also exploited to identify and define the intraretinal location of a small retinoblastoma 
that was not detectable by the indirect ophthalmoscopy. Hence, the HHSD OCT 
technique can aid the ocular oncologist in the identification of very small retinoblastomas 
before they are visible to the eye, which allows for earlier and potentially vision-sparing 
treatment of these lesions[73-74]. 
 
Color doppler imaging reveals slightly vascularized tumor areas and can depict blood 
flow of retrobulbar vessels and inside the tumor[75]. 
 
Cranial/orbital computed tomography (CT) scan can detect intraocular tumor and its 
calcifications and determine how far Rb may have spread within the eye[76]. Furthermore, 
tumor is seen as a mass predominantly located in the posterior ocular pole and it may 
present distinct contours and an inhomogeneous structure. CT scan can make a series of 
detailed pictures of the eye, taken from different angles. CT scanning has high sensitivity 
and helps in staging of intraocular tumors, the detection of extra bulbar growth, and the 
determination of further treatment approaches. CT scanning can be used to follow up 
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tumors to determine the effect of treatment and to establish a timely diagnosis of 
malignant tumor relapses[77]. 
 
Magnetic resonance imaging (MRI) of the orbit is the most sensitive mean of evaluating 
extraocular extension into the optic canal. This technique based on the elaboration of 
images collected by exciting the tissue using radio frequencies under a magnetic field 
provides detailed pictures of the eye. It has become a benchmark technique for detecting 
retinal detachment and intracranial tumors[78-79].  
Children with a family history of retinoblastoma are recommended for a MRI scan of the 
brain at regular intervals for up to 5 years to check for a trilateral retinoblastoma. Visible 
extension to the retrolaminar optic nerve must be investigated, especially in case of optic 
disc involvement, as it determines the medical approach for future treatments. 
 
Distant staging can be performed by different imaging procedures for identifying 
metastasis all over the body outside the eye. It may be performed when enucleation is 
necessary and histopathological risk factors have been identified.  
Scintigraphy involves a minimal amount of radioactive material is injected into a vein 
enriching into the rapidly dividing cells constituting the metastatic lesion that bright up in 
the picture. Moreover, if the cancer invades the brain, a lumbar puncture can reach the 
cerebrospinal fluid (CSF) to collect sampling for cancer cell checking. Bone marrow 
aspiration and blood analysis may also provide microscopic material for investigation of 
signs of cancer[40].  
 
1.1.1.7 Classifications. After retinoblastoma has been diagnosed, tests are done to find 
out if cancer cells have spread within the eye or to other parts of the body. There is the 
need to evaluate both the extent of disease in the eye and if it has spread outside, to 
determine the most appropriate care of the child. Moreover, knowing the tumor stage and 
classify it is essential to decide the best treatment and to predict its outcome  
Retinoblastoma will be classified and described at different stages, depending on where 
the cancer is located, if or where it has spread, and whether it is affecting other parts of 
the body. Tumor is then classified based on the results of eye exams, imaging tests, and 
any biopsies that were done. A staging system is a standard way to sum up how far a 
cancer has spread. Several detailed guidelines and codes, called staging systems, can be 
used to stage retinoblastoma, and there are two main classifications for grouping Rb 
presently in use: the Reese-Ellsworth and the International classifications. 
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Reese-Ellsworth classification is an old model of staging developed in the 1960s and it 
has been originally used to predict visual prognosis of affected eyes and globe salvage 
after external beam radiotherapy. At that time, in fact, radiotherapy was the most 
common first line therapeutic approach widely administered to the majority of patients. 
This presurgical classification therefore was in use until 1980, when the preferred line of 
treatment shifted from radiotherapy to chemotherapy. It is divided into 5 groups, ranging 
from Group I with "very favorable" cases for saving the eye, to Group V with "very 
unfavorable" cases that are unlikely to be controlled with chemotherapy or radiation. 
Each group is then divided into two sub-Groups (A and B), depending on the disc 
diameter in size of the tumor lesions.  
 
International classification is currently used to quantify retinoblastoma and its associated 
features without need to refer to complex qualification criteria. This staging system was 
designed to simplify grouping, to assist in choosing the appropriate treatment and 
predicting its outcomes and allowing the highest chance of success especially after 
chemoreduction[80]. Clinicians found this new classification more reliable as it better 
predicts the chances of cure for intraocular retinoblastoma without the need for 
enucleation or radiation treatment. It is based on tumor size, location, and associated 
seeding. This classification is divided into 5 groups, ranging from Group A "small 
tumor" that is still only in the retina and up to 3mm in size, to Group E "extensive 
retinoblastoma", bleeding or causing glaucoma with no chances to salvage the eye; 
proceeding from the lowest to the highest grouping means the worsening of ocular 
prognosis[81-82]. 
At the International Symposium of Retinoblastoma held in Paris in May 2003, a 
committee of experts from centers worldwide drafted yet another staging system. This 
staging system was designed to be used in conjunction with the new intraocular grouping 
system and it combines clinical and pathological staging and has a single end point, the 
survival of Rb patients, who are classified according to extent of disease, the presence of 
microscopic or overt extraocular extension and metastatic extension[83]. This combined 
system included the use of the International Retinoblastoma Staging System (IRSS). The 
latter classification is in fact applied for classifying subjects after surgery to ascertain 
how much cancer has remained and whether the cancer has spread. The IRSS different 
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It needs to be said that doctors operating in developing countries may use other 
classification systems that include both intraocular and extraocular retinoblastomas. In 
these regions, at time of presentation, cancers are more likely to have widely spread. It is 
therefore worthy to mention the other systems that characterize advanced stage of the 
disease. 
 
The AJCC TNM staging system, developed by the American Joint Committee on Cancer, 
can be used to describe the extent of disease progression in cancer patients in detail, 
particularly for those that have spread outside the eye. It utilizes in part the TNM scoring 
system and it is based on size, numbers and location of the primary tumor, the lymph 
node involvement and presence of metastasis[85].  
 
The St. Jude's Children's Research Hospital staging system includes ophthalmologist 
data and embraces the whole spectrum of Rb, that is classified into four stages, ranging 
from Stage I, in which the tumor is confined to the retina, to Stage IV, where Rb has 
spread through the optic nerve to the brain, or through the blood to soft tissues, bone, or 
lymph nodes. Each stage is then divided into sub-groups[86]. 
 
In Grabowski-Abramson staging system, patients with CNS invasion are seldom curable 
and categorized as Stage III, while patients with systemic metastases are classified as 
Stage IV and they can often be rescued with high-dose chemotherapy and bone marrow 
rescue[84].   
 
The flourish of so many different attempts to characterize the various stages and severity 
of the disease can be ascribed to the various causes of tumorigenesis, different forms of 
the disease and the biodiversity of the affected subjects. Moreover, this shows the urge to 
find a selective and specific form of treatment more suitable for each case, closely 
leading to personalized medicine. 
 
1.1.1.8 Treatments. The primary goal of management of retinoblastoma is to save the 
patient's life. Salvage of the organ (eye) and function (vision) are the secondary and 
tertiary goals, respectively[87-88]. Additional priorities in Rb management include the 
elimination of the tumor while concurrently minimizing collateral injury to other tissues, 
preventing metastasis and reducing the risk of long-term secondary tumors[89].  
Only one hundred year ago, retinoblastoma was almost universally fatal but its overall 
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management has dramatically evolved in the past few decades and, at present, it has the 
highest cure rate of any pediatric solid tumors in industrial areas[63], although it still 
remains a medical issue in developing countries: where access to healthcare is limited, 
retinoblastoma can still cause blindness and death[89]. In the last ten to fifteen years, 
outcome,  in terms of survival and preservation of eyes and vision, steadily improved, 
together with quality of patients' life. Thanks to early diagnosis and aggressive, 
multimodal treatment strategies, near-complete cure rates are possible in developed 
countries, and many patients retain functional vision in at least one eye. 
 
The management of retinoblastoma needs a multidisciplinary team of specialists, 
involving pediatric oncologists, ocular oncologists, radiation oncologists, ocular 
pathologists, and geneticists to optimize treatment outcome[89]. The cure strategy and 
prognosis depend on tumor stage, number or tumor foci, localization and size of the 
tumor(s) within the eye(s), presence of vitreous seeding, the potential for useful vision, 
the extent and kind of extraocular extension and the resources available. Treatment 
options are also highly individualized and based on several considerations including age 
at presentation, systemic condition, family and societal perception, the overall prognosis 
and cost-effectiveness of treatment in a given economic situation.  
Early diagnosis and appropriate management are crucial to reduce mortality and 
morbidity and increase longevity, save the eye and possibly save the remaining vision.  
The management of intraocular retinoblastoma has evolved to a more risk-adapted 
approach that aims at minimizing systemic exposure to drugs, optimizing ocular drug 
delivery, and preserving useful vision. Depending on the route of administration, the 
possible treatments are named as focal therapy, mainly reserved for subjects presenting 
with small tumors, local and systemic therapies, used instead to treat advanced 
retinoblastoma.  
For patients presenting with extraocular retinoblastoma, treatment with intensive 
chemotherapy is required, including consolidation with high-dose chemotherapy and 
autologous hematopoietic stem cell rescue. This combined treatment is the way of giving 
high doses of chemotherapy and replacing blood-forming cells destroyed by the cancer 
treatment. Stem cell rescue consists in removing stem cells from the blood or bone 
marrow of the patient, freeze and store them. These stem cells are reinfused after chemo 
to grow and restore the body's blood cells. While most patients with orbital disease and a 
large proportion of patients with systemic extra-central nervous system metastases can be 
cured, the prognosis for patients with intracranial disease is dismal. 
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The pattern of development and risk for these tumors are heavily influenced by the 
methods of treatment for retinoblastoma, which may involve surgical and/or conservative 
procedures.  
 
Enucleation is the first line of intervention in case of Rb completely filling the globe with 
no hope of visual salvage due to damage to entire retina, tumor invasion in optic nerve, 
choroid or orbit. It continues to be the treatment of choice for advanced intraocular 
retinoblastoma unresponsive to other forms of conservative treatments, presenting 
secondary painful glaucoma, with neovascularization of iris, anterior chamber tumor 
invasion, necrotic tumors with secondary orbital inflammation, and tumors associated 
with vitreous hemorrhage. In this cases in fact the tumor morphological characteristics 
cannot be visualized, especially when only one eye is involved[90].  
Enucleation is still performed removing the whole eye leaving behind lids and 
extraocular muscles but removing the longest possible segment of optic nerve in 
continuity with the globe, usually under general anesthesia. Care during surgical 
procedure should be taken to avoid perforation of the globe to prevent seeding. Post-
surgical investigation will reveal if the cancer is likely to have spread to other parts of the 
body. This protocol includes the identification of histopathologic high-risk features 
together with the need of adjuvant therapy and leads to a substantial reduction in the 
incidence of systemic metastasis[87]. Adjuvant chemotherapy is thus administrated to 
prevent or at least minimize[91] the risk of metastasis in patients with unilateral sporadic 
retinoblastoma who underwent primary enucleation. Nevertheless, its utility remains 
controversial[92] due to the disagreement over the interpretation of histopathologic 
prognostic factors to define “high-risk” for developing metastasis[93]. Adjuvant orbital 
external beam radiotherapy following enucleation is recommended in patients with tumor 
invading the optic nerve transection, scleral and extra-scleral extension, spontaneous or 
accidental ocular perforation, and intraocular surgery for unrecognized retinoblastoma.  
Either during the same operation or few weeks after enucleation, an orbital implant is 
usually put in place of the eyeball. The implant is made out of silicone or hydroxyapatite 
and it is attached to the muscles that moved the eye, so it should coherently move. After 
several weeks, an ocularist will create an artificial eye for the affected child. This is a 
thin shell that fits over the orbital implant and under the eyelids, like a big contact lens. It 
will match the size and color of the remaining eye. Once it is in place, it will be very hard 
to tell it apart from the healthy eye.  
Removing the eye also can affect the future growth of bone and other tissues around the 
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eye socket, which can make the area looking somewhat sunken. Using an orbital implant 
can sometimes lessen this effect. However, if there is any chance of saving useful vision 
in one or both eyes, other types of treatment should be preferred. 
 
Plaque brachytherapy, also known as internal or episcleral plaque radiotherapy, is a focal 
therapy limited to small tumors and it involves the placement of a radioactive implant on 
the sclera for a trans-scleral irradiation of the tumor, using high energy X-rays or 
particles to kill cancer cells.  
In the 1930s, Henry Stallard introduced small metal disks, called plaques, that allow 
radiation to be delivered to only a portion of the eye without irradiating the whole 
organ[94-95]. Radioactive seeds are attached to one side of a thin piece of metal plaque 
(usually gold) and placed directly on the outside wall of the eye near the tumor. The 
plaque helps protect other nearby tissue from the radiation and keeps radiation from 
damaging healthy tissue. Tissue absorption of ionizing radiation may cause DNA damage 
and cell death. Because retinoblastoma has a high rate of proliferating cells, it is quite 
radiosensitive. Brachytherapy is used for solitary, medium-sized tumors (6-15mm and 
bigger than 3mm from the optic disc or fovea) and, if little subretinal fluid is present, 
plaque radiotherapy can generally be used to achieve tumor control[89]. Iodine 125 and 
Ruthenium 106 radioisotopes are the most common source of radiation currently used in 
brachytherapy; as well Cobalt 60 and Iridium 192 are also used. Plaque brachytherapy 
requires precise tumor localization and basal dimensions, used for dosimetry on a 3D 
tumor model. The plaque is left in situ for the duration of exposure, generally 3 to 7 days 
and radiation travels a much-defined trajectory that focused only on the tumor. The 
plaque is then removed at the end of treatment during a second operation while the child 
is under general anesthesia.  
The advantages of plaque brachytherapy are focal delivery of radiation with minimal 
damage to the surrounding normal tissues, reduced risk of second malignant neoplasm 
and short duration of treatment. The common complications instead are radiation 
papillopathy and radiation retinopathy[96], damage to the optic nerve that can affect vision 
in the long term[97]. 
Brachytherapy has not been linked to an increased risk of developing a second cancer. 
 
External beam radiotherapy has traditionally been done with conventional radiotherapy 
techniques that resulted in high dose delivery to the surrounding healthy tissues. It is a 
cancer treatment that uses high-energy X-rays or other types of radiation to kill cancer 
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cells or keeping them from growing. Radiation therapy focuses radiation beams from a 
source outside the body on the cancer and it has been a useful treatment tool of 
moderately advanced retinoblastoma up to the 1940s[98-99]. Until the late 1980s, 
radiotherapy represented the preferred form of management of retinoblastoma; 
accordingly the survival rate in affected children in the Western world exceeded 90%. 
Compared with surgery, it has in fact the advantage of possibly saving vision in the eye. 
However, in the long term, these young patients often presented midfacial hypoplasia[100] 
and developed second non-ocular cancers in the irradiated field[101]. Because these 
secondary neoplasms occurred at a rate of 0.5 to 1% per year, and because half of the 
children who developed these other tumors died, by the 1990s, one of the most common 
cause of death in retinoblastoma patients was the secondary cancers related to the their 
radiation treatment, rather than the lesion itself[95]. Therefore, the risk of radiotherapy-
related secondary cancers in children has led to dramatically reduce the use of external 
beam radiotherapy in Rb. Currently radiotherapy is still considered necessary only for 
patients with large tumors who are not candidates for chemosurgery but who have visual 
potentials. Furthermore, external beam radiotherapy can be used to treat eyes 
unresponsive to other treatments, those with a tumor located at the optic nerve resection 
margin and extraocular retinoblastoma extending through the sclera, orbit, or 
intracranial[97].  
Radiation is given 5 days a week for several weeks and the treatment for each day takes 
only a few minutes, usually under anesthesia. Before treatments start, the radiation team 
takes careful measurements with imaging tests such as MRI scans to determine the 
correct angles for aiming the radiation beams and delivering the proper dose of radiation. 
The lowest possible radiation dose combined with systemic or local chemotherapy and 
focal surgery may yield the best clinical outcomes in terms of local control and 
treatment-related toxicity.  
 
Nowadays, many specialized centers use newer types of external low dose radiation 
therapy, called intensity modulated radiation therapy (IMRT), a type of 3D radiation 
therapy that uses a computer to make pictures of the size and shape of the tumor. IMRT 
allows doctors to shape the radiation beams and aim them at the tumor from several 
angles, as well as adjust the intensity (strength) of the beams to limit the dose reaching 
the nearby normal tissues[102]. Among those low doses radiation therapies, stereotactic 
radiation therapy uses special equipment to position the patient and precisely deliver 
radiation to a tumor. A rigid head frame is attached to the skull to keep the head still 
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during the radiation treatment. Proton beam radiotherapy is another new type of high-
energy external radiation therapy and it can be used for treatment of Rb, reducing the 
radiation dose delivered to the adjacent orbital bone while maintaining an adequate dose 
to the tumor[103]. Early results with proton beam therapy are promising, because reduces 
the risks of second malignancy and cosmetic and functional sequelae[104]. Long-term 
follow-up of retinoblastoma patients demonstrates that proton beam radiotherapy can 
reach high local control rates, even in advanced cases, and many patients retain useful 
vision in the treated eye. Treatment-related ocular side effects are uncommon, and no 
radiation-associated malignancies have been observed[105]. 
 
Laser photocoagulation was introduced in the 1950s by Meyer-Schwickerath[106], using a 
white laser beam aimed through the dilated pupil to destroy small tumors. This type of 
therapy is performed under general anesthesia and it uses a 520nm argon laser to 
coagulate the blood supply of the tumor by generating heat with temperatures in excess 
of 65°C within the treatment spot. Direct photocoagulation to the tumor must be avoided. 
Indirect ophthalmoscope laser photocoagulation is an effective conservative method to 
manage only selected small primary or recurrent posterior retinoblastomas up to 4.5mm 
in basal diameter and 2.5mm in thickness[90]. Hence, the focal treatment is directed to 
delimit the tumor and coagulate the blood supply to the tumor by surrounding it with two 
rows of overlapping argon/diode or xeron laser burns. The related increase of 
temperature generated by the laser spot constitutes a second anti proliferative physical 
mechanism. Moreover, in this region, it is possible to create a synergism with the use of 
chemotherapy (carboplatin), given 24 hours before the beam treatment. Small posterior 
tumors without seeding respond well to laser photocoagulation. Most tumors require 2 to 
3 sessions to be cured, with about a month between treatments. On the other hand, 
photocoagulation is not recommended for tumors located at or near macula or pupillary 
area, for those arising from a vitreous base and for mushroom shaped lesions. It is not 
even used for tumors impinging on the fovea, because of the risk of compromising a 
patient's central vision.  
Complications after laser therapy include transient serous retinal detachment, vascular 
occlusion and preretinal fibrosis and vitreous seeding if the laser power is too high. 
 
Cryotherapy introduced in the 1960s by Lincoff, utilizes a frozen metal probe for 
destroying abnormal tissue, tumor cells and preserving vision abilities[107]. It is a focal 
treatment performed under general anesthesia for small primary or recurrent retinal 
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tumors anteriorly located to the equator of the globe, measuring up to 3.5mm in basal 
diameter and 2mm in thickness[90]. Cryotherapy involves the use of a pencil-like probe by 
which liquid nitrogen is delivered and directly applied to the outer surface of the sclera 
adjacent to the tumor, directly behind the intraocular focus of the lesion. The cryoprobe 
is then frozen and thawed several times. Rapid freezing causes intracellular crystal 
formation, which breaks tumor cells and originates vascular occlusion. Cryosurgery is 
usually given 2 or 3 times for each treatment and it is applied at 4-6 week intervals until 
complete tumor regression. Cryotherapy can produce a large scar and cause the eye and 
eyelid to swell for a few days. Besides, it can damage the retina, which leads to blind 
spots or can temporarily cause retinal tears and detachment. Further complications 
include vitreous hemorrhage, choroidal effusion and localized periretinal fibrosis, 
proliferative vitreoretinopathy and chorioretinal atrophy. Cryosurgery, if administered 2-
3 hours prior to chemotherapy, can increase the delivery of chemotherapeutic agents 
across the blood retinal barrier inducing a synergistic effect. 
 
Thermotherapy, also called transpupillary thermal therapy, employs the heat to destroy 
cancer cells. It may be given using a laser beam aimed through the dilated pupil or onto 
the outside of the eyeball. Thermotherapy can be used alone for local control and for 
small tumors posteriorly located to the equator of the globe and outside retinal arcade up 
to 4.5mm basal diameter and 2.5mm thickness, without vitreous or subretinal seeds. It is 
a focal therapy and suitable for lesions adjacent to fovea and optic nerve in which plaque 
therapy or laser photocoagulation would possibly induce more profound visual loss. For 
larger tumors, it can be used along with chemotherapy (called thermo-chemotherapy) or 
with radiation therapy (called thermo-radiotherapy) as the heat benefits the efficacy of 
these other treatments. Thermotherapy is performed under general anesthesia and this 
type of focal therapy uses a focused heat generated by infrared light, using an 810nm 
diode laser, to heat and kill the tumor cells up to sub-coagulation. The temperatures, 
ranging from 42 to 60°C, are not quite as high as those used in photocoagulation therapy, 
so some of the blood vessels on the retina may be spared. It is noteworthy that laser is 
applied to eye tissue at sub-photocoagulation levels. Its mechanism of action is related to 
cell membrane and chromosomal damage, protein denaturation and ischemic necrosis of 
the tumor[108]. The standard treatment for transpupillary thermotherapy is given for about 
10 minutes at a time and it involves radiation from a semiconductor diode laser delivered 
with an indirect ophthalmoscope, in order to produce a grey white scar without 
photocoagulate retinal vessels. Alternatively, trans pupillary delivery can be performed 
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through an operating microscope or via a trans-scleral route with a diopexy probe[87]. 
Complete tumor regression can be achieved in over 85% of tumors using 3-4 monthly 
sessions of thermotherapy. When used as part of thermo-chemotherapy, the heat is 
usually applied at a lower temperature over a slightly longer period, starting within a few 
hours after chemotherapy. The common complications are focal iris atrophy and focal 
paraxial lens opacity, retinal damage retinal fibrosis, tumor seeding into the vitreous. 
 
Chemotherapy is the use of anti-cancer drugs to stop the growth of retinoblastoma cells, 
either by killing the cells or by stopping them from dividing. The way the chemotherapy 
is delivered depends on the stage of and the localization of the cancer in the body. 
Depending of the route of administration, it is classified as systemic and local.  
 
Systemic chemotherapy was first described by Kupfer[109] in the 1950s, but the real 
interest for chemoreduction as a management option for retinoblastoma grew only in the 
mid-1990s, when the use of radiation-derived therapeutics was recognized as a potential 
cause of secondary malignancies and following preliminary observations that systemic 
chemotherapy delivered prior to external beam radiotherapy contributed to tumor control 
and ocular salvage[110]. A subsequent study on eyes treated with systemic 
chemoreduction combined with focal treatments demonstrated tumor regression and 
decreased need for additional external beam radiotherapy and enucleation. This was a 
major advancement in management because it was evident that satisfactory tumor control 
could be attained with systemic chemotherapy while saving the eye and avoiding the 
adverse events of external beam radiotherapy[111]. Using the International Classification 
of Rb, treatment success was found in 100% of group A, linear decreasing until nearly 
50% in group D eyes. This launched the so-called "systemic chemotherapy era", from the 
1990s to 2006; however, with the advent of novel local routes of administration, the use 
of systemic chemotherapy has decreased in recent years[89]. 
In most cases, a combination of 2 to 4 chemical compounds is injected into a vein 
through a catheter, into muscle or given by mouth. These drugs enter the bloodstream 
and reach throughout the body. Systemic chemotherapy has recently become the standard 
of care for the management of moderately advanced intraocular retinoblastoma, even 
though it fails in more than two-thirds of eyes with advanced stage disease, requiring 
more invasive treatments such as radiotherapy or enucleation. It is mainly used to 
achieve the reduction of tumor size, but it is also a mean to aim at decreasing second 
malignancies and the risk of local and systemic relapse in advanced stage, resulting in a 
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good survival rate after treatment[87].  
Chemoreduction is now commonly used as the first treatment to shrink tumors that have 
not spread beyond the eye and it is indicated as initial therapy for bilateral advanced 
disease in which attempts are made to salvage both eyes.  
Unfortunately, chemotherapy alone rarely cured the whole of the tumor, but it can benefit 
size reduction and the effect of other additional local methods, such as laser, cryotherapy 
or plaques. With these adjunctive treatments, the success rate of systemic chemotherapy 
was comparable to radiation but without the radiation-related side effects[63]. 
The combination of chemoreduction and aggressive focal therapies has indeed formed 
the new standard approach to most patients with advanced intraocular Rb. However, 
seeding of the vitreous cavity continues to be the primary reason for treatment failure in 
these patients[112].  
On the other hand, the drug administration after local treatments is under investigation 
because it might help prevent the recurrence of retinoblastoma, especially outside the 
eye. Chemotherapy may be also a postoperative adjuvant for histopathologic high-risk 
features and for the reduction of systemic metastasis in patients with unilateral sporadic 
retinoblastoma who underwent primary enucleation. It is in fact utilized quite often when 
the eye has already been removed, but the tumor was found to have spread into some 
adjacent areas in the eye. More relevantly, the systemic chemotherapy could be used to 
treat children whose retinoblastoma has extended beyond the eye, in patients with optic 
nerve invasion posterior to the lamina cribrosa, massive choroidal invasion, or any 
combination of optic nerve and choroidal invasion (for which local treatments will bring 
limited improvements). If the cancer has spread to the brain, chemical compounds may 
also be given directly into the cerebrospinal fluid that surrounds it, using a technique 
called intrathecal chemotherapy.  
Systemic chemotherapy is administered in cycles, with each period of treatment followed 
by a rest period to give the body time to recover. Each cycle typically lasts for a few 
weeks and the total length of treatment is often several months[113].  
 
The Food and Drug Administration (FDA) approved a list of generic and brand names of 
cyclophosphamide for retinoblastoma. Three classes of agents are also commonly 
employed: DNA-crosslinking agents (carboplatin, cisplatin), DNA topoisomerase 2 
inhibitors (etoposide, topotecan, teniposide) and Vinca alkaloids (vincristine). Regimen 
and doses are managed for intraocular retinoblastoma and the most commonly used 
combination to shrink the tumor is vincristine/etoposide/carboplatin[88]. Doxorubicin and 
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other chemotherapeutic drugs might be used if the standard combined therapy is not 
effective.  
For instance, three cycles of carboplatin-based chemotherapy over 3 months can reduce 
the size of tumors by almost 50%[114].  
Unfortunately, when given into the bloodstream chemotherapy can cause adverse effects 
in different parts of the body. Children tend to have less severe side effects from 
chemotherapy and to recover from these more quickly than adults do. For this reason 
doctors might even decide to give them a high dose of drug needed to eradicate the 
tumor. These side effects depend on the type of drugs, the doses used and for how long 
they are given. Possible side effects might be temporally or permanent hearing loss[115], 
mouth sores, loss of appetite, nausea and vomiting, diarrhea or constipation, increased 
chance of infections, bruising or bleeding and fatigue. Other adverse events, such as 
neurotoxicity, hyponatremia, nephrotoxicity, ototoxicity and febrile neutropenia, can also 
occur. Treatment failure in the form of persistent vitreous and subretinal seeds and 
intraretinal tumors following therapy have been attributed to the inability of the treatment 
drugs to reach the tumor[116-117]. Tumor resistance or unresponsiveness to chemotherapy 
is thought to occur more often in well-differentiated tumors, presumably because cells 
are not cycling, so they are less likely to respond to treatment modalities affecting cell 
division[118]. Secondary acute myelocytic anemia, a virulent form of leukemia that is 
difficult to treat and has a high mortality rate, has been reported after chemotherapy in 
some children with retinoblastoma[119] and it is now the most common second cancer in 
some countries. In addition, frequent complications of chemotherapy include the need for 
transfusions and ports[120].   
The occurrence of several serious side effects limits the doses of systemic drug that can 
be given to treat retinoblastoma. Newer techniques help keeping the drug concentrated in 
the areas around the tumors and they are exploited with the hopes of both getting higher 
doses of chemo exclusively to the target tumors and reducing the morbidities and side 
effects associated with systemic therapy.  
Therefore local chemotherapy delivery methods, including periocular injections, intra-
ophthalmic artery infusions, and intravitreal injections, have been developed in the hope 
of controlling disease in advanced cases[112].  
 
Periocular chemotherapy is involved in the treatment of some advanced intraocular 
cancers with vitreous seeds and it has been used for retinoblastoma control as an adjunct 
to systemic chemotherapy and local treatment in order to avoid enucleation, to treat 
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tumor recurrence and whenever high doses of chemo are needed directly inside the eye, 
either as subconjunctival or subtenon delivery. Along with systemic chemotherapy in 
fact, one of the drugs may be injected through the membrane covering the muscles and 
nerves in the tissues around the eye, where it slowly diffuses into the back of the eyeball, 
achieving high levels within the vitreous[121]. Periocular injection is performed usually 
under general anesthesia and it enables transcleral drug delivery, using the large surface 
area of the sclera and its high permeability to small molecules without the hazard of 
puncturing the globe. Either carboplatin or topotecan can be employed and complications 
of periocular chemotherapy include redness, orbital and eyelid edema, ecchymosis, 
orbital fat atrophy, muscle fibrosis leading to strabismus, and optic atrophy. Because of 
its significant toxic effects, it is rarely used in current practice[122] .  
 
Intra-arterial chemotherapy represents a new approach for the management or 
retinoblastoma and it consists in injecting drugs directly into the ophthalmic artery, the 
main vessel that supplies blood to the eye. During the last decade, Suzuki and colleagues 
started treating patients with intracarotid artery melphalan[123],   developing a technique 
to safely and effectively cannulating the ophthalmic artery for chemotherapy infusion. 
According to this technique, usually performed under general anesthesia, a long and very 
thin catheter is inserted into a large artery on the inner thigh and slowly threaded through 
the blood vessels all the way up into the ophthalmic artery, where drugs, such as 
melphalan, topotecan or carboplatin are then infused. 
The treatment is slowly delivered for 30 minutes in a pulsatile fashion taking care not to 
occlude the artery and to minimize reflux into the internal carotid artery. This process 
may then be repeated every few weeks, depending on how much the tumor shrinks, and 
most patients receive 3 monthly sessions. This technique seems to elicit promising results 
obtaining good tumor control and minimal side effects, mainly due to the low amount of 
drug occurred for treatment. Most notably, enucleation or external-beam radiotherapy 
could be avoided in two-thirds of affected eyes with advanced intraocular retinoblastoma 
managed primarily with intra-arterial chemotherapy. 
 
To treat tumors that are widespread within the eye and not responsive to other treatments 
or have come back after treatment, intra-vitreal chemotherapy can be used, injecting the 
therapeutic agent directly into the vitreous cavity of the eyeball through the pars plana 
under aseptic precautions. The main concern with this technique is that placing the 
needle into the eye to give the drug might open a small hole that could allow tumor cells 
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to spread outside, so medical specialists are required. A recent improvement added to the 
technique is to create a zone of transient intraocular lower pressure so to minimize cell 
spreading during administration of a small-volume dose of melphalan, topotecan, or a 
combination of both injected into the eye using a fine frozen needle[124]. The first-line 
indication for intravitreal chemotherapy includes vitreous seeds refractory to standard 
therapy and recurrent vitreous seeds after previous therapy[125].  
 
Children with retinoblastoma that has spread outside the eye and who are unlikely to be 
cured with conventional treatments need multiple-agent, high-dose chemotherapy and 
autologous hematopoietic stem cell transplantation as rescue therapy for the bone 
marrow[126], although this is a complex treatment that can cause life-threatening side 
effects. Regimens with chemical compounds proven to be effective include vincristine, 
cyclophosphamide, doxorubicin, and platinum as well as epipodophyllotoxin-based 
drugs[127].  
 
1.1.1.9 Recurrence. During and after treatment for retinoblastoma, the main interest for 
patients and physicians is about the tumor itself, the short- and long-term tumor effects 
and its treatment.  
Follow-up care is a central part of the process once the treatment is finished and it offers 
children the best chance for recovery and long-term survival. Cancer recurrence is in fact 
a possible side effect of certain treatments. 
Orbital recurrence of retinoblastoma following successful treatment of intraocular disease 
is rare, however, Rb may regrow after a period of time during which the tumor could not 
be detected. Following chemoreduction and focal consolidation, tumor relapse is found in 
almost one fifth of total Rb at 7 years and increasing of tumor thickness is the most 
important predictive factor of recurrence[128]. Cancer may recur into the eye in the same 
place as the original (primary) tumor, in tissues around the eye, or in other places in the 
body.  
Recurrent retinoblastoma in the only remaining eye represents a worse scenario and after 
the failure of conventional treatments, enucleation is the only option left[129].  
The potential for recurrence of Rb during treatment and active follow-up raises the 
possibility of complex and challenging treatment. The relapse of tumor is crucial source 
of concern following intraocular surgical procedures and aggressive laser treatment. As 
well, risk related to medical procedures concern extraocular extension of Rb or tumor 
seeding in the needle tracks, following the violation of the sclera or aspiration of 
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intraocular retinoblastoma, respectively[130].  
Furthermore, high-energy focal treatment can disrupt the internal limiting membrane, 
causing dispersion of malignant cells from the tumor[131]. Repeated, aggressive laser 
treatment may cause a focal thinning of the sclera within the atrophic scar, easing a portal 
of entry for active tumor cells to seed the orbit[132]. Although external beam radiotherapy 
represents the most reliable method to treat retinoblastoma with vitreous seeding, tumor 
recurrence after this procedure can occur generating the need for other types of 
treatments to preserve the eyeballs[133]. In children with hereditary retinoblastoma, 
formation of new tumors is common up to 3 or 4 years given to the generic nature of the 
disease.  
 
1.1.1.10 Non-ocular tumors associated with Rb. Effort to ensure survival rate and 
saving of the eyes and vision steadily increased success during last decades: due to the 
early diagnosis and the improved treatment techniques, the 10-year survival rate of 
primary retinoblastoma has been among the highest of all childhood cancers at greater 
than 90% in developed countries[134].  
Before the 1970s, the majority of new malignancies in survivors of retinoblastoma arose 
in the prior radiation fields, and could be labeled as radiation-induced neoplasias[135]. 
Secondary tumors arising from non-irradiated areas were initially reported by Jensen and 
colleagues in 1971[136]. Few years later, Abramson demonstrated the association of the 
risk of non-ocular cancers with heritable retinoblastoma[137]. Bader and colleagues firstly 
identified the trilateral retinoblastoma in addition to having hereditary retinoblastoma[138].  
Retinoblastoma survivors and their offspring increased during the mid-twentieth century 
as diagnostics and treatments improved. However, as treatment methods for 
retinoblastoma continue to evolve, the type and distribution of second non-ocular 
malignancies will continue to change. Second primary tumors are new primary lesions 
that occur in a person who had cancer in the past, they are unrelated to the first cancer 
and may occur months or even years after the initial tumor was diagnosed and treated. 
Currently, secondary malignancies represent an increasingly significant topic, becoming 
the leading cause of death of germinal retinoblastoma survivors, who become susceptible 
to developing second non-ocular cancers[139]. 
Hence, long-term survivors of hereditary retinoblastoma have a significantly high risk for 
secondary malignancies and they are at an increased 20-fold risk of developing and dying 
from subsequent non-ocular cancers, especially bone and soft tissue sarcomas that 
account for approximately 40% to 60% of all second cancers[120]. 
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Other second primary tumors among retinoblastoma survivors include trilateral Rb, 
malignant melanomas and neoplasms of brain and meninges. These tumors usually 
persist decades after the retinoblastoma diagnosis and manifest in childhood, adolescence 
or even adulthood.  
This predisposition to pediatric second primary sarcomas and other tumors has been 
attributed to genetic susceptibility as well as past invasive therapies[140]. The pattern of 
development and risk for these tumors are so heavily influenced by the initial methods of 
treatment for retinoblastoma. There is convincing epidemiologic evidence linking past 
radiotherapy with sarcomas in hereditary patients. In these view, the specific extraocular 
new neoplasms might be caused by treatments with radiations. Their incidence is in fact 
increased to more than 50% in individuals with Rb who have received external beam 
radiation therapy[141]. In addition to radiotherapy, chemotherapy, specifically alkylating 
agents, have been associated with the risk of bone cancer after Rb[142], but less so for soft 
tissue sarcomas[143].  
Survivors of heritable retinoblastoma who are not exposed to high-dose radiotherapy 
have a high lifetime risk of developing a late-onset cancer[144].  
Another risk factor for the development of second malignancies is 
retinoma/retinocytoma, a rare intraocular malignancy that appears to be either an inactive 
form indicative of spontaneous remission or a benign variant of retinoblastoma and it is 
characterized by homogenous, translucent greyish masses, calcifications, with pigment 
migration and proliferation bordering the tumor[27]. These lesions display genetic 
inactivation and represent a step towards Rb development[145-146]. 
 
The majority of bone and soft tissue sarcomas among hereditary Rb survivors occur in 
the head, within the radiation field, but they also take place outside. Sarcomas account 
for almost half of the second primary cancers in hereditary Rb survivors, arising at ages 
similar to the pattern of occurrence in the general population.  
There has been a trend over the past two decades to replace radiotherapy with 
chemotherapy and other focal therapies, in order to reduce the incidence of second 
cancers in Rb survivors. Screening for second primary malignancy is an important part of 
pediatric oncological follow-up in patients with heritable retinoblastoma. Given the 
excellent survival of most Rb patients treated in the past, it is important for survivors, 
their families and health care providers to be aware of the heightened risk for sarcomas in 
hereditary patients and they should then undergo regular medical surveillance in adult 
years[140].  
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Survivors of non-hereditary Rb do not present genetic changes in all of their cells, so 
they are at much lower risk of a subsequent primary cancer, similar to the risk in the 
general population[147], making second primary sarcomas very rare in these patients. Still, 
their risk of some cancers might be higher from getting chemotherapy and/or radiation 
therapy.  
 
Second tumors after retinoblastoma are frequent in children with hereditary form, due to 
their genetic impairments in each cell. They have a much higher risk for developing other 
types of cancer throughout their lives and this is even higher in any parts of the body that 
received radiation during treatment for Rb. Younger children treated with radiation 
therapy are more likely than older children to develop side effects such as second cancers 
or problems with bone growth in the irradiated area. Chemotherapy with certain drugs 
can also increase the risk of some cancers.  
Survivors of retinoblastoma, particularly patients carrying a germinal mutations or who 
have a retinoma, should undergo lifelong surveillance for second primary tumors. They 
should also avoid smoking, damaging exposure to sunlight, and ionizing radiation when 
possible. 
Most of second tumors are very treatable if detected early, and so it is very important that 
these children are followed closely throughout life. The entire body must be examined 
carefully to avoid missing these second tumors and they are classified in four main types 
depending on their general features[139].  
 
Benign tumors, especially lipomas, are frequently reported in patients with hereditary 
disease[148]. These lipomas are preferentially located on the face, neck, shoulders, and 
upper chest[149]. Additionally, many patients with both hereditary retinoblastoma and 
lipomas easily develop other secondary malignancies and these results suggest that the 
presence of benign tumors may indicate an elevated second cancer risk. Certain germline 
mutations may also predispose the patient to both lipomas and secondary tumors and this 
finding may have future implications on follow up and screening of retinoblastoma 
survivors for second malignancies[150]. 
 
Second malignancies appear to be closely related to the initial treatment procedure. As 
trends in treatment continue to change and the length of follow-up increases, the rate of 
bone and soft tissue cancer development may decline while the rate of epithelial cancers 
are likely to increase. It is thus described an incidence rate of approximately 2% per year 
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from the time of diagnosis of the second malignancy and the latency period decreases as 
each additional cancer is diagnosed. It has also been reported a predictable pattern for 
third, fourth, and fifth malignancy development based on location of the second 
tumor[151]. 
Risk of bone and soft tissue sarcomas begins within 10 years of treatment for hereditary 
Rb and continues throughout adulthood.  
Bone sarcomas are one of the most common second primary cancers occurring after 
hereditary retinoblastoma, accounting for 25-30% of all second primary cancers[152]. 
They are typically diagnosed in Rb survivors between 10 and 20 years of age, similar to 
the incidence pattern in the general population. The majority of second primary 
osteosarcomas occurred within the radiation field in the head region, but up to 40% was 
diagnosed outside the treatment field, primarily in the lower legs[153], and their clinical 
outcomes in Rb survivors may be more favorable than those of conventional 
osteosarcoma[154]. 
Soft tissue sarcomas are also one of the most common subsequent cancers following 
hereditary Rb accounting for 12% up to 32% of all second cancers[152]. An increased risk 
for soft tissue sarcomas was observed within 10 years of Rb diagnosis and continued 
through adult life up to 50 years after Rb, with the specific subtypes leiomyosarcomas 
and rhabdomyosarcomas, both occurring at similar ages as in the general population[155]. 
 
Trilateral retinoblastoma is a well-recognized syndrome that consists of unilateral or 
bilateral retinoblastoma associated with an intracranial neuroblastic tumor, commonly in 
the region of the pineal gland (pinealoblastoma), developing also a primitive 
neuroendocrine tumor in the brain[156-157]. The vital prognosis for these cerebral tumors is 
very poor[59]. The intracranial mass is often located in the pineal region, but may also be 
a suprasellar or parasellar tumor, presenting variable incidence of 0.5% to 6% among Rb 
patients[158]. 
It has historically been a highly fatal malignant tumor and a specific subset of patients are 
more likely to develop these lesions including those with a family history of 
retinoblastoma, bilateral disease, diagnosis within the first 6 months of life, and prior 
treatment with external beam radiation[35]. In the pre-chemoreduction era, pineoblastoma 
was found in 6% of bilateral retinoblastoma patients and 10% of patients with hereditary 
retinoblastoma[127]. It is an important cause of mortality in retinoblastoma patients during 
in the first 5 years of life[160]. 
Trilateral Rb incidence has decreased recently, but the underlying cause for this shift 
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remains disputable. In the past, these tumors demonstrated a poor prognosis and they are 
still the most frequent cause of death in retinoblastoma survivors between the ages of 5 to 
10 years[161]. 
It is important to note that the classification of pineoblastoma as a second malignancy as 
opposed to a variant of the primary tumor is controversial. It often cannot be 
differentiated from retinoblastoma histologically and has occasionally been documented 
to occur prior to the development of ocular manifestations in some patients[162]. For these 
reasons, some studies have not included trilateral retinoblastoma as a second malignancy, 
but the classification has varied over the years causing some discrepancy in the literature. 
 
An independent second non-ocular retinoblastoma located in the ovary of a bilateral 
ophthalmic Rb survivor has been reported in literature. Eighteen years after radiation of 
the right eye and enucleation of the left eye, the patient was found to have a large left 
ovarian tumor involving the fallopian tube, mesentery, and lymph nodes. Histologically, 
the concurrent presence of Homer Wright and Flexner-Wintersteiner rosettes confirmed 
the identification as retinoblastoma. Additionally, molecular analysis demonstrated 
genetic alterations in different pattern in the patient and this difference suggests that the 
ovarian tumor was of a separate clonal origin from the original eye tumor[163]. 
 
1.1.1.11 Psychosocial and financial care. Retinoblastoma emerges in infancy or very 
early in life and presents unique psychosocial and financial challenges to patients and 
caregivers. Support for Rb families is important at the time of initial diagnosis, during 
active treatment and throughout long-term follow-up.  
Relatives  affected by a childhood cancer experience present anxiety and distress for a 
long period, remaining after treatment is complete and the child is considered cured[164]. 
Rb diagnosis induces short-term emotional distress for parents and long-term concerns in 
affected children because they are all forced to suddenly change their lives. Psychosocial 
effects could manifest as increased levels of depression, anxiety, and concerns about 
mortality[165].  
An integrated multidisciplinary team of pediatric cancer specialists is then important in 
the management of retinoblastoma; it incorporates the skills of the following health care 
professionals and others to ensure that children receive treatment, supportive and 
rehabilitation that will achieve optimal survival and quality of life[166]. Pediatric 
psychosocial oncology particularly provides emotional assistance and palliative care for 
families and children, including sibling and spiritual support, anticipatory grief 
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counseling, and bereavement follow-up[167], facing challenging experiences during 
hospitalization. Access to care is one of the most difficult issues that Rb families must 
overcome. Not all patients in fact receive optimal treatments yet, due to inadequate 
knowledge of Rb in primary care settings and wide variations in access to care. 
Specialists in retinoblastoma are in fact available in only a few centers of excellence, so a 
patient's province of residence significantly affects access to high-quality Rb care and 
cures are not still accessible to all. Most patients in developing countries are required to 
costly traveling great distances to receive appropriate and high-quality care[64]. Hence, for 
many families treatment will imply moving to another city and separation from precious 
social support networks.  Moving may impose changing terms of employment for at least 
one parent and significant financial burdens on the family[168].  
Many children and families need constant assistance during the school years and some of 
those need support as they enter adulthood, when both the disease and high-stressed 
treatment have major implications[168]. Growing children report medically related phobias 
during or after treatment and they become aware of vision loss or impairment, focusing 
on the ocular prosthesis and the asymmetrical facial structure, especially after teasing or 
bullying episodes at school. Parents commonly also express anxiety over the integration 
process and the need for classroom support[164]. Adult Rb survivors face new and 
different challenges. Rb has been associated with reduced levels of education attainment, 
social integration, employment, and income[170]. Re-educating Rb survivors about their 
diagnosis and treatment as they get older is extremely important and it is done by easy 
access and open communication with medical experts[120]. As young adults then consider 
having children of their own, they need to understand the communicating risk to future 
offspring when heritable Rb is present. Some affected patients have in fact a family 
history of the disease and they need genetic counseling[171], providing individuals and 
families with information on the nature, inheritance, future health risks and implications 
of genetic disorders. This will help them make informed medical and personal decisions, 
risks of developing Rb, screening protocols and reproductive options. The genetic cancer 
risk assessment is important for identifying at-risk individuals and the molecular 
predictive and/or prenatal testings are useful to identify individuals with heritable 
retinoblastoma and clarify the genetic status for all family members[172].   
Retinoblastoma is a severe disease that carries a heavy burden in term of personal, 
familiar and social commitments. For this, researchers and clinicians, together with 
psychologists and policy makers should convey a huge effort toward patients' life 
improvement. In this view, there is an urgent need for innovative therapeutic approaches 
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to fight this invalidating and aggressive disease. The first step to defeat Rb is deeply 
understanding the molecular bases that sustain cell proliferation, environmental hosting 
and finally cell migration and spreading. It becomes more and more evident that although 
common mechanisms and features of retinoblastoma can be found in the majority of 
patients, individual characteristics, such as genetic treats and epigenetic modifications 
may play a pivotal role in the development of the disease. 
 
 
1.1.2 Molecular basis 
 
1.1.2.1 Knudson's two-hit hypothesis. Retinoblastoma was the first tumor to draw 
attention to the genetic etiology of cancer. The chain of events inside cells that leads to 
retinoblastoma is complex and it has been known that there are variable components to 
this condition and Rb is mainly brought about by the biallelic loss or inactivation of the 
recessive human retinoblastoma susceptibility tumor-suppressor gene RB1/p105[173]. It is 
located on sub-band 13q14.2 and consists of 27 exons, spanning approximately 180 kb of 
genomic DNA[174].  
The gene usually encodes the ubiquitously expressed 110 kD nuclear RB protein with a 
regulatory function in the cellular growth cycle at the G1 checkpoint[63].  
Cell cycle progression is dependent on a series of molecular regulation after cells are 
stimulated by growth factors that bind to corresponding membrane receptors and relay 
the signals through protein phosphorylation and trigger gene expression[175].  
 
In the '60s, first Henry Stallard and then Kusum Lele investigated cytogenetically 
peculiarities in cases of retinoblastoma. They both identified germline deletions of 
chromosome 13 in rare patients with bilateral retinoblastoma and presenting mental 
retardation and a dysmorphic syndrome suggested that the retinoblastoma susceptibility 
gene was localized in this chromosomal region[176]. 
In 1971, Alfred Knudson advanced understanding of cancer when he analyzed the long-
known fact that children unilaterally affected by this tumor are commonly diagnosed at 
an older age than are bilaterally affected children, and formulated the hypothesis that two 
events must be rate limiting for the Rb development[49]. Knudson described the "two-hit" 
mechanism to explain the genetic events that give rise to tumorigenesis in patients with 
retinoblastoma: two active copies of the RB1 gene are normally carried in human cells 
and inactivation of both alleles in the developing retina is then required for tumor 
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initiation[178]. David Comings then expanded the notion to include malignancy-
suppressing loci, recognizing that Knudson's hits might be either mutations or gene 
silencing inactivating both copies of the retina-specific gene[179]. 
In 1986, Friend characterized a gene localized in the region of interest and constituting a 
site of inactivating germline mutations in children with bilateral retinoblastoma, 
confirmed that this gene corresponds to the retinoblastoma susceptibility gene, then 
called RB1[174]. Its identification proved the complementary hypotheses of Knudson and 
Comings, opened the way to cancer susceptibility gene testing and allowed definition of 
the risk of retinoblastoma within particular families. 
This malignancy results from loss-of-function of both RB1 alleles, although other genes 
might be involved in tumor development[180].  
The theoretical model proposed by Knudson was accepted and used worldwide to explain 
some of the most important features concerning the different genetic, clinical, and 
epidemiological aspects of retinoblastoma, although the model itself has been considered 
controversial.  
Steward and colleagues observed some cases of spontaneously regressed retinoblastoma 
more than a decade before the formulation of the mutational "two-hit" model[23], and it 
still represents a theoretical challenge to it. In fact, Knudson's hypothesis gives no clear-
cut explanation of how a structurally modified DNA could lead to a whole array of 
cancer phenotypes, including the spontaneous remission of retinoblastomas, unless the 
tumor presents high penetrance (90%)[181]. Penetrance, however, is an undefined concept, 
which does not correspond to any known biochemical/molecular mechanisms, and is 
presently viewed as a pure stochastic fluctuation in gene expression[44].  
The mutational "two-hit" model has been recently challenged by evidences showing that 
aneuploidy and genetic instability play an essential role in the genesis of cancer[182]. 
Nevertheless, neither the mutational nor the aneuploidy models seem to exhaustively 
explain the variegated phenotypic expression of retinoblastoma[3].  
In addition, imprinting is a process by which human genes are functionally inactivated 
and its detection in retinoblastoma represents another argument against the mutational 
model, which assumes that gene expression can be altered only in the presence of 
structural DNA modifications, and in favor of the epigenetic one[44]. 
Depending on when and where the change in the RB1 gene occurs, two different types of 
retinoblastoma can arise based on whether or not the child inherited the condition from 
the genetics of one or both parents.  
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Hereditary retinoblastoma occurs if one RB1 allele is mutated or deleted in germline 
cells[183], whereas the other allele is inactivated at the cellular level, in a somatic cell of 
developing retina. The abnormality is congenital, that is present at birth, and it is in all 
the cells of the body[184]. Affected patients started with heterozygous alleles (RB1-/RB1+) 
or inherited germline RB1 pathogenic variant[185] and hereditary Rb is then characterized 
by early onset and presence of multifocal tumors in both the eyes, due to the more 
probable loss of heterozygosity (LOH) in rapidly dividing cells, and multiple tumors 
occur.  
More than 2500 nucleotide variants have been observed in patients with hereditary 
Rb[186]; the majority of RB1 pathogenic variants result in a premature termination codon, 
usually through single base substitutions, small length mutations[187], frame-shift variants, 
out-of-frame exon skipping caused by splice site variants. Pathogenic variants have been 
found scattered throughout exon 1 to exon 25 of RB1 and its promoter region (5′-end). 
Recurrent pathogenic variants are observed at methylated CpG dinucleotides that are part 
of CGA codons or the splice donor site of intron 12. Other important types of pathogenic 
variants in Rb are complex rearrangements and small deletions, that are identified in 
about 10% of patients with bilateral or familial retinoblastoma[188-189], resulting in the 
inactivation of one RB1 allele. The loss or inactivation of the remaining normal RB1 
allele might then occur as the second event, leading to loss of function and Rb 
tumorigenesis[190]. In most of affected children, there is no family history of this 
cancer[19]. The defective RB1 gene can be inherited from either parents (in about 25% of 
Rb cases) or the gene change first occurs de novo in parental germline cells before 
conception or in utero during early embryonic development. About 5-10% of patients 
have familial Rb, in which the disease is searched in the subject known as proband, a 
person serving as the starting point for the genetic study that will uncover more than one 
affected member in the family[7]. 
In case of hereditary retinoblastoma, only one more "hit" is required to produce disease 
and it occurs in any retinal cell. During early childhood, these patients are predisposed to 
retinoblastoma because a mutation in the wild type allele will lead to biallelic 
inactivation of the RB1 gene and thereby initiate the development of a tumor focus.  
Hereditary Rb cases represent only approximately 1/3 of total retinoblastoma and tend to 
have bilateral and multifocal tumors. They also have a significantly increased risk for 
second primary neoplasms[19] and the high incidence among patients suggests that this 
tumor-suppressor gene plays a key role in the etiology of several other primary 
malignancies[190]. 
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Their offspring will have a 50% chance of inheriting the pathogenic variant and a higher 
incidence of developing retinoblastoma, as this trait is transmitted in an autosomal 
dominant fashion with high penetrance (90%)[181]. The penetrance of the RB1 mutation 
(laterality, age at diagnosis and number of tumors) is probably dependent on concurrent 
genetic modifiers such as MDM2 and MDM4 genes, whose polymorphisms may 
influence development and/or survival in Rb[180].  
 
Non-hereditary (sporadic) retinoblastoma occurs if both the RB1 alleles are inactivated 
at the cellular level, in a somatic cell after conception in uterus or in early childhood in 
developing retina[191] and they represent approximately 2/3 of total retinoblastoma cases. 
Affected patients started with two wild type alleles and both of these must become non-
functional to produce the disease. The probability of both events occurring in the same 
cell in the eye is low and hence most of sporadic Rb tumors are unilateral and occur as a 
single tumor with late onset[7]. In the majority of cases, there is no other member of the 
family affected with the tumor and children with this type of retinoblastoma do not have 
the same increased risk of other cancers as children with congenital retinoblastoma.  
The biallelic RB1 gene inactivation in patients occurs through LOH at polymorphic loci 
located on chromosome 13[4]. LOH can result from deletions and several chromosomal 
mechanisms such as mitotic recombination and non-disjunction[192]. The first "hit" of 
sporadic Rb is due to a mutation or a deletion, whereas the second somatic event could be 
either another oncogenetic event or an epigenetic modification.  
Therefore, the absence of detectable RB1 mutations in some patients suggests that 
alternative genetic and/or epigenetic mechanisms may underlie the development of non-
heritable Rb[193].  
Gene silencing after epigenetic variations is then observed in about 10% of unilateral 
sporadic retinoblastoma[194]. Approximately 3% of unilateral, non-familiar 
retinoblastomas have no somatic RB1 alterations and in one-half of these cases, the 
amplification of MYCN oncogene might initiate the disorder in presence of non-mutated 
RB1 genes. This gene encodes for N-Myc, a transcription factor controlling the 
expression of cell cycle genes involved in promoting cell proliferation and regulating in 
particular the global chromatin structure through histone acetyltransferases[195], both in 
gene-rich regions and at sites far from any known gene[196].  
These MYCN-involved tumors are larger and more invasive than RB-/RB-, characterized 
by distinct histological features and diagnosed at a significantly younger median age[197-
198]. In another small subset of tumors without detectable somatic RB1 mutations, an 
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acute genomic event concerned chromosomal "shattering" is rarely occurring focally on 
chromosome 13 spanning the RB1 locus. This chromothripsis is responsible for 
inactivating the RB1 gene, leading to loss of protein expression and can be considered as 
an additional mechanism for retinoblastoma initiation and tumorigenesis. 
Aside from RB1, recurrent gene mutations were very rare. Other genomic changes that 
occur in a small minority of patients include BCOR or CREBBP mutation/deletion and 
OTX2 amplification [199].  
Although it is not expressed in normal human retinas, the proto-oncogene SYK was found 
to be upregulated in retinoblastoma and is required for Rb cell survival[200]. 
Both amplification of the MDMX, a gene related to MDM2, and increased expression of 
its protein are strongly selected during tumor progression as a mechanism to suppress the 
p53 response and inactivate the p53 pathway in RB1-deficient retinal cells[201]. MDMX 
promotes Rb progression in mice and human patients, even though it can be blocked by 
Nutlin-3, a small-molecule inhibitor of the MDMX-P53 interaction that efficiently kills 
retinoblastoma cells[202]. 
Among other identified oncogenes and tumor suppressors, some have become targets 
motivating the search for novel therapeutic solutions. Candidate driver oncogenes that 
were recently emphasized in retinoblastoma studies include the following genes: MDM4, 
KIF14, DER (chromatic remodeling factor), E2F3, a transcription factor and a tumor 
suppressor, CDH11 (cadherin)[195]. 
 
Genetic test may ascertain hereditary or non-hereditary form of retinoblastoma in 
subjects. Moreover, RB1 genetic investigation provides important information for other 
family members. After identifying the genetic alteration in the affected member, target 
test may be performed screening other members for the same genetic alteration.  
DNA is isolated and the two copies of the RB1 gene are evaluated by direct DNA 
sequencing from available eye tumor tissue from affected individual. DNA from 
peripheral blood is then screened for the presence of one of the two gene alterations that 
was found in the tumor. If one of the RB1 pathogenic variant identified in the tumor 
sample was also present in the affected individual's blood sample, this would strongly 
support a diagnosis of hereditary retinoblastoma. The absence of any retinoblastoma gene 
abnormalities in DNA from the blood sample typically confirms a diagnosis of sporadic 
disease. In addition, there are several options for an affected parent to preserve the 
offspring from transmitting familial RB1 mutation. These include both prenatal and 
preimplantation genetic diagnoses. 
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1.1.2.2 Rb family members. RB1, p107 and RB2/p130 tumor suppressor genes are 
collectively called Rb family members. RB1 is the central gene involved in Rb 
tumorigenesis, although it is not the only one interested in tumor initiation and 
dysfunction of the other retinoblastoma-related genes is indeed central for Rb 
development[203]. RB1 is fundamental for regulating cell growth and cell cycle 
progression and its "loss of function" initiates retinoma and causes genomic 
instability[145-146], but is insufficient to cause retinoblastoma. Failure of both cell cycle 
control and genomic stability leads to changes in other tumor-suppressor genes, 
differently involved in cancer progression[204]. 
Some events that directly or not, via alteration of upstream components, inhibit the three 
Rb family members activities can contribute to cancer development, inducing 
uncontrolled cellular proliferation[205-206]. Genetic and/or epigenetic events can lead to the 
failure of these tumor-suppressor gene functions, contributing in transformation to cancer 
phenotype[207]. These two complementary mechanisms are implicated in every step of 
carcinogenesis, from the responses to carcinogen exposures to the progression into 
malignancy[208]. Either oncogenetic or epigenetic alterations in addition to RB1 
inactivation and/or silencing are therefore commonly found in Rb[191]. 
RB1 and the other retinoblastoma-related genes normally encode for "pocket 
proteins"[209], with a highly conserved region domain and their expression is differently 
regulated throughout the cell cycle[210].  
The three members of the Rb gene family have a crucial role as negative regulators of 
cell cycle progression through modulation of transcription factors[211]. RB protein 
controls the expression of genes that mediate cell fate through a critical phase of its 
growth cycle[212].  
Rb family members negatively interact with various E2F transcription factor proteins, 
thereby blocking different subsets of gene promoters, through phosphorylation by cyclin-
dependent kinases (CDKs) regulation[213]. The CDKs are responsible for cell cycle 
transition through different phases. For G1 phase progression, the G1 cyclins associated 
CDKs can phosphorylate and inactivate RB. Because the phosphorylation sites of the 
protein are multiple, they become a family of checkpoint to prevent release of E2F family 
transcription factors under a stress condition, such as DNA damage. In addition, the 
CDKs activity and RB phosphorylation are decreased by the family of CDK inhibitors 
(CKIs), including INK4 and CIP/KIP family proteins[214]. Rb family members exert their 
function interfering with the coordinated regulation of the enzymatic activity of CDKs, 
which are indeed key regulatory factors of the cell cycle progression[215].  
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After gene dysfunction or gene silencing, the nuclear RB phospho-protein results 
inactivated or absent in retina cells and this is a fundamental event in retinoblastoma 
tumorigenesis, due to its ability to regulate the cell cycle with a central role in controlling 
the commitment of a cell to initiate DNA replication and cell division[216]. Hence, the RB 
protein may be non-functional after phosphorylation and it appears to release E2F from 
the inhibitory complex, enabling it to promote the transcription necessary for cell 
progression into late G1 and S phase[217]. Loss of RB function deprives the cell of an 
important mechanism for slowing down cell proliferation through modulation of gene 
expression. Pathogenic variants in RB1 and in other family members lead to the 
expression of proteins that have lost cell cycle-regulating functions.  
Moreover, phosphorylation of RB controls its interaction with other proteins[218] and if 
the binding activity of the pocket domain is lost, this results in the release of cellular 
proteins[219].  
Silencing RB activity is a frequent feature in cancer because it allows deregulated cell 
cycle progression and promotes tumor growth[218]. Moreover, RB may hold additional 
tumor-suppressor functions, in several cancers, including alternative roles in the cell 
cycle, maintenance of genome stability and apoptosis[203]. At the same time, RB protein 
is also involved in control of termination of cellular differentiation and in exit of the cell 






















1.2.1 Epigenetic revolution 
 
1.2.1.1 Epigenetic landscape. During an emerging scientific and philosophic revolution 
in the last century, the biologist Conrad Hal Waddington contended that classical 
Darwinian evolution ought to be revised by considering phenotype. In 1940, he 
formulated a theory called canalization, to explain reciprocal internal and external 
interactions between environment and phenotype on the one hand (nurture) and genotype 
and phenotype on the other (the nature of nature)[221]. Waddington proposed a dynamic 
model of evolution, introducing the concept of an "epigenetic landscape" to represent the 
process of cellular decision-making during development[222]: his epigenetic landscape can 
be seen as a metaphor for how gene regulation modulates development. At various points 
in this dynamic visual metaphor, a heritable phenotype (a cell or a nucleus), depicted by a 
ball rolling down a hillside, can take specific permitted trajectories, leading to different 
outcomes or cell fates[223]. Waddington portrayed this epigenetic landscape as a tilted, or 
rather undulated, surface, which is tilted so that points representing late states are lower 
than those corresponding earlier ones (Fig. 1.2). The surface presents with a cascade of 
branching ridges and valleys (the environment), called creodes, which in the context of 
cell lineage selection, represent the series of either/or fate choices made by the 
developing cell. Therefore, a creode represents the developmental pathway followed by a 
cell as it grows to form part of a specialized organ. In the case of a pathway or a creode, 
which is deeply carved in the hillside, external disturbance is unlikely to prevent normal 
development. When progression may undergo alteration by external forces, the embryo 
so attempts to regulate its growth and differentiation by returning to its normal 
developmental trajectory. Small differences in placement atop the hill can lead to 
dramatically different results by the time the ball reaches the bottom. This represents the 
tendency of neighboring regions of the early embryo to develop into different organs 
with radically different structures. Since intermediate structures rarely exist between 
organs, each ball that rolls down the hill is canalized to a region distinct from the others.  
Moreover, the formation of the body depends not only on its genetic makeup, but also by 
the different ways genes are expressed in different regions of the embryo. The more 
deeply creodes are carved into the epigenetic landscape, the weaker is the influence of 
genes over development[224]. 
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Waddington then envisioned that on this landscape the presence or absence of particular 
genes acts by determining which path should be followed from a certain point of 
divergence, thus providing in a single image an appealing, and influential, metaphor for 
the connection between genotype and phenotype. Successive generations of the same 
phenotype will tend to seek the same path and the phenotype will become fixed, or 
canalized regardless of the variability of its environment or genotype[225].  
 
The question of whether the epigenetic landscape can be mapped out quantitatively to 
provide a predictive model of the directionality of the cellular differentiation remains 
largely unanswered. In the '70s, the mathematician René Thom tried to interpret the 
undulating surface of the landscape, although after several studies he considered it was 
impossible[226]. 
Wang and colleagues have then proposed a probabilistic method to quantify the 
epigenetic landscape for a gene network regulating cell fate, where the elevation of the 
surface is inversely related to the likelihood of occurrence of a particular state[227-228]. 
More recently, a rigorous quantification of the gene regulatory circuits that govern cell 
lineage choice was studied and a subsequent mapping of the epigenetic landscape was 
created that could potentially help identify optimal routes of cell fate reprogramming[229]. 
 
Fig. 1.2: Epigenetic landscape[222] 
 
1.2.1.2 Origins and definitions. The history of epigenetics is linked with the study of 
evolution and development. During the past 50 years, the meaning of the term 
"epigenetics" has itself undergone an evolution that parallels the impressive rate to which 
knowledge has increased to unveil the molecular mechanisms underlying regulation of 
gene expression in eukaryotes. Present definitions of epigenetics reflect the 
understanding that although the complement of DNA is essentially the same in all of an 
organism's somatic cells, patterns of gene expression differ may greatly differ among cell 
types, and these patterns can be clonally inherited[230]. 
It is now widely accepted that one of the most effective and investigated epigenetic 
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changes, among others, is methylation of cytosine residues; however this was a colossal 
step to take at the beginning of the epigenetic studies. Historically in fact, DNA 
methylation was described in mammals as early as DNA, although his biological 
meaning was not immediately evident[231-232]. Later, Hotchkiss first described two 
different bands in a preparation of calf thymus using paper chromatography: one for 
cytosine and a band for "modified cytosine"[233]. He reconciled this evidence by 
hypothesizing that this second band was 5-methylcytosine, as it separated from cytosine 
band in a manner that was similar to how thymine separated from uracil, and he further 
suggested that this modified cytosine naturally existed in DNA. At this time, however the 
term epigenetic modification was still not in use.  
In 1942, Waddington introduced the term "epigenetics" as a refinement of his conception 
of the "epigenetic landscape", to denote a phenomenon that conventional genetics could 
not explain[234]. 
The prefix "epi-" is derived from the Greek preposition ἐπι, meaning above, on, or over. 
This word  derived from the Aristotelian word "epigenesis" and it was used to describe 
events that could not be explained by genetic principles and literally means "in addition 
to changes in genetic sequence",  in order to study the processes by which genotypes give 
rise to phenotypes. Waddington coined this term defining epigenetics as "the branch of 
biology which studies the causal interactions between genes and their products, which 
bring the phenotype into being" and it involves understanding chromatin structure and its 
impact on gene function[235]. The term epigenetics was originally used to denote the 
poorly understood processes by which a fertilized zygote developed into a mature, 
complex organism, and in fact, the Waddington's definition was rooted exclusively in 
embryology and developmental biology[236].   
Until the 1950s, the word "epigenetics" was used more broadly and less precisely to 
categorize all of the developmental events leading from the fertilized zygote to the 
mature organism, that is, all of the regulated processes that, beginning with the genetic 
material, shape the final product[237]. 
In 1958, David Nanney, revisiting Waddington's theory, suggested the hypothesis about a 
cellular epigenetic control system. This system has been involved in determining cellular 
characteristics and the term epigenetic was chosen to emphasize the reliance of these 
systems on the genetic systems and to underscore their significance in developmental 
processes. Certain patterns of expression, although specifically induced, may be 
perpetuated in the absence of the inducing conditions. Some epigenetic systems show a 
wide range of stability characteristics and the cellular memory may be heritable. For this 
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reason, cells with the same genotype may not only manifest different phenotypes, but 
these differences' in expressed potentialities may persist indefinitely during cellular 
division. Nanney also hypotized epigenetic devices may be localized in the nucleus and 
on the chromosomes, like the genetic system[238].  
Two years later, Salvador Luria firstly defined epigenetics in cellular manner. The most 
important distinction is between genetic and epigenetic mechanisms of cellular 
alteration[239]. Luria in fact wrote: "A change is defined as genetic (or nucleic) if it alters 
the genetic materials of the cell, that is, the structure, size, or number of the coded 
macromolecules -nucleic acids- that carry large amounts of detailed information usable 
for coding other molecular species. Epigenetic (or epinucleic) changes are changes in 
the expression of genetic potentialities, such as activations, inhibitions, or competitive 
interactions, whether exerted at the level of primary action of genetic elements or at 
other levels of cellular metabolism"[240]. 
In 1969, Griffith and Mahler suggested that modifications of DNA bases may modulate 
gene expression and that DNA methylation may be important in long-term memory 
function[241], and although many researchers then proposed DNA methylation as a 
regulation mechanism, it was not until the 1980s that several studies showed that this 
epigenetic alteration was involved in gene regulation and cell differentiation[242].  
At the time of Waddington's experiments, genetics was an infant field, and little 
knowledge of the genome and its biology existed. The field of epigenetics has grown 
during the last decades, surely motivated by the increasing knowledge on DNA 
molecular biology, gene regulation, and many related aspects. Thus, over the following 
years, with the rapid growth of genetics, the meaning of the word epigenetics has 
gradually narrowed and been refined. Hence, Holliday and Plough proposed, among 
others, the methylation of cytosine-guanine (CpG) dinucleotide rich regions of the 
DNA[243], as the biochemical basis of epigenetic regulation of gene expression, showing 
that gene expression can be either entirely stopped or increased in total absence of 
evident or detectable changes (mutations) of the basic DNA structure of the genes. In 
1987, Holliday then demonstrated the inheritance of epigenetic defects in a malignant 
cell and explained the "epimutation" concept, to describe a mutation that alters the DNA 
activity without changing its chemical sequence. Now it is known that the control of gene 
expression in higher organisms is related to the methylation of cytosine in DNA and 
requires that the patterns of methylation become inherited. Loss of methylation, which 
can result from DNA damage, will lead to heritable abnormalities in gene expression, and 
these may be important in oncogenesis and aging. Transformed permanent lines often 
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lose gene activity through de novo methylation. Epigenetic defects in germline cells due 
to loss of methylation can also be repaired by recombination at meiosis but some are 
transmitted to offspring[244]. In the attempt to refine further the concept, epigenetics has 
been defined and it was generally accepted as "the study of changes in gene function that 
are mitotically and/or meiotically heritable and that do not entail a change in DNA 
sequence"[245]. Most of the heritable epigenetic changes are established during 
differentiation and are stably maintained through multiple cycles of cell division and 
reverberate on multiple generations[246]. This enables the daughter cells to have distinct 
identities while containing the same genetic information. This heritability of gene 
expression patterns mediated by epigenetic modifications is collectively referred to as the 
"epigenome". It provides a mechanism for cellular diversity by regulating what genetic 
information can be accessed by cellular machinery. Failure of the proper maintenance of 
heritable epigenetic marks can result in inappropriate activation or inhibition of various 
signaling pathways and lead to disease states such as cancer[247].  
The discovery that epigenetic (or functional) modulation of gene expression is dependent 
on the environment, can give rise to is stable changes, and can these might be transmitted 
from one generation to the next, has opened a completely new perspective in the study of 
the interactions between environment and human genome. This appears as the way to 
ultimately clarify how gene-environment interaction leads to the development of many 
different human diseases, including cancer. Epigenetics investigates the causative 
mechanisms through which genes bring about their phenotypic effects that necessarily 
involve adaptive interaction with the environment. One of the most recent definitions of 
epigenetics quotes: "an emerging branch of investigation in cancer research (but also in 
other fields of clinical pathology) which studies the interactions between environment 
and genome in determining disease"[248]. 
More recently, the term has been used to refer to any potentially stable and heritable 
change in gene expression or cellular phenotype that occurs without changes in Watson-
Crick base pairing of DNA[223]. In a broad sense, epigenetics is considered a bridge 
between genotype and phenotype; a phenomenon that changes the outcome of a locus or 
chromosome without changing the underlying DNA sequence. It is clear therefore that 
the definition of epigenetics has evolved over time following the flight of new evidences 
that would implicate it in a wide variety of biological processes and it has temporarily 
landed to indicate the study of cellular and physiological phenotypic trait variations that 
result from external or environmental factors that switch genes on and off and affect how 
cells express genes[249]. 
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Epigenetics has morphed from a phenomenon to a branch of science whose molecular 
underpinnings are now reasonably well understood. The current state of knowledge of 
epigenetics has in fact evolved to include the understanding of DNA methylation, 
chromatin modifications, non-coding RNA and their effects on gene expression[234]. 
The current definition of epigenetics is indeed "the study of heritable changes in gene 
expression that occur independent of changes in the primary DNA sequence"[250].  
 
Even though the vast majority of cells in a multicellular organism share an identical 
genotype, organismal development generates a diversity of cell types with disparate, yet 
stable, profiles of gene expression and distinct cellular functions. It is noteworthy 
therefore that even cellular differentiation may be considered an epigenetic phenomenon, 
largely governed by epigenetic changes rather than alterations in genetic inheritance.   
For this, over the years, numerous biological phenomena have been lumped into the 
category of epigenetics. These include seemingly unrelated processes, such as 
paramutation in maize, type switching in yeast, position effect variegation in the fruit fly 
Drosophila and the discordant course of disease in identical twins.  
 
 
1.2.2 Epigenetic mechanisms 
 
1.2.2.1 Chromatin structure and function. Chromatin is the complex of conserved 
histone proteins and genomic DNA that makes up chromosomes and it is tightly bundled 
to fit into the nucleus. Namely, it is made of repeating units of nucleosomes, which 
consist of 146-147 base pairs of DNA wrapped around a histone octamer formed by four 
histone partners, an H3-H4 tetramer and two H2A-H2B dimers proteins[251]. Each 
octamer contains two units of each principal or variant histone[252]. Histones are small 
basic proteins rich in amino-acids lysine and arginine. The four nucleosomic histones 
involve two domains: the C-terminal domain, which is located inside the nucleosome 
core, and the N-terminal domain with lysine residues extending out of the nucleosome. 
Among the four amino-terminal tails extending from the globular region of the histones, 
H3 and H4 become accessible and they are targeted for various post-translational 
modifications, such as acetylation, methylation, phosphorylation, and ubiquitination[253-
254]. Linker DNA connecting nucleosomes associates with the main form or variants of 
the linker histone H1.  
Chromatin structure defines the state in which DNA information is organized within a 
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cell. Histone modification can in fact subsequently affect DNA processes, such as 
transcription, DNA repair and replication, and chromosomal organization. This 
arrangement of the genome into a precise compact structure greatly influences the 
abilities of genes to be activated or silenced[250]. Epigenetic modifications can modulate 
gene expression in physiological mammalian development, occurring not just in the 
womb, but also over the full course of a human life span. These modifications are 
heritable and reversible, and determine cell-type and tissue specificity during cell growth 
and the development of an organism. Critical examples of epigenetic regulation in 
eukaryotic biology are indeed the process of cellular differentiation and development of 
germ cells. 
Epigenetic changes work together to regulate the functioning of the genome by altering 
the local structural dynamics of chromatin, primarily regulating its accessibility and 
compactness. The interplay of these modifications creates an epigenetic landscape that 
regulates the way the mammalian genome manifests itself in different cell types, 
developmental stages and diseases[255].  
During morphogenesis, cells start in a pluripotent state, from which they can fully 
differentiate into many cell types, and progressively falls into a state of narrower 
potential, by activating some genes while inhibiting the expression of others. Their gene-
expression programs become more defined, restricted and, potentially, "locked in"[256]. 
Therefore, epigenetic changes regulate gene expression so defining cellular identity. 
These modifications form the basis of cellular differentiation, imposing memories upon 
the cells that determine both lineage specification and potential for production of specific 
cell types[257].  
 
As a consequence it is not difficult to accept how epigenetic changes could be strongly 
implicated a wide variety of major pathological conditions, such as several kind of 
tumors, schizophrenia and reproductive, autoimmune, or neuro-behavioral illnesses, 
mental retardation[258], and other health threatening conditions, such as alcoholism, 
obesity and cognitive dysfunctions. The abnormal gene expression profile in fact alters 
the cellular identity and contributes to the switch into a malignant phenotype.  
Recognized or suspected drivers behind epigenetic processes include many agents, such 
as heavy metals pollution, exposure to pesticides, diesel exhaust, tobacco smoke, 
polycyclic aromatic hydrocarbons, radioactivity, viruses, bacteria and solicitations from 
hormones basic nutrients[251].  
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Epigenetic mechanisms that modify chromatin structure can be divided into some main 
categories: 1) DNA hyper-/hypo-methylation, 2) covalent histone modifications, like 
acetylation and methylation, 3) non-covalent histone mechanisms, such as incorporation 
of histone variants and nucleosome remodeling and 4) non-coding RNAs, including 
miRNAs. 
The interactions between these mechanisms, especially DNA methylation machinery and 
histone modifying enzymes, determine the complexity of epigenetic regulation of gene 
expression, chromatin organization and cellular identity[259]. 
  
1.2.2.2 DNA methylation. DNA methylation is perhaps the best-characterized chemical 
stable and heritable modification of chromatin.  
It results from the transfer of a methyl group (-CH3) from a methyl donor substrate, 
namely S-adenosyl-L-methionine (AdoMet), to a cytosine in a CpG context. This 
addition of the methyl group is almost exclusively found on the 5'- position of the 
pyrimidine ring of cytosines (5mC) adjacent to a guanine, predominantly where these 
bases occur consecutively. Although methylation of cytosine bases in mammalian DNA 
has been primarily described in the context of CpG dinucleotides[260], evidence suggested 
that cytosines in non-CpG sequences are also frequently methylated, especially in 
embryonic stem cells[261].  
Other rare modifications in mammalian DNA are methylation of adenine and guanine 
bases[262]. 
DNA methylation is a covalent modification of nucleic bases that can confer stable 
silencing and, thus, transcriptional repression[263] of repetitive elements, imprinted genes, 
X chromosome in females[264]. It is noteworthy to mention that these alterations are 
mediated by a group of highly conserved enzyme called DNA methyltransferases 
(DNMTs).  
 
Roughly 70% of cytosine residues of all CpG dinucleotides undergo covalent 
methylation in mammals[265] and their patterns occur in gene regulation and chromatin 
organization during embryogenesis and gametogenesis. Most of the CpG dinucleotides 
sites in mammalian genome, especially the repetitive DNA elements, transposons, CpG 
poor intergenic regions and imprinted gene promoters, are scattered throughout bulk 
chromatin[266]. They are generally heavily methylated, accompanied by repressive histone 
marks, which together determine a silent chromatin state[267] that contributes to the 
transcriptional repression. In many organisms, the formation of heterochromatin, the 
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tightly packed and inactivated form of DNA, is therefore mediated in part by methylated 
DNA and the proteins bound to it, in combination with RNA and histone modifications. 
Most genomes with high levels of DNA methylation are depleted of CpGs due to the 
frequent deamination of 5-methylcytosine into thymidine. This generates mCpG:TpG 
mismatches which, if unrepaired, are further stabilized by DNA replication[268]. 
However, CpG dinucleotides are not evenly distributed across the human genome, but 
are concentrated in short CpG-rich DNA stretches and regions of large repetitive 
sequences[269]. These regions have a high density of unmethylated dinucleotide CpGs and 
they are referred to as "CpG islands". Approximately 15% of the CpG dinucleotides are 
in CpG islands, often found in the promoters of both "housekeeping" genes and tissue 
specific genes[265]. Apart from the inactivated X chromosome and imprinted genes, CpG 
islands are normally unmethylated, at least in germ cells, and perhaps throughout the 
developing and adult organism[270] for most CpG islands. Therefore, most mammalian 
gene promoters are embedded within CpG islands that remain unmethylated during 
normal development and in differentiated tissues[271]. When active, as in the case of 
tumor suppressor genes, they are accompanied by active histone marks allowing for a 
transcriptionally active open chromatin structure.  
Tissue specific genes with non-CpG island promoters have been shown to exhibit tissue 
specific methylation[272]. CpG islands can become methylated in normal adult tissues and 
this phenomenon may be related to age[273].  
The decreased occurrence of CpGs is best explained by the fact that methylated cytosines 
are mutational hotspots[274] leading to CpG depletion during evolution.  
The first large-scale computational analysis of CpG islands using vertebrate sequences in 
GenBank was performed in the '80s by Gardiner-Garden, who defined a CpG island as 
being a 200 bp-5kb regions of DNA with a high GC content (greater than 50%) and an 
observed to expected ratio (ObsCpG/ExpCpG) of CpG greater or equal to 0.6[275]. The 
exact definition of what constitutes a CpG island is somewhat arbitrary because the 
cutoffs for the parameters used to describe them can make significant differences to what 
sequences are included within the definition[269]. 
Embryonic stem cells, the pluripotent stem cells derived from the blastocyst of early 
mammalian embryos, undergo bimodal distribution pattern of DNA methylation: they 
present a global CpG methylation, whereas their CpG islands and pluripotency gene 
promoters are mostly unmethylated.  
An extensive epigenetic reprogramming, mainly due to DNA demethylation, leads to the 
conversion of germ cells into immortal cells that can pass on the genome to the next 
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generation during early embryotic development. In the absence of germline-specific 
reprogramming, germ cells would preserve the old, parental epigenetic memory, which 
would prevent the transfer of heritable information to the offspring.  
Furthermore, a large number of experiments have shown that methylation of promoter 
CpG islands is involved in many cellular processes during development, which results in 
long-term transcriptional silencing, including autosomal imprinting and X chromosome 
inactivation in female mammals[276]. These are classic examples of such naturally 
occurring CpG island methylation during development[277] and all of them seem to be 
stably maintained.  
Taken together, DNA methylation of CpG clusters, located in the promoter regions of 
genes, gives a stable, heritable, and critical component of epigenetic regulation[223], 
correlating with transcriptional repression[278]. It so provides a stable gene silencing 
mechanism that plays an important role in regulating gene expression and chromatin 
architecture, in association with histone modifications and other chromatin associated 
proteins. 
 
Somatic cells show tissue-specific methylation of some CpG islands, occurring at 
developmentally important genes[279]. Most non-CpG island promoters are also 
methylated together with pluripotency gene promoters, however these cannot reset 
epigenetic information by preserving the full methylation pattern on imprinting genes.  
On the other hand, several in vivo studies showed that germline undergoes extensive 
epigenetic regulation, and thus genomic reprogramming[280]. In contrast, the repetitive 
genomic sequences that are scattered all over the human genome are heavily methylated, 
which prevents chromosomal instability by silencing non-coding DNA and transposable 
DNA elements[267]. DNA methylation can lead to gene silencing by either preventing or 
promoting the recruitment of regulatory proteins to DNA. Alternatively, it can provide 
binding sites for methyl-binding domain proteins, which can mediate gene repression 
through interactions with histone deacetylases[281].  
Pluripotent stem cells express genes that encode a set of core transcription factors, while 
genes that are required later in development are repressed by histone marks: this 
mechanism confers short-term, and therefore flexible, epigenetic silencing. By contrast, 
the methylation of DNA confers long-term epigenetic silencing of particular sequences in 
somatic cells. Long-term silencing can be reprogrammed by demethylation of DNA, and 
this process might involve DNA repair[256].  
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DNA methylation may exert its repressive effect on gene transcription in two ways: on 
one hand, methylation of CpG in the promoter region impedes the binding sites of 
specific transcription factors and directly interferes with gene activation[282], while on the 
other hand, methylated cytosines attract mediators of chromatin remodeling, such as 
histone-modifying enzymes or other repressors of gene expression. CpG islands serve as 
docking sites for proteins that specifically recognize these binding sites and repress 
transcription indirectly, via recruitment of co-repressors that modify chromatin[283]. It is 
evident therefore that the inhibitory effect of CpG island methylation on gene expression 
can reverberate throughout the involvement of proteins with high affinity for methylated 
CpGs towards additional proteins that eventually contribute to changing the chromatin 
structure. A pivotal role in gene modulation is therefore played by cellular machinery 
that regulates the methylated state of CpG residues: the enzymatic family of DNA 
methyltransferases and the methyl CpG-binding proteins.  
 
DNA methyltransferases (DNMTs) is a family of nuclear enzymes and they catalyze 
DNA methylation[284-286] (Fig 1.3).  
The precise DNA methylation patterns found in the mammalian genome are generated 
and heritably maintained by the cooperative activity of the maintenance or de novo 
methyltransferases, playing a role in gene regulation and chromatin organization. 
Maintenance methyltransferases add methyl groups to hemi-methylated DNA during its 
replication, whereas de novo DNMTs act after DNA replication. Changes in DNMTs 
function may result in a gain or loss of DNA methylation, often found in altered patterns 
associated with cancer. In general, the mammalian DNMTs (DNMT1, DNMT2, 
DNMT3A and DNMT3B), in conjunction with accessory proteins (DNMT3L), are 
responsible for DNA methylation during gametogenesis, embryogenesis and somatic 
tissue development[287]. DNMT1 is the most abundant DNA methyltransferase and is 
considered the key maintenance hemi-methyltransferase in mammals[288], which acts 
residing at the replication fork and copying DNA methylation patterns at hemi-
methylated DNA onto the newly synthesized strand[289]. It can ensure the mitotic 
inheritance of methylated DNA bases throughout the life of the organism. Moreover, its 
inactivation did not affect global methylation in cancer and it may be responsible for both 
de novo and maintenance methylation of tumor suppressor genes.  
In contrast, DNMT3A and DNMT3B are responsible for the de novo methylation of 
unmethylated DNA sites[290]; they are associated with nucleosomes and expressed mainly 
in early embryonic development, for imprinting and X-chromosome inactivation. They 
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act independent of replication, methylating newly replicated DNA, but they may also 
assist in maintaining methylation patterning at highly methylated genomic regions[291] 
and interact with HDACs, targeting them to heterochromatin. Various studies have 
shown that DNMT3A and DNMT3B target different sites for methylation depending on 
the cell type and the stage of development[292]. De novo methyltransferases may be 
directly targeted to specific DNA sequences, may necessitate the interaction with other 
DNA binding proteins or may be guided by RNA interference (RNAi) in a process called 
RNA-directed DNA methylation (RdDM)[282]. Inhibition of DNMT3B reduces overall 
global methylation, with demethylation being markedly potentiated when both DNMT1 
and DNMT3B are simultaneously deleted[293]. 
DNMT3L has no enzyme activity and is not a methyltransferase, but it has a similar 
expression pattern to DNMT3A and DNMT3B[294]. 
 
Fig. 1.3: DNMT enzyme[286] 
 
Methyl CpG-binding proteins exert their function as transcriptional repressors via 
chromatin modification and they are often part of large repressor complexes as NuRD, 
NoRC, mSin3A and SWI-SNF. They recognize methylcytosine residues and a subset 
may biochemically recruit transcriptional repressor complexes, including histone 
deacetylase enzymes[295-298], suggesting an indirect repressive effect of DNA methylation. 
These proteins present a highly conserved DNA interaction surface, termed the methyl 
CpG-binding domain or MBD.  
Currently two major families of methyl-CpG binding proteins are known in vertebrates: 
MBDs and Kaiso-like proteins, that both recognize more complex sequences than a 
single methylated CpG, thus favoring a gene or locus specific role for each member.  
 
MBDs family proteins are classified as MeCP2, MBD1, MBD2, MBD3 and MBD4[299] 
and they are highly conserved in all vertebrates[300]. MeCP2 was discovered at first and 
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represents a 53 kDa protein containing an N-terminal methyl-CpG binding domain 
(MBD) and a C-terminal transcriptional repression domain (TRD)[281]. It is noteworthy 
how MeCP2 is now widely known to be strictly associate with Rett syndrome, a girl 
afflicting mental retardation arising after birth in the child phase of development. This 
syndrome is one of the epigenetic diseases, such as X-fragile syndrome in which the 
cause is a malfunction of methylation machinery[301]. 
All MBD proteins, except MBD3, specifically recognize and bind to methylated DNA in 
vitro and in vivo[283].  
 
Kaiso-like family was discovered a DNA binding factor involved in non-canonical Wnt 
signaling[302] and as a protein that binds to methylated DNA[286]. Kaiso and the two 
recently identified Kaiso-like proteins ZBTB4 and ZBTB38 contain a conserved POZ 
domain involved in protein-protein interactions and three C2H2 zinc finger motifs, two 
of which are essential for binding to methylated DNA[303]. In addition, in some 
circumstances these proteins may bind to even unmethylated DNA[304].  
 
1.2.2.3 Chromatin Variations. In addition to methylation at CpG islands in DNA, 
another significant epigenetic processes occurring during embryonic development and in 
somatic cells contribute to chromatin modification. The chromatin complex can be 
modified by introducing acetyl- groups (acetylation), enzymatic proteins and other 
nucleic acid in forms of RNAs. These changes alter the way chromatin is arranged, 
which, in turn, can determine whether the associated chromosomal DNA will be 
transcribed, influencing gene expression. In general, tightly folded chromatin, also 
known as condensed or hetero- chromatin, tends to be shut down, and remain not 
expressed, while more open chromatin is functional and is associated DNA that can be 
transcribed[305]. Histone variations work by either changing the accessibility of chromatin 
or by recruiting and/or occluding non-histone effector proteins, which decode the 
message encoded by the modification patterns. Their specific patterns are present within 
distinct cell types and are proposed to play a key role in determining cellular identity[306].  
Chromatin plays a key role in regulating transcriptional activity and any modification in 
these core histone proteins can have an impact in the activation and/or repression of the 
transcriptional process[287]. Such modifications product highly positively charged histone 
tails that can strongly interact with the negatively charged DNA making it inaccessible 
for the transcriptional machinery[307]. Alternatively, modified histone tails can create an 
interface for the recruitment of transcription factors.  
54 
An innovative epigenetic strategy for retinoblastoma treatment 
There is an apparent interdependence between DNA methylation and histone 
modifications (i.e. methylation, acetylation etc.), that regulates genome-wide changes in 
chromatin structure and transcriptional regulation[308] acting as a key mechanisms in cell 
fate, including malignant transformation[223].  
To date, the best-characterized modifications are acetylations and methylations of lysine 
residues on histones H3 and H4[276]. In particular, histone H3 modifications are notorious 
for affecting transcriptional activity[309] and they can be considered as epigenetic 
biomarkers, and can be further exploited as powerful clinical tools in cancer diagnosis, 
prognosis and risk assessment[310]. 
 
Chromatin modifications can be divided into two main groups, depending on the 
chemical interactions, and these covalent and non-covalent mechanisms could be 
mechanistic linked each other.  
 
Covalent modifications affect histone proteins that contain a globular C-terminal domain 
and an unstructured N-terminal tail[311]. Histone can receive a variety of posttranslational 
histone modifications (PHMs), including acetylation, methylation, ubiquitylation, 
sumoylation and phosphorylation on specific amino acid residues on histones. Therefore, 
histone tails may undergo a number of covalent modifications, and it is thought that the 
conserved transfer of these posttranslational modifications between cell generations is 
essential for epigenetic inheritance.  
 
An important histone modification is the acetylation of lysine residues at the N-terminal 
region of histones (mainly H3), which regulates whether chromatin is in the open or 
closed formation. This chemical process adds an acetyl- group to the amino acid lysine 
and is usually associated with active de-condensed chromatin and correlates with 
transcriptional activation[252]. Acetylated lysines provide in fact an open chromatin 
conformation, whereas deacetylated lysines are generally associated with 
heterochromatin and inhibit transcription[312].  
 
Histone methylation is involved in several biological processes, including DNA repair, 
cell cycle, stress responses, development, differentiation, and aging. A prominent histone 
modification is the transfer of one, two, or three methyl groups to lysine or arginine 
residues of histone H3[313]. These variations in charge due to these modifications can 
directly alter the physical properties of the chromatin fiber, leading to changes in higher-
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order structures; specific distribution patterns of histone marks in fact contribute to 
chromatin organization. Any change in histone methylation can alter any one of these 
biological functions, resulting in the development of disease[314].  
During embryonic development, stem cells present a bivalent domain structure, 
consisting of the active and repressive methylation state and thus showing a coexistence 
of active and repressive marks at site of promoters of developmentally important genes 
and a plastic genome. On the contrary, somatic cells in normal conditions present a 
restricted epigenome and tissue-specific domains. Methylation of lysine (K) or arginine 
(R) in histone proteins alters the compaction or relaxation of chromatin depending on the 
position of amino-acidic residues and the number of methyl groups[315]. For instance, 
active promoters are enriched in trimethylated histone H3 at K4 and active enhancers are 
enriched in monomethylated H3 at K4 and acetylated H3 at K27. In contrast, repressed 
promoters are enriched in methylated H3 at K27 (H3K27me) and K9, that inhibits gene 
transcription, marks silent DNA and it is widely distributed throughout 
heterochromatin[316]. This is the type of epigenetic change that, together with DNA 
hypermethylation, is responsible for the inactivated X chromosome of females. These 
histone modifications regulate key cellular processes such as transcription, replication 
and repair[252].  
 
Covalent histone modifications are dynamically regulated by enzymes that add and 
remove chemical groups to histone proteins. This variety of histone-modifying enzymes 
is then responsible for a multiplicity of posttranslational modifications on the specific 
amino-acid residues on histones[317]. These modifications are almost reversible reactions 
and play a significant role in the regulation of transcription[318].  
 
Histone acetyltransferases (HATs) are enzymes that acetylate lysine amino acids on 
histones by transferring an acetyl group from acetyl-CoA to form acetyl-lysine. There are 
many forms of these enzymes, such as HAT p300, CREB-binding protein (CBP), 
P300/CBP-associated factor (PCAF), and general control of amino acid synthesis protein 
5 (GCN5). They all play a potential pathological role in asthma, chronic obstructive 
pulmonary disorder (COPD), and different types of cancers as well as learning and 
memory deficits[319-320]. It is thought that HAT p300 and CBP regulate expression of 
tumor suppressor and promoter genes, and PCAF and GCNF perform global acetylations 
and non-histone acetylations. GCNF is also crucial in cell-cycle progression, which is 
significant in cancer therapies[320]. HATs p300 and PCAF often induce increased gene 
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transcription in airway inflammation disorders such as asthma and COPD, leading to 
excessive expression of inflammatory genes.  
 
Histone deacetylases (HDACs) are enzymes that remove acetyl- groups from an acetyl-
lysine that resides within the NH2-terminal tail of core histones, allowing the histones to 
wrap the DNA more tightly (Fig. 1.4). To achieve proper development and function, it is 
essential to not only acetylate and open certain regions of chromatin, but also to 
deacetylate and close other regions of the genome. HDACs are involved in the regulation 
of integrated cellular functions in the nucleus and cytoplasm. Hence, HDACs lead to 
heterochromatin and gene silencing and work in concert with co-activators, corepressors, 
transcription factors and HATs to change the structure of histones and modulate 
transcription of genes[322]. 
So far, eighteen HDACs have been identified in humans, which are subdivided into four 
structurally and functionally different phylogenetic classes.  
Class I HDACs are zinc-dependent proteases, mostly localized within the nucleus and 
they involve in cellular growth and development, especially playing a role in cell survival 
and proliferation[323]. They remove acetyl groups from specific lysine residues on 
histones in the nucleosome. This modification affects how tightly DNA is wound around 
the histone structure, thus HDAC-mediated modifications can lead to induction of gene 
silencing[324]. Class I HDACs are also implicated in regulation by a process involving the 
methylation of CpG residues in upstream promoter regions of silenced genes. When these 
CpG residues are methylated, methyl domain-binding proteins (MDBP) actively recruit 
HDACs (mainly HDAC I, II, and III) to the histone, further inhibiting gene 
transcription[325].  
Classes II HDACs are as well zinc-dependent proteases, shuttle between nucleus and 
cytoplasm and they are involved in cellular growth and development, in particular with 
tissue-specific roles[326]. They are able to shuttle back and forth between the nucleus and 
cytoplasm and to remove acetyl groups from proteins other than histones[327]. 
Class III HDACs, also known as sirtuins, are mainly involved in metabolic processes and 
require the cofactor NAD+ for their deacetylase function. They and are not targeted by 
the currently available HDAC inhibitors[328]. Additionally, several sirtuins are known to 
regulate ATP production while others are known to protect against tumorigenesis during 
oxidative stress.  
Class IV is a zinc-dependent protease, comparatively new and less investigated. 
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Fig. 1.4: HDAC enzyme[286] 
 
Together HATs and HDACs define the pattern of histone acetylation. It has been 
proposed that histone modifications, acting alone, sequentially, or in combination, 
represent a "code" that can be recognized by non-histone proteins, which form complexes 
that are important for regulation of gene transcription[329]. These enzymes do not bind to 
DNA directly, but rather interact with DNA through multiprotein complexes that include 
corepressors and coactivators[330]. Class I and class II HDACs form multiprotein 
complexes containing transcription factors with diverse functions[33]. 
 
Other two kind of histone-modifying enzymes are histone methyltransferases (HMTs) 
and histone demethylases (HDMs) that add or remove methyl groups, respectively[332].  
 
These histone-modifying enzymes interact with each other as well as other DNA 
regulatory mechanisms to tightly link chromatin state and transcription. They may be 
targeted to specific DNA sequences directly[281] or necessitate the interaction of 
intermediate group proteins[333] and/or RNAi[334]. In contrast to DNA methylation, it is 
still unclear how and if histone modifications are correctly replicated during mitosis, and 
as a result, it should be questioned whether covalent histone modifications are epigenetic 
marks[276]. 
 
Non-covalent mechanisms, such as nucleosome remodeling and replacement of canonical 
histone proteins with specialized histone variants, are labile epigenetic regulatory 
mechanisms and provide the cell with additional tools for introducing variations into the 
chromatin structure.  
In addition to serving as the basic modules for DNA packaging within a cell, 
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nucleosomes act as ATP-mediated chromatin-remodeling complexes. Both the sliding of 
already existing and incorporation of new nucleosomes may regulate gene expression by 
altering the accessibility of regulatory DNA sequences to transcription factors[255]. 
Precise positioning of nucleosomes around gene promoters[335] correlates with either gene 
silencing or gene activation by modulating chromatin accessibility[336].  
The interaction of nucleosome remodeling machinery with methyl CpG-binding protein 
MeCP2   and histone methyltransferases plays a crucial role in establishing global gene 
expression patterns and chromatin architecture[337]. 
In addition to physical alterations in nucleosomal positioning via nucleosome 
remodelers, the incorporation of histone variants, e.g. H3.3 and H2A.Z, into nucleosomes 
also influences nucleosome occupancy and thus gene activity[338]. Unlike the major 
histone subtypes whose synthesis and incorporation is coupled to DNA replication in S 
phase, these variants are synthesized and incorporated into chromatin throughout the cell 
cycle[339]. H3.3 and H2A.Z are preferentially enriched at promoters of active genes or 
genes poised for activation and can mediate gene activation by altering the stability of 
nucleosomes[340]. H2A.Z incorporation may also contribute to gene activation by 
protecting genes against DNA methylation[341]. Acetylated H2A.Z associates with 
euchromatin and ubiquitylated H2A.Z with facultative heterochromatin. Like canonical 
histones, histone variants undergo various posttranslational modifications, which 
determine their nuclear localization and function[250]. 
 
1.2.2.4 Non-coding RNAs. It is debatable whether the role of non-coding (ncRNAs) 
constitutes an epigenetic phenomenon. Some researchers will claim that non-coding 
RNAs are a fundamental part of nature coding and do not satisfy the definition of 
epigenetics. However, the majority of them feel that since ncRNAs do indeed affect 
regulation of genes, they are a bona fide mechanism of epigenetic change[315]. The family 
of ncRNAs is diverse and complex. It can be divided into eight groups: ribosomal 
(rRNAs), transfer (tRNAs), micro (miRNAs), long non-coding (lncRNAs), small 
nucleolar (snRNAs), small interfering (siRNAs), small nuclear RNAs (snRNAs) and 
piwi-interacting (piRNAs). In general, ncRNAs are important epigenetic regulators in 
development and disease, especially miRNAs and lncRNAs.  
DNA information is transcribed into RNA molecules, of which only about 3% are 
translated into proteins through with messenger RNA (mRNA); the remaining is 
considered ncRNAs. Some of these ncRNAs are functional molecules, such as rRNAs 
and tRNAs, which play different roles in mRNAs translation, and snRNAs, which are 
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involved in RNA splicing. Other ncRNAs are instead implicated in gene regulation, by 
tampering with different phases of the full process, including mRNA expression, 
maturation, degradation and translation[342]. Regulatory ncRNAs might affect gene 
expression by altering chromatin conformation[343], or by triggering histone modifications 
and DNA methylation[258] and thus, they are involved in controlling multiple epigenetic 
phenomena, in almost all eukaryotes.  
 
miRNAs are short non-coding RNA sequences (21-25 single-stranded nucleotides) that 
regulate gene expression by targeting specific mRNAs for degradation. In particular, they 
act binding to complementary sequences in the 30 UTR of multiple target mRNAs, 
leading to translational repression (imperfect sequence match) or mRNA cleavage 
(perfect match)[313]. It has been recently discovered that they can also recruit chromatin-
modifying factors, altering chromatin conformation[344].  
Since the first miRNA was characterized in 1993, an increasing number of other 
miRNAs have been identified. Altered expression profiles of miRNAs in patients 
revealed their crucial role in cellular events and the development of diseases[345].  
They are expressed in a tissue-specific manner and control a wide array of biological 
processes including cell proliferation, apoptosis and differentiation. miRNAs show an 
extensive role in maintaining global gene expression patterns[346].  
Like normal genes, the expression of miRNAs can be regulated by epigenetic 
mechanisms[347]. In addition, miRNAs can also modulate epigenetic regulatory 
mechanisms inside a cell by targeting enzymes responsible for DNA methylation and 
histone modifications[348].  
 
lncRNAs are functional ncRNAs, each exceeding 200 nucleotides in length and lacking 
functionally open reading frames. They regulate gene expression through different 
molecular mechanisms. lncRNAs can mediate the activity of proteins involved in 
chromatin remodeling and histone modification, or act as an RNA decoy or sponge for 
miRNAs. They can also bind to specific protein partners to modulate the activity of that 
particular protein[349]. Recent advancements in technology to identify lncRNAs using 
microarrays provide a great bulk of novel data from genomewide studies, and have 
revealed potential use of ncRNAs as diagnostic and prognostic biomarkers in various 
human disorders including skin diseases[350]. 
A classic example of lncRNA involved in gene silencing by heterochromatin formation is 
Xist, which has a key role in the X chromosome inactivation process[351]. However, 
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beyond Xist also other lncRNAs have been demonstrated to have a role in altering 
chromatin structure[352]. 
 
Non-coding RNAs often act in concert with various components of the cell's chromatin 
and DNA methylation machinery to achieve stable silencing. Several of these RNAs, and 
particularly the repeat-associated siRNAs, are clearly epigenetic, as they can induce long-
term silencing effects that can be inherited through cell division[353]. Such interaction 
among the various components of the epigenetic machinery re-emphasizes the integrated 




1.2.3 Epigenetics in cancer 
 
Epigenetic mechanisms are essential for normal development and maintenance of tissue-
specific gene expression patterns in mammals and, therefore, their disruptions can lead to 
altered gene function and malignant cellular transformation. The initiation and 
progression of cancer, traditionally seen as a genetic disease, it is now involved in 
epigenetic abnormalities along with genetic alterations[250]. After several studies, it is 
well known that the precise epigenomic landscape found in normal cells may undergo 
extended distortion in tumors and its global change is thus a hallmark of cancer. 
Moreover, the transition to transformed cells during tumorigenesis involves an extensive 
reconfiguration of the genome's expression program. Therefore, malignant cells present 
aberrant somatic reprogramming leading to gene silencing through formation of a 
compact repressive chromatin structure that results in reduced cellular plasticity. The 
epigenetic modifications, along with widespread genetic alterations[354], play an 
important role in tumor initiation and progression[247]. Both alterations interact at all 
stages of cancer development, working together to promote its development[355]. 
The cancer epigenome is characterized by global changes in DNA methylation and 
histone modification patterns as well as altered expression profiles of chromatin-
modifying enzymes. DNA methylation (especially de novo hypermethylation) and 
histone modifications (mostly methylated histone H3 at K9) work independently and in 
concert to alter gene expression during tumorigenesis. Hence, the epigenetic changes 
result in global dysregulation of gene expression profiles leading to the development and 
progression of disease states[258]. Epi-changes also can lead to silencing of tumor 
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suppressor genes independently and in conjunction with deleterious genetic mutations or 
deletions; thus, serving as the second hit required for cancer initiation according to the 
"two-hit" model proposed by Knudson[356]. In addition to inactivating tumor suppressors, 
epigenetic variations can also promote tumorigenesis by activating oncogenes. 
Nevertheless, since epigenetic alterations, like genetic mutations, are mitotically 
heritable, they are selected for in a rapidly growing cancer cell population. 
 
Epigenetic regulation was first confirmed to occur in human cancer in 1983 by Feinberg 
and Vogelstein, using primary human tumor tissues[357], and it has since been observed in 
many other illnesses and health conditions[351]. Researchers found that diseased tissue 
from patients with colorectal cancer had less DNA methylation than normal tissue from 
the same patients. Furthermore, Ushijima and colleagues recently proposed to consider 
epigenetic mechanisms as one of the five most important causal issues in the cancer field, 
accounting for one-third to one-half of known alterations[358], indicating that epigenetic 
changes may be more common in human cancer than DNA sequence mutations[305]. 
 
1.2.3.1 DNA methylation aberrations. The intricate organization of DNA methylation 
and chromatin conformation, known to regulate the normal cellular homeostasis of gene 
expression patterns, somehow becomes unrecognizable in almost all types of cancers, 
leading to aberrant gene expression profiles[359].  
Environmental exposure to nutritional, chemical, and physical factors may stably modify 
gene expression through aberrant methylation of CpG islands, such as at the promoter 
regions of "housekeeping" genes, transposable elements adjacent to genes with 
metastable epi-alleles, and regulatory elements of imprinted genes[3].  
Most human cancers have been found to host global DNA hypomethylation, including 
hypomethylation of repetitive elements, coupled with an increased de novo methylation, 
and subsequent hypermethylation of CpG islands, at specific tumor suppressor gene 
promoters[360]. A tumor epigenome is thus marked by genome-wide hypomethylation and 
site-specific CpG island promoter hypermethylation[247] leading to transcriptional 
repression and then, the abnormal increase in de novo methylation can be critical factors 
in cell transformation[361]. Furthermore, promoter hypermethylation of CpG islands plays 
a causal role in the initiation and the progression of cancer, through the transcriptional 
silencing of critical growth regulators and tumor suppressor genes[362], including RB1, 
p16INK4A, MLH1 and BRCA1[363], and genes controlling the immune response and drug 
sensitivity[364]. This abnormality is the trademark epigenetic change and happens early in 
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the development of cancer[258].  
Therefore, pathological patterns of DNA methylation are consistently found in human 
tumors, including both widespread genomic hypomethylation and regions of abnormally 
increased methylation. Because methylated genes are typically turned off, loss of DNA 
methylation is thought to cause abnormally high oncogene activation by altering the 
arrangement of chromatin, whereas hypermethylation is proposed to silence protective 
tumor suppressor genes[365].  
 
Under normal conditions, CpG islands are unmethylated and their hypermethylation, 
during carcinogenesis, is hypothesized to have profound effects in mammalian gene 
expression[359]. In fact, it has been estimated that aberrant methylation of cytosine 
residues, within these CpG islands, is the single most common lesion in cancer cells even 
when compared to the overall rate of both mutations and cytogenetic abnormalities[366]. 
Although about 60% of all genes in humans are associated with unique CpG islands[362], 
aberrant methylation is initiated at approximately 1.4% of 45000 CpG islands in the 
human genome, and may continue to accumulate to as many as 10% of these islands 
during tumor development[367]. The aberrant hypermethylation indeed leads to gene 
silencing because promoters become embedded in heterochromatin and they are 
surrounded by tightly compacted nucleosomes, which contain deacethylated histones 
impeding transcription. 
In Rb, CpG island hypermethylation occurs early and correlates with loss of 
transcription[368]. For these reasons, an over-expression of all DNMTs was described in 
several cancer types, suggesting that methyltransferase cooperativity (specifically 
between DNMT1 and DNMT3B) maintains DNA methylation and gene silencing in 
human cancer cells[362].  
In addition to direct inactivation of tumor suppressor genes, DNA hypermethylation can 
also indirectly silence additional classes of genes by silencing transcription factors and 
DNA repair genes, leading to inactivation of their downstream targets and allowing cells 
to accumulate further genetic lesions, respectively. Furthermore, gene silencing may also 
be in part mediated by elevated occupancy of methyl-DNA-binding proteins[369] that 
recruit in turn transcriptional repressors and render histones hypoacetylated at promoter 
regions.  
Other examples of repression mediated by hypermethylation include silencing of miRNA 
that in turn results in upregulation of proteins regulated by miRNA or deregulation of 
non-coding RNA[370]. 
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While evidence has strongly linked tumor-specific CpG island hypermethylation to 
cancer development, via silencing tumor suppressor genes, there is as well a strong 
correlation between global genomic hypomethylation and carcinogenesis. DNA 
hypomethylation leads to aberrant activation of genes and non-coding regions through a 
variety of mechanisms that contributes to cancer development and progression, 
increasing abnormal chromosomal instability and activating transcriptional regulation of 
proto-oncogenes[371]. Therefore, global DNA hypomethylation plays a significant role in 
tumorigenesis and occurs at various genomic sequences and large chromosomal domains 
located in lamin-associated regions[372], including repetitive elements, retrotransposons, 
CpG poor promoters, introns and gene deserts[373].  
In tumors, a general reduction of approximately 10% of the 5-methylcytosines (5-mC), 
also known as the "fifth base", was described: a high 5-mC content of CpG islands in 
tumor suppressor genes as well as an increased global DNA hypomethylation status both 
contribute to the carcinogenic process[293]. It has been estimated that malignant cells have 
20-60% less 5-mC content than their normal counterparts, with approximately 70-80% of 
those 5-mC residues occurring within rich CpG sequences[359]. The presence of such 5-
mC amount has been strongly implicated in mutagenicity, partly because of its ability to 
promote deamination of cytosine bases to uracil ones. In fact, 5-mCs are estimated to 
deaminate at a rate of two to four times more rapidly than their cytosine equivalent[374].  
Recently, another modified form of cytosine, 5-hydroxymethylcytosine (5-hmC), has 
been identified and is now recognized as the "sixth base" in the mammalian genome[375]. 
This novel independent epigenetic marker is derived from 5mC in a process catalyzed by 
ten-eleven translocation (TET) enzymes[376] and it acts not only as an intermediate in the 
DNA demethylation process, but also playing an important role in the regulation of gene 
expression in severe diseases, such as Rett syndrome and cancer[377]. 
Loss of DNA methylation at repeat sequences accounts for about 20-30% in the human 
genome[378] and it leads to increased genomic instability by promoting chromosomal 
rearrangements[379], activation of retrotransposons and translocation to other genomic 
regions[380]. 
One of the most well established epigenetic markers is the hypomethylation-induced 
activation of proto-oncogenes, including c-Myc and H-ras, which has been strongly 
linked to an increased risk of many cancers[359].  
A frequently occurring consequence of abnormal DNA methylation, both hyper- and 
hypo-, is an aberrant expression of enzymes involved in these processes. Genetic 
mutations of enzymes involved in DNA methylation has been recently been reported in 
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human cancer, thus emphasizing the synergic contribution of genetic changes and  
epigenetic alterations to the development of the disease[313]. 
 
1.2.3.2 Changes in histone modifications. In higher eukaryotes, modifications in DNA 
methylation patterns, although important, are not sufficient to induce cellular 
transformation and subsequent induction of tumor. Recent advances in high-throughput 
sequencing have enabled genome-wide mapping of chromatin changes occurring during 
tumorigenesis. These studies have revealed a global loss of histone acetylation, which is 
mediated by HDACs, resulting in gene repression[381]. Similarly to what seen for 
methylation enzymes, HDACs are often found overexpressed in various types of 
cancer[382] and HATs, which work in concert to maintain histone acetylation levels, can 
also be altered. HDAC activity is recruited by co-repressor proteins to certain regions of 
the chromatin and the consequent aberrant histone acetylation is in fact responsible for 
the pathogenesis of certain cancers[383]. 
In addition, tumor cells also display widespread changes in lysine and arginine histone 
methylation patterns and they are associated with aberrant silencing of tumor suppressor 
genes[384]. Both HMTs and lysine specific-demethylases work in coordination to maintain 
global histone methylation patterns and their dysregulation results in altered distribution 
of these marks in cancer and leads to cancer progression. 
 
1.2.3.3 Other epigenetic mechanisms. The global epigenetic alteration in tumor 
involves other epigenetic mechanisms, like nucleosome remodeling and histone variants, 
miRNAs deregulation and epigenetic switching, that work together with DNA 
methylation and histone modifications in the changes of chromatin structure. 
 
Nucleosome remodeling and histone variants are labile epigenetic regulatory 
mechanisms and play a central role in both tumor-specific gene silencing and gene 
activation by modulating chromatin accessibility. MBD proteins may involve DNA 
methylation-induced silencing of tumor suppressor genes in cancer. It concerns distinct 
changes in nucleosome positioning, resulting in nucleosome occupancy at transcription 
start site. Nucleosome remodeling can also lead to aberrant gene silencing via the 
transmission of repressive epigenetic marks to tumor-suppressor gene promoters.  
A significant proportion of methylated promoters are bound by a single MBD protein, 
most often MBD2[385].  
For instance, the SWI/SNF complex is a multi-subunit ATP-dependent chromatin-
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remodeling complex[386], whose aberrations are associated with cancer development[387] 
and abrogation of SWI/SNF function through alterations in its various subunits is 
observed in around 20% of human cancers[388], suggesting that this complex may have a 
functional role in preventing tumor development in diverse tissues.  
In addition to remodeling complexes, the histone variant H2A.Z is overexpressed in 
several types of tumor and has been associated with the promotion of cell cycle 
progression[389]. 
 
miRNAs deregulation is responsible for a widespread change in miRNA expression 
during tumorigenesis[390-391]. Since miRNAs regulate genes involved in transcriptional 
regulation, cell proliferation and apoptosis, alteration in their expression can promote 
tumorigenesis. miRNAs can function as either tumor suppressors or oncogenes 
depending upon their target genes. Many tumor suppressor miRNAs that target growth-
promoting genes are repressed, whereas oncogenic miRNAs, which target growth 
inhibitory pathways, are often upregulated in cancer[392]. 
Changes in miRNA expression can be achieved through various mechanisms including 
chromosomal abnormalities, transcription factor binding and epigenetic alterations[393]. 
 
Epigenetic switching may be performed in tumor cells for gene silencing. The detailed 
mechanisms by which discrete genome regions undergo hyper- or hypomethylation are 
still unclear. Early evidence suggested that elevated DNMT levels might trigger 
hypermethylation of tumor suppressor gene promoters, which would consequentially 
result in cancer cell proliferation[394]. In addition to this "selection" model, an alternative 
mechanism has been proposed that takes advantage of the current genome-wide 
epigenetic studies in stem cells. Investigators have suggested that the establishment of 
aberrant epigenetic profiles in cancer may undergo a process that is similar to epigenetic 
reprogramming during development[259]. In embryonic stem cells, developmentally 
important genes are reversibly silenced by polycomb proteins that are able to remodel 
chromatin structure for gene silencing, through the establishment of the repressive mark. 
After differentiation of normal cells, these genes continue to be inhibited, due to 
polycomb-group proteins associated with H3K27m, that work independently of DNA 
methylation to aberrantly repress genes in cancer cells[395]. 
Controversially, during cancer initiation the promoters might become methylated and 
thereby set up for long term silencing. The reversible gene repression by polycomb mark 
is so replaced with long-term silencing by de novo DNA methylation, possibly performed 
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through the recruitment of DNMTs via the polycomb complex[396]. This tumor-specific 
"epigenetic switching" of the plastic polycomb mark with more stable DNA methylation 
results in the permanent silencing of key regulatory genes that may contribute to cell 
proliferation and tumorigenesis[397] and it is involved in the gene silencing through 
formation of a compact chromatin structure and reduced cellular plasticity. 
 
1.2.3.4 Epigenetics in retinoblastoma. Recent whole-genome sequencing of Rb 
uncovered a tumor that had no coding-region genetic mutations or focal chromosomal 
lesions other than in the RB1 gene. Consequently, the overall mutational rate and number 
of structural variations resulted one of the lowest seen in human cancer to date, indicating 
Rb to be characterized by a relatively stable genome[398]. It becomes clear therefore that 
epigenetic alterations of multiple tumor-promoting pathways is required for the 
development of retinoblastoma and that epigenetics, rather than the classical genetic 
model, fits the variegated phenotypic expression of the disease, opening new outstanding 
scenarios in the fields of diagnosis, treatment and prevention. The epigenetic model of 
retinoblastoma development emphasizes the role of environment and its interaction with 
the genome. For instance, it is possible that certain chemical compounds or low levels 
radiation can initiate biological perturbations that can lead to malignancy, despite being 
weak mutagens or lacking mutagenic activity altogether[399]. Environmental toxicants, 
including radiations, wrong diets, and infectious diseases also play a major role in 
conditioning the degree of DNA methylation in embryos during pregnancy, thus leading 
to stable, functional alterations of the genome, which can be also transmitted through 
generations, thus mimicking a hereditary disease[3].  
In addition, both covalent/non-covalent modifications of DNA and histone proteins 
changes can influence the overall chromatin structure. Rb also may develop quickly 
because of the epigenetic deregulation of key cancer pathways as a direct or indirect 
result of RB1 loss[200].  
 
Methylation described for Rb tumorigenesis induce silencing of both alleles of tumor 
suppressor gene RB1 and other genes such as MLH1 and RB2/p130[400], resulting in 
complete loss of function. Aberrant methylation of CpG island of the promoter region of 
the  additional genes such as RASSF1A[401-402], MGMT[401,403] and p16INK4A (CDKN2)[404], 
LDHA[405], NEUROG1, DAPK, RUNX3[406], APC-2[407] and TFF3[408] has also been 
shown in Rb. Recently, Livide and colleagues distinguished a novel set of 
hypermethylated genes in Rb, including MSH6, CD44, PAX5, GATA5, TP53, VHL, 
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GSTP1[409]. Moreover, Zhang and colleagues identified fifteen cancer-related genes that 
were deferentially expressed and which also exhibited correlative histone modifications 
in Rb, when compared to normal tissue. In particular, downregulated genes with 
associated inactivating histone modifications included CTNND1, SRY, SOX2 and 
ADAMTS18[200]. 
 
Methylation of the promoter region of RB1 has been first demonstrated in 1989 by 
Greger and colleagues, who identified CpG 106, an island overlapping the promoter and 
exon 1, to be methylated in some retinoblastomas[410], thus silencing gene expression. 
Since then, multiple CpG islands within the RB1 promoter and gene have been identified 
and characterized in Rb, demonstrating an epigenetic component to gene inactivation and 
subsequent development of the tumor[411]. Methylation of the RB1 promoter occurs in 
about 10% of unilateral, sporadic retinoblastoma tumors[183,412], leading to loss of 
function. 
RB1 is one of "housekeeping" gene, and its function is to regulate cell growth by 
preventing cells from dividing too fast or in an uncontrolled way[413]. The promoter 
region of RB1 lies 185-206 bp upstream of the initiation codon and contains putative 
binding sites for the transcription factors RBF-l, Spl, ATF, and E2F[414]. The RB1 gene 
has a small CpG island that encompasses the promoter, and this cluster remains 
unmethylated in all tissues during development. However, both in vitro and in vivo 
studies have suggested that partial CpG methylation decreased promoter activity to 
intermediate levels[415], whereas abnormal hypermethylation of the RB1 promoter 
dramatically reduces RB expression. Decreased RB level has been found particularly in 
sporadic retinoblastoma that, on the other hand, is the most commonly accepted form of 
non-hereditary disease, suggesting that Rb is an epigenetic, rather than a genetic disease.  
Interestingly, as a key gene in cell cycle control, RB1 has been found aberrantly 
methylated, alone or together with other cell cycle regulating genes in different types of 
cancers[416].   
 
Methylation of transposable elements adjacent to the genes with metastable epialleles is a 
second epigenetic modification occurring during retinoblastoma development. 
Metastable epialleles are defined as rare gene loci that can be epigenetically modified in 
a variable and reversible manner, so that a distribution of phenotypes can occur from 
genetically identical cells.  
The phenotypic expression of retinoblastoma is not only highly variable, but can also be 
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modulated as if it would depend on variable environmental exposures[44].  
Epigenetics, by looking at gene expression as the result of the functional interaction 
between genes and the environment, admits that the resulting phenotype could be 
regulated and consequently it exhibits different degrees of variability and plasticity. 
Alterations in phenotypic expression can be also explained by the presence of 
transposons, repetitive transposable elements dispersed throughout the mammalian 
genome, that are epigenetic silenced by the methylation of their CpG islands. The 
epigenetic state of a subset of transposable elements is metastable; these mobile elements 
are variably expressed in genetically identical individuals due to epigenetic modifications 
occurring during the early development[417]. In contrast with other regions of the human 
genome, the epigenetic changes occurring at the insertion site of transposable elements 
can be considered as a stochastic event, which causes individual variation. Therefore, 
given their role in silencing genes and their variability within the same individual, 
transposons are responsible for both inter- and intra- individual variations in phenotypic 
expression of the same genes within different cells of the same organism, thus leading to 
aneuploidy and/or epigenetic cellular mosaicism. 
By adopting the epigenetic model, phenotypic variation in the clinical expression of 
retinoblastoma is easily explained by the variable exposure of the fetus to environmental 
toxicants that, in turn, may determine the degree of hypomethylation of different key 
genes. Within this conceptual framework, Rb mosaicism can be viewed as the result of 
the interaction between the environment and the transposable elements of the genome[44]. 
 
Methylation of regulatory elements of imprinted genes is another epigenetic modification 
occurring during retinoblastoma development. Imprinting is defined as a non-Mendelian, 
germline inherited epigenetic form of gene regulation involving heritable DNA 
methylation and histone modification. The human genome is subject to imprinting, which 
represents the consequence of epigenetic inactivation of different genes in either the male 
or the female gametes, so that in the resulting zygote they complement each other, and 
the normal embryo development proceeds. Because imprinted genes are epigenetically 
modified trough the methylation of CpG islands in both the male and female gametes, the 
expression of different genes in the zygote, embryo, and fetus, derived from the fusion of 
the two, will depend on the parental environment in which both gametes have grown and 
differentiate.   
Abnormal expression of imprinted genes during development may result in severe 
pediatric disorders, where epigenetic alterations have an important contributory or 
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causative role. Moreover, imprinted gene dysregulation can also occur in somatic cells, 
by either epigenetic modifications or genetic mutations, causing cancer. In Knudson's 
hypothesis, inheriting an imprinted RB1 gene means that one copy of the gene is already 
functionally inactivated, representing the first "hit", and only a single event is further 
requested for both copies to be inactivated. 
Recent data show that RB1 gene is imprinted in retinoblastoma with a shift of expression 
in favor of the maternal allele[418]. 
 
Gene co-expression profiling and new markers for retinoblastoma. A new way to 
investigate possible new genomic markers involved in a multifactorial disease such as 
retinoblastoma is to analyze the microarray-based differential gene expression (DGE) 
reporting evidence for up- or downregulated gene sets. A recent paper analyzed 
microarrays data from Weri-Rb1 before and after treatment with DAC, using network 
analysis to design a map of gene-gene interaction of epigenetic pathways regulated by 
DNA methylation. Potentially epigenetically regulated biomarkers were identified and 
their time-related profile was studied to decipher their involvement in the pro-apoptotic 
effect of DAC. Selected gene methylation analysis was performed to confirm the direct 
regulation of the treatment on those hypermethylated genes responsible for cancer 
associated silencing: DAC treatment of the Weri-Rb1 cell line induced the re-expression 
of RB2 and its related pro-apoptotic E2F1, p73 and p53 genes, thus highlighting a crucial 
role of epigenetic events[195].  
This kind of newtwork integration between experimentally collected evidence and 
statistical inference study also hold potential for predictive analysis indicating possible 
co-expression gene associations that would not be predicted otherwise, to unveil relevant 
pathway cross talks, and to identify unexpected correlative or causal relationship because 
of non-canonical gene interplay[419].  
 
 
1.2.4 Integrated epigenome analysis for personalized therapeutic targets 
 
It has been described as genome and epigenome alterations may cooperate to promote 
oncogenic transformations. The disruption of epigenomic control is pervasive in 
malignant conditions. Recent innovations in chromatin immunoprecipitation technology, 
paired with microarrays and high-throughput sequencing, have enabled unprecedented 
insights into protein-DNA interactions and chromatin architecture in a wide range of 
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biological models, and particularly in cancer-related ones. Recently, the development of 
Next Generation Sequencing (NGS) technology allowed a deep investigation on the 
emerging role played by epigenetics in cancer[420]. 
NGS allows drawing a precise landscape of gene expression where the epigenetic 
variations can be targeted and reversed, suggesting a rationale for cancer therapies aimed 
to achieve epigenetic reprogramming. It follows that epigenetic changes in protein-
coding genes and ncRNAs activity form a sort of signature to the genetic landscape of 
each individual, revealing different molecular mechanisms responsible for cancer 
development. The identification of such expression signatures can further characterize 
patient groups according to diagnostic, prognostic and therapeutic factors. 
If one pushes the concept further, it should be expected therefore that each tumor type 
might have, for example a characteristic DNA methylation pattern. In addition, it could 
be uncertain whether altered DNA methylation patterns are unique for a specific tumor 
type or instead comparable across different types of cancers. Recently, an atlas of DNA 
methylation was generated across a variety of samples from several cell lines and tissues, 
providing insight on gene regulation aspects and disease that lead to the identification of 
methylation signatures in part cancer-associated and in part cell-type specific[286].  
 
High-throughput techniques, including microarray and sequencing-based technologies, 
provide genome-scale whole methylomes, confirming the role of aberrant methylation as 
a cancer hallmark. This has allowed identifying novel types of biomarkers and is 
expected to shed light over new cancer subtyping[420-421]. 
From these studies, it emerges that although chromatin regulation and thus control of 
gene expression have been central to epigenetic drug developments; other epigenetic 
mechanisms have therapeutic potential: "Big Omics Data" analysis is destined to reveal 
the role for new actors in cancer, such as the usually lowly expressed lncRNAs, which 
are detected in wide-spectrum transcriptome profiling[422]. This new development will 
expand cancer phenotyping, through increased marker detection, deeper sub-typing and 
more stratified methylation. This will also provide new candidate targets, together with 
generating hypotheses for innovative clinical trials design. 
Understanding the mechanisms of anticancer activity of epi-drugs, such as inhibitors of 
methyltransferase or deacetylase, is essential for drug design in targeted therapies. 
Knowledge of the involved patterns of activity is needed to design optimized clinical 
protocols as well as to develop new classes of drugs. In this view, the screening of 
already approved library of epigenetic active molecules could represent a cost-effective 
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approach to discovery suitable candidates for alternative clinical applications[423]. 
This new approach is used in "Disease stratification studies" that aims at identifying 
patterns of epigenetic variation such as DNA methylation, to correlate the expression of 
these altered pathways with an increased risk of cancer development, therefore 
pinpointing specific driver mutations. Such investigations are mostly taking place 
during clinical trials, at a stage when patient cohort genetic profiles might indicate 
shared epi-mutations to be targeted with specific drug. Editing the epigenome and its 
built-in players is the new frontier of drug discovery, the one shaping the road map of 
personalized medicine in cancer[424]. 
 
Progresses in NGS and Omics approaches have allowed systematic analysis and 
identification of novel epigenetic marks (top-down mapping of epigenetic changes). The 
most salient achievement is however to define epi-modification in space to identify 
landmark distribution across the genome. For this, computational analysis is used with a 
bottom-up epigenetic investigation to map the spatial reconstruction of localized changes 
on the epigenome searching for possible markers. Computational efforts are currently 
directed towards building integrative comparative analyses of multi-platform outsourced 
datasets, paving the way for the design of algorithmic pipelines aimed at detect clinically 
relevant biomarkers and to provide more accurate patient stratification.  
 
 
1.2.5 Epigenetics in cancer drug resistance 
 
In recent years, the different classes of drugs and regimens used clinically have provided 
an improvement in tumor management. However, cancers have the ability to develop 
resistance to traditional therapies and thus, treatment is often palliative for the majority of 
cancer patients. Tumors often are made of a mix of malignant cells, some of which are 
drug sensitive while others resist to drugs. Therefore, transformed cells respond poorly to 
chemotherapy mainly due to the development of the multi-drug resistance phenotype. 
Response to treatment does not generally result in complete remission and disease cure is 
uncommon for patients presenting with advanced stage cancer. Consequently, the 
remaining resistant cells make the tumor grow again, causing chemotherapy failure. The 
development of drug resistance is in fact one of the major challenges in cancer therapy 
and a limiting factor in patient survival[425].  
There are several categories of mechanisms that can enable or promote direct or indirect 
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drug resistance in human cancer cells. These mechanisms can act independently or in 
combination and through various signal transduction pathways and are classified as: drug 
inactivation, alteration of drug targets, drug efflux, DNA damage repair, cell death 
inhibition, epithelial-mesenchymal transition and metastasis and cancer cell 
heterogeneity. Both intrinsic and acquired drug resistance in tumors occur as a result of 
an alteration in gene expression, which, in some cases, is due to aberrant epigenetic 
regulation.  
Epigenetic alterations probably contribute to chemo-resistance at several steps of drug 
response pathways in tumors. The two coexisting processes of global hypomethylation 
and regional hypermethylation confer a selective advantage by turning on and off 
different sets of genes with opposite roles. Hypermethylation of CpG islands at specific 
tumor suppressor gene promoters causes the downregulation of genes whose products are 
required to suppress tumorigenesis, while global hypomethylation induces activation of 
genes with crucial roles in the transformation process. It is obvious that single gene 
alteration is sufficient neither for cancer development nor for drug resistance 
acquirement, but it is rather the concerted work of several genes that eventually 
determines the cell state and the drug fate inside the tumor cell[426].  
Successful treatment of cancer requires a clear understanding of chemotherapeutic 
resistance. Therefore, one major research goal is to identify the critical genes involved in 
chemotherapy response to predict the best therapy option for patients, and numerous 
studies have been suggested a direct role for epigenetic gene inactivation in determining 
tumor chemosensitivity[427-430]. Likely for us, the majority of the epigenetic mechanisms 
are reversible, and researchers may be able to take advantage of this opportunity to 
develop treatments that can counteract drug resistant malignancies[431].  
 
Recent studies suggest that epigenetic alterations, mainly due to DNA methylation, play 
a role in the development of acquired multidrug resistance. For instance, methylation at 
MDR1 promoter increases drug resistance, making it an excellent target for epigenetic 
treatment. Moreover, the tumor-suppressor gene p73 is generally silenced by epigenetic 
alterations and it is related to poor response to therapy[432-433]. Besides, several studies 
have demonstrated that some pro-apoptotic genes, such as Apaf-1[434] and CASP8, are 
frequently inactivated by methylation[435]. Their expression can be restored by treatment 
with DNMTs inhibitors, which can increase chemosensitization. Demethylating agents in 
fact might be useful in sensitizing multidrug resistant cancer cells to other types of 
drugs[431], enhancing chemosensitivity. 
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Epigenetic mechanisms can also influence DNA damage repair. For example, 
inactivation of FancF, through promoter methylation or ncRNA, has been observed in 
many malignancies[436]. Moreover, DNA mismatch repair processes can be lost due to 
hypermethylation of MLH1 gene promoter, that is also important to determine 
chemotherapeutics sensitivity, and this can lead to tumor development. In these cases, 
treatment with demethylating agents was used to decrease methylation level and to 
restore tumor sensitization to other drugs, including cisplatin, carboplatin, temozolomide 
and epirubicin[437].  
 
The DNA repair enzyme MGMT inhibits the killing of tumor cells by alkylating 
chemotherapy agents. Methylation of MGMT causes gene silencing and decreased 
MGMT production. Epigenetic alteration of MGMT expression has been associated with 
a modified chromatin configuration. Cells can acquire resistance to a methylating agent, 
by either reactivating a previously silenced MGMT gene, or by repressing the hMSH6 
mismatch repair gene. The number of active MGMT molecules at the time of 
methylation determines the capacity of a cell for MGMT repair. Treatment with chemical 
methylating agents alters gene expression patterns by increasing genomic DNA 
methylation, which ultimately leads to increased repair or tolerance of O6-methylguanine 
and the emergence of chemotherapy resistance[438].  
 
Epigenetically mediated forms of drug resistance are observed in several cancers. The 
first experimental evidences were collected in the early 2000:  for example, methotrexate 
resistance in breast cancer cells is caused by an inherent defect in drug uptake and a lack 
of reduced folate carrier (RFC) expression. In one study, the treatment of these cells with 
a methylation inhibitor improved methotrexate uptake but also restored RFC expression, 
which promoted methotrexate efflux. These results suggest that the demethylating agent 
counteracts some methotrexate-resistance mechanisms while improving others[439].  
Melanoma cells can also exhibit drug resistance via epigenetic mechanisms. They are 
notoriously unresponsive to conventional chemotherapy and can be resistant to 
fotemustine. This acquired resistance is associated with high MGMT activity and the 
MGMT gene appeared hypermethylated. However, these cells were effectively sensitized 
when treated with demethylating agent[440]. 
As well, drug resistance in melanoma cells seems to be due, at least in part, to Apaf-1 
inactivation through epigenetic alterations. This gene encodes for a cell-death effector 
that binds to cytochrome C to activate Caspase-9 and induces apoptosis. Some other 
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studies, involving malignancies spanning from myelodysplastic syndromes to solid 
cancers, have demonstrated that Apaf-1 expression can be restored by treatment with 
DNA methylation inhibitors and that return of physiological levels of this cell-death 
effector enhances chemosensitivity[440]. Similarly, in various tumors also Caspase-8 is 
frequently inactivated by methylation and treatment with demethylating agents can 
restore its expression, increasing chemosensitization[435]. 
Additionally, some prostate cancers exhibit androgen resistance that may be due to 
transcriptional inactivation of the androgen receptor gene caused by DNA methylation. 
Cytosine DNA methyltransferase inhibitors have been found to restore androgen 
responsiveness in androgen-refractory tumor cells, though, and these cells are then 
responsive to growth inhibition by anti-androgens[441]. Overall, as epigenetic alterations 
have been increasingly recognized as a cause of drug resistance in many different kinds 
of cancer, thus, epigenetic therapy could be utilized as a priming therapy to sensitize 
drug-resistant cancer cells in conjunction with conventional and targeted chemotherapy. 
 
 
1.2.6 Epigenetic therapy 
 
Unlike specific mutations that permanently turn off gene expression, epigenetic promoter 
methylation and histone modifications are potentially reversible processes. Therefore, 
epigenetic abnormalities involved in tumor progression provide the rationale for the 
development of an "epigenetic therapy" as a treatment option to restore the abnormal 
epigenome. It has encouraged the use of DNA demethylating and chromatin-remodeling 
compounds, with the consequent reactivation of silenced genes[442]. In the recent past, 
many epigenetic drugs have been discovered that can effectively reverse DNA 
methylation and histone modification aberrations occurring in cancer[250]. 
 
Epigenetic therapy development represents an important part of pharmacology for human 
cancer and the pharmacoepigenetics is now emerging as a new branch of personalized 
medicine, which can individually interfere on the patient epigenomic state. In the near 
future, one can forecast that this customized epigenetic intervention will improve the 
individual response to the treatment[443]. 
However, to date clinical practice may exploit the two most prominent classes of drugs 
used in reactivating epigenetically silenced genes, including those that inhibit DNMTs 
and HDACs enzymes (Table 1.1). 
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Table 1.1: Chemical classification of epigenetic drugs. 
 
Here below the most prominent categories are listed. 
 
1.2.6.1 DNMTs inhibitors. DNMTs inhibitors are among the first epigenetic drugs 
proposed for use as cancer therapeutics. The remarkable discovery that the mechanism by 
which some cytotoxic agents lead to the inhibition of DNA methylation and the 
consequent induction of gene expression that caused differentiation in cultured cells led 
to the potential exploitation of these drugs in cancer therapy[250]. After these preliminary 
observations, reactivation of tumor suppressor genes by inhibiting DNMT1 has become a 
promising strategy for cancer therapy. Several DNA hypomethylating agents are 
currently being evaluated in preclinical and clinical studies. They belong to different 
chemical classes and nature: the commonly used DNA demethylating agents include 
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cytidine or deoxycytidine analogues, but also antisense oligonucleotides, small molecules 
and non-nucleoside analogues. Despite their efficacy, most of the DNA hypomethylating 
agents show severe drawbacks that include molecule instability and relatively high 
toxicity due to their incorporation into DNA or into both DNA and RNA[444]. 
 
Nucleoside analogues are the oldest form of methylation inhibitors, and some of these 
compounds such as 5-Azacytidine and 5-Aza-2'-deoxycytidine have been Food and Drug 
Administration (FDA) approved for the treatment of certain cancers[361]. These 
nucleoside analogs are incorporated into the DNA of rapidly growing tumor cells during 
replication and they inhibit DNA methylation by anchoring DNA methyltransferases 
onto the DNA, leading to their depletion inside the cell[258]. They reduce DNA 
methylation, activating tumor suppressor genes aberrantly silenced in cancer and 
reestablishing differentiation cycle. However, the ability of these drugs to be 
incorporated into DNA raises concerns regarding their potential toxic effect on normal 
cells[250], therefore providing driving for the study of delivery system that might reduce 
effective dosage administration.  
 
5-azacytidine (Aza, Vidaza) is a cytidine analogue, with a nitrogen atom in the place of 
carbon 5. Inside the cell, it is triphosphorylated by uridine cytidine kinase to 5-
azacytidine 5'-triphosphate and gets incorporated into RNA and, to a lesser extent, into 
DNA during replication. It is recognized by DNMTs as a site of action, and the normal 
reaction involving the transfer of a methyl group begins to take place. The nitrogen group 
in the fifth position causes the formation of an irreversible DNMT1-Aza linkage, which 
triggers the degradation of the enzyme and leads to widespread reductions in 
methylation[445]. Because Aza integrates into DNA during replication, rapidly dividing 
cancer cells are more susceptible to its effects. Aza has been shown to delay the onset of 
leukemia[446] and in 2004 it was FDA approved for use in myelodysplastic syndromes 
(MDS)[447]. However, it is relatively unstable, not available to be taken orally and it can 
present severe toxic side effects, especially at high doses, when it can cause 
neutropenia[448]. 
 
5-aza-2'-deoxycytidine (DAC, Decitabine, Dacogen®) is an analogue of deoxycytidine, 
with a nitrogen atom in the place of carbon 5 (Fig. 1.5). Like Aza, Sorm and co-workers 
synthesized this compound in 1964[449]. It was initially used as antimetabolite agents in 
leukemia chemotherapy until its hypomethylating properties were discovered.  
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DAC can be considered as a prodrug that requires metabolic activation: it is transported 
into cells by human concentrative nucleoside transporter-1 and converted to active 
phosphorylated form by deoxycytidine kinase to 5-aza-2'-deoxycytidine-5'-
triphosphate[450]. The deoxyribose analogue is incorporated into DNA strands during 
replication, in place of 5-methylcytosine and it is integrating into the genome of rapidly 
proliferating cells during the S-phase of the cell cycle[451]. The nitrogen atom in place of 
a carbon in the 5-position allows the break of interaction between DNA and the 
DNMT[452]. DNA methyltransferase results in fact inactivated due to covalent bond 
between the 5-azacytosine ring of DAC incorporated into DNA and the active site of the 
enzyme. In addition, the irreversible covalent protein adduction precludes the resolution 
of the complex and it compromises the functionality of DNA and triggers DNA damage 
signaling, resulting in the degradation of the trapped DNMTs[453]. The result of this 
process is hypomethylation of DNA and cellular differentiation or apoptosis. Further 
methylation of cytosine residues is so inhibited, causing the passive loss of cytosine 
methylation in the daughter cells after replication. 
Various studies indicated that the efficacy of DAC might be due to the re-expression of 
genes that control cell apoptosis, cell cycle arrest, cancer testis antigens, MHC molecules 
and co-stimulation molecules by DNA demethylation. As a result, DAC enhanced the 
anti-tumor immune response and inhibited tumor development[454].  
Clinically, previous observations indicated that higher doses of DAC induce cytotoxicity, 
while low-dose, prolonged infusion with DAC correlates with clinical response in 
hematological disorders[455]. In 2006, FDA approved DAC for MDS and promising 
results have emerged from the treatment of other hematological malignancies, such as 
acute and chronic myeloid leukemia[456], even though about half of treated patients 
reported granulocytopenia[452] and myelosuppression[457] as the major adverse effects.   
Over the past two decades, several other clinical trials have focused on the DAC-based 
injectable anti-proliferative therapy in patients with solid tumors, indicating that lower 
doses but high intensity, multi-day, and multi-cycle DAC administration was effective, 
especially for patients with ovarian cancer[458], non-small cell lung cancer 
(NSCLC)[452,459] and colorectal cancer[460].  
Although DAC showed clinical activity as single agent, it shows a better outcome in 
combination therapies with cytotoxic drugs, molecular targeted agents and other 
epigenetic agents or immunotherapy. Nevertheless, the drug combinations might generate 
undesired hematological toxicity. To avoid or reduce this occurrence, the use of 
relatively low doses of DAC would be desirable. Interestingly, the sequential 
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administration regimen with DAC given as first agent produced a better outcome than 
that observed after concurrent administration. DAC effect could in fact reverberate on 
cancer cells that completed several division cycles[461]: DAC might enhance the 
sensitivity of the current available agents to tumor cells, overcoming the resistance of 
molecular targeted therapy, inducing cell reprogramming and activating the immune 
responses[462].   
DAC is characterized by poor chemical stability, which depends on temperature and pH 
if free in blood. It is quite unstable; however, its degradation products are thought to have 
pharmacological effects. These degradation compounds are four guanylurea derivatives 
(α-pentose, β-pentose, α-hexose, β-hexose isomers) and one formylate derivative. DAC 
may be classified also in α- and β- anomers[463] and it has a short half-life of 15 to 25 
minutes, due to its rapid inactivation. In particular, together with Aza, DAC is 
metabolized by cytidine deaminase (CDA), the enzyme that renders this drug inactive by 
converting them into 5-azauridine compounds. The high level of CDA in the human liver 
and spleen is largely responsible for shorter half-lives of both agents in vitro and in vivo. 
Therefore, an increase in CDA activity may reduce efficacy by lowering drug levels and 
shortening the half-life times[464].  
Furthermore, the oligo dinucleotide SGI-110 contains DAC as a half of the molecule and 
it has been found to be very effective in inhibiting DNA methylation, but its stability and 
cytotoxicity is comparable with that of Decitabine alone[465]. This compound could be 
used for effective delivery and cellular uptake of nucleotide drugs, as it is resistant to 
cytidine deaminase. 
 
   Fig 1.5: 5-Aza-2'-deoxycytidine          
 
Zebularine is a ribonucleoside analogue that has a mechanism similar to Aza. Once into 
DNA, the fraudulent bases forms covalent bonds with DNMTs, resulting in the depletion 
of active enzymes and the demethylation of DNA. Although the drug is not yet FDA 
approved, it presents good results in mouse models and its possible clinical use has been 
still under investigation[466]. Zebularine is more stable than Aza and it can inhibit DNA 
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methylation and induce re-expression of methylation-silenced genes [467]. 
Another nucleoside analogue is 5,6-dihydro-5-azacytidine (DHAC), a hydrolytically 
stable congener of Aza, which in past was tested showing an antileukemic activity in 
preclinical models[468] and the possibility to restore the estrogen sensitivity in ER-breast 
cancer[469]. Hydralazine hydrochloride (also known Apresoline) is an antihypertensive 
agents and a DNMT inhibitor that has been used to hypomethylate T cells in 
experimental systems[470].  
 
The nucleoside-like compounds 1-β-D-arabinofuranosyl-5-azacytosine (also called 
Fazarabine) and 5-fluoro-2'-deoxycytidine (also called FdCyd) are other DNMT 
inhibitors under investigation in clinical trials[471-472].  
 
Antisense oligonucleotides are also used to inhibit abnormal methylation as a treatment 
option. MG98 is a second-generation DNMT1 inhibitor and it is a 20-base pair antisense 
oligonucleotide that binds the 3' untranslated region of the enzyme, preventing 
transcription of the gene[473]. Studies in mouse models of bladder and colon cancer 
showed that administration of MG98 led to re-expression of the tumor-suppressor gene 
p16INK4A. Clinical trials have shown instead controversial results, but MG98 appears to 
have been successful in the treatment of advanced renal cell carcinoma. The most 
promising results came from a study in which MG98 was given in combination with 
Roferon-A, a chemotherapeutic drug. Decreased levels of DNMT1 were observed and 
tumor progression was slowed, with minimal toxicity from MG98[474]. Additional clinical 
trials examining the most effective dosages and dosing schedules for MG98 are currently 
in progress. 
 
Small molecule. RG108 is a relatively new DNA methylation inhibitor presenting high 
specificity and low toxicity. It binds to and directly inhibits the DNMT1 enzyme active 
site. Its in vitro use in human cancer cell lines showed significant demethylation and re-
expression of the p16INK4A and led to slow cancer cell growth. Because the RG108 
mechanism of action does not involve enzyme trapping, the toxicity of the drug is 
reduced. In addition, it did not affect the methylation status of centromeric satellite 
repeats, an unexpected but advantageous trait that is likely to increase stability of 
hypomethylated chromatin[475].  
Development of other small molecule inhibitors such as SGI-1027 represents an 
alternative treatment option to further reduce toxic effects[476]. Either these molecules can 
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achieve their inhibitory activity by blocking catalytic/cofactor-binding sites of DNMTs 
or by targeting their regulatory messenger RNA sequences; however, their weak 
inhibitory potential indicates a need for the development of more potent inhibitory 
compounds in future. 
 
Non-nucleoside analogues are another group of epigenetic drugs that could block 
DNMTs. They can effectively inhibit DNA methylation without being incorporated into 
DNA. Procainamide (also known as Pronestyl or Procanbid) is an antiarrhythmic agent, 
as well as an inhibitor of DNA methylation and thus it has been used to hypomethylate T 
cells in experimental systems and, consequently, to produce overexpression of 
lymphocyte function-associated antigen 1, making T cells autoreactive[477]. It has been 
under investigation in experimental and clinical settings[478]. Procaine hydrochloride (also 
called Novocain) and epigallocatechin-3gallate are currently being investigated in the 
treatment of several diseases, rather than tumors[479]. 
 
1.2.6.2 HDACs inhibitors. Inhibitors of histone deacetylase are an emerging class of 
targeted anticancer agents that mediate the regulation of gene expression and induce 
growth arrest, cell differentiation and apoptosis of tumor cells. They induce 
hyperacetylation in chromatin usually resulting in activation of certain genes and 
terminal cell differentiation and/or apoptosis in cancer cells[383]. Then, re-establishing 
normal histone acetylation patterns through treatment with HDAC inhibitors have been 
shown to have anti-tumorigenic effects. HDACi selectively alter the expression of a 
relatively small proportion of expressed genes (2-10%) in transformed cells[480], despite 
what it may be anticipated by the wide distribution of HDACs in chromatin. The gene the 
most frequently involved is p21WAF1,CIP1 that resulted to be upregulated. Concerning the 
apoptosis of tumor cells, many mechanisms have been proposed such as alterations in 
BCL2 family protein expression, increase in Caspase activity, increase in sensitivity to 
FAS/FASL interactions and change in the expression of also genes like c-Myc and c-
Ras[481]. HDAC inhibitors regulate gene expression by enhancing the acetylation of 
histones, and thus inducing chromatin relaxation and reactivation of silenced tumor 
suppressor genes[322]. Therefore, the effect on gene transcription may be a consequence 
of acetylation of a particular complex of histones and other proteins. In addition to 
negatively controlling the catalytic sites of HDACs, HDAC inhibitors cause selective 
changes in expression of Class II HDAC proteins[482].  
Due to the promising in vivo results of these agents, numerous clinical trials have been 
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initiated[483], with Vorinostat and Romidepsin already FDA approved. They are currently 
applied for treatment of certain types of T-cell lymphoma with cutaneous 
manifestations[361]. Their cytostatic effect may be in part explained by inhibition of 
abnormal HDAC expression in tumor cells and by interfering with aberrant HDAC 
recruitment to promoter regions[484]. HDACs may also affect other targets other than 
histones, that are acetylated and possibly substrates of HDACs, including transcription 
factors, DNA repair proteins, and cell cycle regulators[485]. 
HDAC inhibitors are heterogeneous, some deriving from natural molecules, whereas 
some developed by synthesis. Their classification is based on their chemical nature and 
mechanism of inhibition, such as their affinity for the HDACs of Classes I, II, and IV. 
They have high specificity, although presenting extreme side effects.  
They are categorized into several groups, including hydroxamic acids, cyclic 
tetrapeptides and analogues, short-chain fatty acids (aliphatic acids), benzamides and 
epoxides[483]. The numerous clinical trials designed for these drugs may elucidate some 
critical questions remained to address[486]. 
 
Hydroxamic acids are the most important class of HDAC inhibitors; they are very 
effective, targeting the catalytic site of Class I and II HDACs and they have emerged as 
promising and potent treatments for cancers[481]. 
 
Trichostatin A (TSA) was the first natural hydroxamate discovered to reversely inhibit 
HDACs[487]. In the '70s, trichostatin A (TSA) and trichostatin C were initially isolated as 
fungistatic antibiotics from Streptomyces hygroscopicus[488]. Later, it has been 
demonstrated the very potent activity of trichostatic acid in inducing Friend cell 
differentiation and specific inhibition of the cell cycle of normal rat fibroblasts in the G1 
and G2 phases at the very low concentrations. TSA also causes an accumulation of 
acetylated histone species in a variety of mammalian cell lines and its in vivo effect can 
be attributed to the inhibition of the histone deacetylase enzyme of Classes I and II[487]. 
More recently, it has been reported that TSA can regulate the expression of the gene Drg-
1, identified as a candidate suppressor of metastases in colon cancer[489]. 
TSA-induced histone acetylation causes decondensation of interphase chromatin and it 
exerts its activity by complex linking of a zinc ion that is supposed to mediate the 
acetamide cleavage at the catalytic site[490]. (Fig. 1.6).  
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  Fig. 1.6: Trichostatin A 
 
Suberanilohydroxamic acid (SAHA also known as Vorinostat), is similar to TSA and it 
has been shown to inhibit cell proliferation in very low concentrations. It was previously 
selected among a library of 600 second-generation synthesized hybrid polar compounds 
as an active inducer of differentiation of murine erythroleukemia cells[491]. Later on, it 
has been discovered that SAHA inhibits different classes of HDACs. In 2006, FDA 
approved it as a treatment for progressive, persistent, or recurring cutaneous T-cell 
lymphoma, or for patients following two systemic chemotherapies[492-493]. It leads to 
hyperacetylation of histones as well as non-histone proteins, inducing apoptosis and 
sensitizing tumors to cell death processes and other drugs. The ability of SAHA to 
sensitize cancerous cells to other drugs makes it an interesting candidate for combination 
therapies, including epigenetic and non-epigenetic drugs. However, as SAHA has 
multiple targets, it also frequently induces many side effects such as anemia, diarrhea, 
fatigue, nausea, hyperglycemia, thrombocytopenia and anorexia[494].   
 
M-Carboxycinnamic acid bishydroxamate (CBHA) is another potent HDACi[495] and the 
structural basis for several derivatives, including Dacinostat[496] and Belinostat[497], that 
was FDA approved in 2015 for the treatment of patients with peripheral T-cell lymphoma 
(PTCL)[498]. 
 
Amino-suberoyl hydroxamic acids (ASHAs) have recently been discovered to inhibit 
HDACs and transform cell proliferation at nanomolar concentrations[499]. Other 
hydroxamates inhibitors, such as Oxamflatin[500] and Givinostat (also known as ITF2357) 
are under investigation for several diseases, including cancer [501]. 
 
LAQ824 is a cinnamic hydroxamic acid analogue that significantly enhances the anti-
tumor activity of adoptively transferred antigen-specific T-cells in preclinical models[502]. 
LAQ824 inhibits in vitro enzymatic activities and transcriptionally activates the p21 
promoter in reporter gene assays. It also selectively suppress growth of cancer cell lines 
at sub-micromolar levels after 48-72 hrs. of exposure, whereas higher concentrations and 
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longer exposure times are required to retard the growth of normal dermal human 
fibroblasts[503]. 
 
Panobinostat (also known as LBH-589) is a cinnamic hydroxamic acid analogue and it 
has been recently tested in combination of radiotherapy for the treatment of lung 
cancer[504]. In 2015, FDA approved Panobinostat in combination with Bortezomib and 
Dexamethasone for the treatment of patients with multiple myeloma[505].  
 
A series of aryloxyalkanoic acid hydroxamides have also been synthesized and they are 
HDACi at nanomolar concentrations[506].  
 
Cyclic peptides and analogues are a structurally complex group of HDAC inhibitors, 
naturally occurring and synthetic that all contain an unusual amino acid with a 
hydroxamic acid, epoxyketone, or ketone function in the side chain. Cyclic tetrapeptides 
contain a 2-amino-8-oxo-9, 10-epoxy-decanoyl as a half of the molecule, whereas cyclic 
peptides do not.  
 
Trapoxins A and B belong to the family of hydrophobic cyclotetrapeptides, with the 
epoxyketone attached to the cyclic peptide core and they were isolated from Helicoma 
ambies. They can revert the altered morphology of cells induced by oncogene expression, 
due to an irreversibly and potent inhibition of HDAC activity. Despite this efficacy, both 
compounds have not yet been introduced in clinical trials owing to their instability and 
toxicity[254]. 
 
Cyclic depsipeptides are polypeptides in which one or more amino acid is replaced by a 
hydroxy acid, resulting in the formation of at least one ester bond in the core ring 
structure. Many natural cyclic depsipeptides possessing intriguing structural and 
biological properties, including antitumor, antifungal, antiviral, antibacterial, 
anthelmintic, and anti-inflammatory activities, have been identified from fungi, plants, 
and marine organisms. In particular, the potent effects of cyclic depsipeptides on tumor 
cells have led to a number of clinical trials evaluating their potential as chemotherapeutic 
agents. Although many of the trials have not achieved the desired results, Depsipeptide 
(also known as Romidepsin or FK228), is a natural bicyclic depsipeptide isolated from 
Chromobacterium violaceum[507]. It is a stable prodrug that is activated by reduction with 
glutathione, after uptake into cells. Its reduced form, namely redFK, is the active 
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form[508]. FK228 is more effective than other HDACIs in vivo models because of its fair 
stability in medium or serum and its hydrophobic nature facilitating its penetration 
through the cell membrane to afford the active species. It was then synthesized and has 
been shown to have clinical efficacy in patients with progressive, persistent or recurrent 
cutaneous T-cell lymphoma and, in 2009, it has received FDA approval for use in 
treatment[509], although anemia, anorexia, hyperglycemia, thrombocytopenia, fatigue and 
nausea have frequently been reported[510].  
 
Cyclic hydroxamic-acid containing peptide (CHAPs), which are hybrids of trichostatin 
and trapoxin, have been further designed and synthesized[511]. In such hybrids, a 
hydroxamic acid side-chain is attached to the cyclic peptide core. Several products have 
thus been prepared which differ by changing, the number of the amino acids constituting 
the ring structure, the chirality of amino acids and the side-chain structure. Among them, 
CHAP1 and CHAP31 are the most stable and most potent HDAC inhibitors. 
 
Apicidin was initially isolated from two Fusarium species as a novel antifungal 
metabolite[512]. Its potent HDAC-inhibitory activity led to evaluate it as an anti-
proliferative agent and it is still under preclinical investigation[513]. Chlamydocin-
analogues are other cyclic peptides so selective and active, working at millimolar or even 
nanomolar concentrations[514].  
 
Short-chain fatty acids, such as sodium butyrate (also known as Buphenyl) and its 
prodrug AN-9, and phenylacetate are relatively weak inhibitors of the HDACs, with 
activity at millimolar concentrations[515].  
 
Valproic acid (also called VPA) is a relatively weak inhibitor of the HDACs, with 
activity at millimolar concentrations. It was previously used for many years as an 
antiepileptic drug: it is extremely well tolerated by patients, and its long-term effects are 
well known. The most commonly reported complaints are neurological symptoms (such 
as dizziness) that are generally transitory and reversible[516]. Neurological symptoms may 
become excessive when VPA is combined with other agents[459]; as well, its use during 
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Phenylbutyrate is another relatively weak inhibitor that has been in the market for non-
oncological uses and it has been shown to have activity as HDACi. In addition, it is 
currently under clinical trials for cancer treatment[476].  
 
Benzamides and their derivatives do not present structural similarity with other HDAC 
inhibitors. MS-275 (also known Entinostat or Benzamidine) is the most active benzamide 
derivative and induces hyperacetylation of nuclear histone in various tumor cell lines. 
MS-275 is a synthetic compound, showing relative selectivity and it has been under 
clinical investigation[518].  
 
CI-994 (also called as Tacedinaline or Acetyldinaline) is a synthetic benzamide 
derivative that shows relative selectivity in the HDACs inhibited. Its potential was 
confirmed as an oral cytostatic drug and preclinical studies have been conducted for the 
treatment of human acute meylocytic leukemia[519]. CI-994 has been introduced in 
clinical trials for a number of tumor diseases. The clinical potential of this drug has been 
also established against colorectal cancer[520]. 
 
MGCD0103 (also known as Mocetinostat) is dihydrobromide salt of a substituted 2-
aminophenyl benzamide and it is given orally[521]. Two novel synthetic compounds 
SK7041 and SK7068 cause accumulation of acetylated tubulin, but affect neither 
acetylation of histones nor inhibition of cell cycle progression[522]. 
 
Epoxides are inhibitors from natural sources. Depudecin is a fungal metabolite isolated 
from Alternaria brassicicola[523] and it can revert the cell morphology of v-Ras-
transformed cells. It also inhibits HDACs, inducing hyperacetylation of histones in a 
dose-dependent manner[524]. 
 
1.2.6.3 Bromodomain inhibitors. Bromodomains are conserved structural motifs 
associated with chromatin modifying proteins[525], they are considered epigenetic reader 
domains and able to recognize acetylated lysine residues for chromatin modification[526]. 
Bromodomain and extra- terminal (BET) proteins are known to mediate transcriptional 
elongation of acetylated chromatin, binding to the acetyl groups and their clinical 
importance has been investigated in many studies[527]. These proteins present unique 
function and specificity and they are promising targets for therapeutic treatments.  
Bromodomain inhibitors are selective small molecules that competitively bind acetylated 
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lysine residues, causing the disruption of the interaction between BET proteins and 
acetylated histones. Displacing BET proteins from the histone, the inhibitors may lead to 
widespread downregulation of c-Myc gene and its target proteins[528-529]. They also can 
directly regulate expression of BCL2, an anti-apoptotic gene that is highly expressed in a 
number to tumor types[530].  
 
1.2.6.4 HATs inhibitors. These compounds have been identified to inhibit the catalytic 
activity of HATs in many cancers and diseases. Although they are not very selective and 
bind to multiple classes of proteins, HAT inhibitors seem promising for treatment of 
various diseases[314].  
 
Bisubstrate inhibitors were the first discovered to selectively inhibit HATs and re-
express tumor suppressor genes in cancers[531]. Lys-CoA is high selective, however it is 
generally inactive in mammalian cell systems, exhibiting non-drug-like properties unless 
modified with the co-administration of moderately cytotoxic detergents or administered 
via microinjection. C646 may be the only potent and selective HAT inhibitor discovered 
so far. The compound binds at the specific enzyme and acts as a cofactor competitor[532]. 
It can mimic the pro-apoptotic effect of RNA-mediated HAT knockdown, which 
involves both extrinsic and intrinsic cell death pathways[533]. 
 
Natural inhibitors suppress histone H3 and histone H4 acetylation by specific HATs. 
Curcumin seems to inhibit cell proliferation and inducing apoptosis in breast cancer in 
vivo[534]. Garcinol and anacardiac acid inhibits acetylation, as well as they induce 
apoptosis and downregulate global gene expression. These two natural compounds 
however exhibit relatively low potency, which limits the authenticity of their activity[535]. 
 
1.2.6.5 Protein methyltransferase inhibitors. Methylation of lysine and arginine 
residues is catalyzed by protein methyltransferases (PMTs). The enzymatic activities 
have suggested pathological roles in cancer, neurodegenerative diseases, and 
inflammatory diseases. Inhibition of PMTs has been shown to stop these enzymatic 
alterations[536]. 
 
Selective inhibitor BIX-01294 was the first inhibitor of a protein lysine methyl -
transferase. Although the drug has good potency in terms of blocking protein–protein 
interactions, it is toxic in cellular assays at high concentrations[314]. 
87 
An innovative epigenetic strategy for retinoblastoma treatment 
Second-generation inhibitors include E72 and UNC321 incorporate 7-alkoxyamine 
tethered to the quinazoline core as a structural modification[537-538]. UNC0646 has a 
remarkable toxicity/function ratio in certain cell lines and it is also potent, selective, and 
has low cell toxicity making it an excellent inhibitor[539]. 
 
1.2.6.6 Histone methylation inhibitors. Newly synthesized molecules that inhibit 
trimethylation have been shown to re-activate developmentally regulated genes[314].  
 
3-deazaneplanocin A (DZNep) selectively inhibits trimethylation of lysine 27 on histone 
H3 and lysine 20 on histone H4, and reactivates silenced genes in cancer cells. DZNep 
was shown to successfully induce apoptosis in cancer cells by selectively targeting 
polycomb repressive complex 2 proteins, which are generally overexpressed in 
cancer[540]. DZNep specificity was however challenged in a subsequent study, in which it 
has been observed to reactivate developmental genes, not silenced by DNA 
methylation[541].  
 
1.2.6.7 Combined therapy. The interaction between different components of the 
epigenetic machinery has led to the exploration of effective combinatorial cancer 
treatment strategies, which involve use of both DNMT inhibitors and HDAC inhibitors 
together. Such combination treatment strategies have been found to be more effective 
than individual treatment approaches[250]. For instance, the de-repression of certain 
putative tumor-suppressor genes was only seen when DAC and TSA were combined[542]. 
Anti-tumorigenic effects of Depsipeptide were enhanced when leukemic cells were 
simultaneously treated with DAC[543]. Synergistic activities of DNA methylation and 
HDAC inhibitors were also demonstrated in a study showing greater reduction of lung 
tumor formation in mice when treated with Phenylbutyrate and DAC together[544]. 
Another promising strategy for cancer therapy is performed by a combination of 
epigenetic drugs with conventional chemotherapy that has been hypothesized to be more 
effective in treating drug resistant forms of cancer[431,545]. One study has shown that 
HDACi treatment demethylases and re-expresses tumor suppressor genes[546], resulting in 
the sensitization of cancer cells to other cytotoxic drugs. Additionally, HDACi in 
combination with the calpain protease inhibitor calpeptin has been shown to enhance 
growth inhibition of breast and ovarian cancer cells[547]. Furthermore, the combination of 
HDACi and TRAIL in mouse models was found to reduce tumor size by inducing 
apoptosis[548], and the combination of HDACi and GT-oligo increases ovarian cancer cell 
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death[549]. Drug resistant cancer cells may be similarly sensitized by demethylation to 
other cytotoxic agents as well. Recent clinical studies suggest that pretreatment with 
epigenetic drugs can reduce cancer relapse and be more effective for treating drug 
resistant cancers. For example, one study determined that lung cancer patients who were 
treated with the epigenetic drugs DAC and HDACi prior to conventional chemotherapy 
had lower incidences of relapse[550]. Two other studies demonstrated that MAPK pathway 
inhibitors in combination with HDACi suppressed cAMP mediated resistance in 
melanoma cells[551] and that pre-treatment of platinum drug resistant ovarian cancer cells 
with HDACi and methylation inhibitors sensitized these cells to cisplatin-mediated cell 
death[552]. In this last study, epigenetic drug treatment resulted in the re-expression of 
RGS10, an important regulator of cell survival and chemoresistance in ovarian cancer. 
Hypermethylation and histone deacetylation silence this gene in drug resistant ovarian 
cancer cells, and re-expression of this gene made these cells susceptible to platinum 
drugs. Overall, these results indicate that pretreatment using epigenetic drugs in 
combination with conventional therapies may be beneficial for reducing cancer relapse 
and improving drug resistant cancer treatment. Similarly, to cancer, the role of epigenetic 
drugs in combination with other agent could be beneficial in treating numerous 



















An innovative epigenetic strategy for retinoblastoma treatment 
1.3 DRUG DELIVERY SYSTEMS 
 
 
1.3.1 Economics of drug delivery 
 
Development of a new drug molecule is expensive and time consuming. Since last 
decades, the number of newly developed molecules introduced by pharmaceutical 
industry on the market has been reduced due to the rising of research and process costs, 
alternative investment opportunities and erosion of effective patent life. To avoid these 
drawbacks, interest of investors and researchers has turned towards investing the role of 
drug delivery system (DDS). Drug delivery is entering the forefront of product strategy 
for pharmaceutical companies: using a carrier to deliver an already tested agent 
represents a highly profitable strategy to overcome inherent risks associated with the use 
of new chemical entities[553]. Drug delivery could be described as a formulation or a 
device that enables the introduction of a therapeutic substance in the body to improve 
drug efficacy and safety by controlling its rate, time and place of release in the body. 
Delivering an agent to a specific site will include the administration of the therapeutic 
product (carrier and active compound), the release of the active compound by the 
product, and its subsequent transport across the biological membranes to the site of 
action.  
Moreover, the use of novel drug delivery systems including an "old" chemical compound 
appears a cheaper and more rapid alternative for patients to receive an effective 
treatment. In this case, in fact, pharmaceutical companies may partially skip the 
extremely costly preclinical and clinical investigations, counting on previously proved 
and validated pharmacokinetic and -dynamic features of the drug. Most importantly, 
DDS can also be considered as an interface between the patient and the drug. In this, 
DDS can represent both a safety barrier against host microenvironment metabolic attack 
as well as drug induced undesired side effect.  
The chemical and biological distinction between the drug and the device is important, as 
it is the criterion for regulatory control on delivery system formulations by the drug or 
medicine control agency.  
 
At present, there are 30 main drug delivery products approved for clinical use that 
represent a worthy part of the pharmaceutical market. In the United States for example, 
the total annual income for this sector is approximately US$33 billion with an annual 
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growth of 15% driven by the growing interest in obtaining safe drugs, capable of 
reaching the target and with minimal side effects[554]. Pharmaceutical companies are 
beginning to realize that drug delivery seems as a strong strategic competitive weapon to 
gain market shares and it provides greater return-on-investment even in term of pipeline 
timing: bringing a new drug through discovery, clinical testing, development, and 
regulatory approval is currently estimated to take a decade[555]. On the other hand, 
alternative drug delivery products often can be developed in half the time at usually less 
than 10% of the development cost[556]. Thus, alternative DDS offers opportunities to 
pharmaceutical and biotechnological companies searching for new ways to contribute to 
their business, because it is therefore a good fit for the current environment where fast 
time to market is important. 
Importantly, drug delivery compounds improve patient compliance trough more patient-
friendly delivery and less frequent dosing regimens, thus reducing symptoms and 
reduced long-term management costs.  
Needless to say, the whole society may receive a long-term return-on-investment and 
benefits from the development and implementation of drug delivery technologies since a 
better patient compliance will be followed by optimization of therapy, reduction of health 
system (hospital and home care) costs and eventually by a reduction of community and 
public resource waste.  
 
The main problems associated with systemic drug administration are essentially related 
to the biodistribution and bioavailability of pharmaceuticals throughout the body. To 
achieve the effective concentration the drug must be administered in large quantities, the 
majority of which will follow a different fate from the therapeutic one: in fact, once in 
contact with the blood stream the drug will undergo enzymatic changes, chemical 
degradation and immune system attack. Consequently, adverse toxic reactions and 
sensitization are common and contribute to reduce drug efficacy. 
A "perfect" drug should exert its pharmacological activity only at the target site, using 
the lowest concentration possible and without negative effects on non-target 
compartments. Drug delivery either by means of soluble or particulate components can 
improve drug pharmacokinetic, drug bioavailability, sometime safety and efficacy and it 
is used in the view of having the drug targeted only to the site where its action should be 
exerted. Thus, recently, a new field of biotechnology is focused on improving carriers 
(molecules, polymers and vectors) functionalization, exploring the possibility of having 
selected targeting properties to cell targets. Unfortunately, very often the body recognizes 
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the drug targeting system as non-self and unexpected toxicities could hamper the use of 
the same. It has been envisaged that ideal drug delivery systems should be made of self-
powered, computer-controlled medical nanorobot system, named pharmacyte[557], 
capable of precise transportation, timing and targeted delivery of pharmaceutical agents 
to specific targets in the body.  
  
 
1.3.2 Drug-delivery formulations in cancer therapy 
 
Chemotherapy is the most common conventional treatment option for several cancers and 
it is used either alone or in combination with other therapeutic approaches that kills 
cancer cells by drug toxicity or by preventing cell division, either by stopping the nutrient 
uptake or by inhibiting the mechanism responsible for cell division[558]. However, this 
approach is blunt and rarely successful for advanced stages of cancer, as 
pharmacologically active cancer drugs reach the tumor site with poor specificity and 
dose-limiting toxicity[559]. A large number of pharmacological compounds are in fact 
administered in the blood stream; however, this method of treatment is doomed to result 
in some limitations. Some of the compounds used in therapy can be unstable in 
physiological fluids due to their short half-life or may become unstable because of 
modification by endogenous enzymes. This would in turn result in a reduction of 
effective dosage and in the appearance of metabolites with potential toxic side effects. 
Moreover, blood streamed free drugs may diffuse into any tissues and can exert their 
activity on healthy cells. Currently, available free chemotherapeutic agents are time-
tested (half shelf-life controls) and confer good disease-free survival only for a limited 
period. For all these reasons, many efforts are made to develop new drug delivery 
systems.  
To protect drugs from rapid degradation and increase their bioavailability, several 
authors tried to formulate those using DDS. These systems in fact will convey numerous 
beneficial features: a good DDS should be design to improve drug half-life in the blood 
stream and to shelter the molecule from the host enzymatic attack; moreover, DDSs also 
form a barrier to avoid unwanted interaction of drug with host tissues[560].  
Furthermore, DDS can be also engineered to time-deliver the active molecule, delaying 
and prolonging the biological interaction at site, to control the rate at which a drug is 
released. Improving safety-efficacy ratio of classical drugs has been attempted using 
different methods, such as individualizing drug therapy, dose-titration and therapeutic 
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drug monitoring and it would allow opening the drug therapeutic window. DDSs are also 
flexible to be design for different delivery routes of administration: the choice depends 
on the disease, the effect desired and the product available. Drugs may be administered 
directly to the organ affected by disease or given systematically and targeted to the 
diseased organ. Various methods of systemic DDS are classified depending on the 
anatomical routes, including gastrointestinal, parenteral (such as subcutaneous or 
intravenous), transmucosal, transnasal, transdermal[561].  
 
Controlled-release technology can be applied to virtually all routes; for example, 
transdermal delivery, aerosol sprays, encapsulated cells, soft gels and a variety of 
programmable and implanted drug-delivery devices.  
The delivery systems currently available enlist carriers that are either simple, soluble 
macromolecules (such as monoclonal antibodies, soluble synthetic polymers, 
polysaccharides and particulate biodegradable polymers) or more complex 
multicomponent structures (microcapsules, micelles, liposomes, and cell-based-carriers).  
Here below an overview of the most common nano-evices in use and implemented in 
research and common practice, some of them even used in clinics for diagnostics and 
treatments. 
 
1.3.2.1 Beads. Beaded system consists of multiple, small beads that are composed of 
inert (such as polystyrene) or magnetic substances. These elements are normally 
designed for oral delivery; in fact, they are often pH sensitive so that the release can be 
selectively achieved in different part of the gastric system depending on the 
environmental acidity. The active drug is overlaid on the beads surface and encased in a 
delivery capsule. This process is used to achieve long-acting drug levels associated with 
the convenience of once-a-day dosing and it produces a pharmacokinetic pattern roughly 
similar to a zero-order pattern, with Cmax obtained approximately 4 to 6 hours after 
ingestion and sustained levels observed for 24 hours after initial dosing. Normally 
particles may range from 50nm to 20µm, with surface functional groups such as 
carboxyl- or amino- groups for covalent coupling of proteins or other ligands[555].  
 
1.3.2.2 Carbon nanotubes. Carbonanotubes (CNTs) have received a great deal of 
attention in biomedical fields: in fact, they are characterized by unique structures and 
properties. Nanodimensional sheets of carbon polymer (single wall SWCNT) or several 
layers wrapped around coaxially (multi walls, MWCNT) provide large hole axial space 
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to accommodate molecules and vast surface areas for rich surface functionalities. Indeed, 
the majority of applications are not performed using pristine CNTs but using oxidized 
CNTs that expose reactive carboxyl- groups to favor biointeraction. In this fashion, they 
show increased solubility in biological fluids and reduced toxicity together with 
increased reactivity so that can be used as transporters for the delivery of biomolecules 
and drugs in vitro and in vivo. Functionalized CNTs have been employed to deliver 
treatment in several sites of the body, given their ability to be transported through the 
blood stream and to enter the cytoplasmic space as non-viral vector for gene therapy 
thanks to needle-like endocytosis processes that pierce the cell membrane. Most 
relevantly, functionalized MWCNTs have been used to deliver therapies to the central 
nervous system, like siRNA-based anti-stroke therapy injected to animal brain, resulting 
in motor functional amelioration of injured animal[562]. More specifically, CNTs have 
been used as nanocarriers to transport anticancer drugs, genes, and proteins for 
chemotherapy[563], including topoisomerase inhibitors, platinum (Pt)-based drugs, and 
antimicrotubules. Given the negative charge concentrated on functionalized CNTs, these 
carriers are excellent vectors for gene, protein and nucleotides in cancer treatment 
especially achieved with the delivery of siRNA to tumor cells resulting in a significant 
inhibition of tumor growth[564]. 
Moreover, using combinations of light energy, CNTs have also been applied as mediators 
for photo-thermal therapy (PTT) and photo-dynamic therapy (PDT) to directly destroy 
cancer cells without severely damaging normal tissue using infrared energy[565].  
 
1.3.2.3 C-60 fullerene. Similar to CNTs, fullerenes (C60) are nanoscale carbon materials 
with unique photo-, electro-chemical, and physical properties; however, their inherent 
hydrophobicity limits their use in biology and thus leads to the research in developing 
water-soluble fullerene derivatives[566]. 
In recent years, various fullerene derivatives and surfactant-coated C60 had been 
reported, such as C60-(OH)n[567], C60-PEI[568], malonic acid derivatives[569] and sugar 
derivatives[570]. Nevertheless, the employment of fullerenes for drug delivery is still at an 
early stage of development[571], and up to now, there are only a few reports about 
fullerene derivatives being used for the delivery of anticancer drugs[572]. 
 
1.3.2.4 Nanodiamonds. Another carbon-based delivery and diagnostic system is the so-
called nanodiamonds (NDs), attractive agents for use in medico-biological applications, 
largely due to their great biocompatibility, stable photoluminescence, commercial 
availability, minimal cytotoxicity, and ease of purification[573]. NDs could be 
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functionalized and conjugated to a variety of molecules for the purpose of cell labeling 
and drug delivery that can improve their solubility, direct them to specific binding sites 
on target cells and tissues, and reduce their effects on normal tissues[574]. The diversity of 
ND functionalization broadens the scope of their potential diagnostic and therapeutic 
applications. They are suitable for controlled drug-delivery applications because of their 
capability to release drugs slowly and consistently and have abundant capacity for drug 
loading due to their large surface area:volume ratio[575]. Moreover, NDs could also be 
used to solubilize and efficiently deliver water-insoluble chemotherapeutic agents to 
several tumor cells[576]. They can be used as biomarkers or for cell labeling and tracing 
because they do not interrupt cell division or differentiation and have less 
cytotoxicity[577].  
 
1.3.2.5 Virus-mediated nanocarriers. Several virus-based nanocarriers have been 
reported as an emerging drug delivery system[578]. The versatile hierarchical assembly of 
viral coat protein subunits provides a natural and easy way of drug packaging. Virus-like 
particles (VLPs) can easily meet the requirements needed for a drug nanocarrier system, 
such as biocompatibility, water solubility, and high uptake efficiency. Moreover, VLPs 
can be modified with polymers such as PEG to improve their half-life in the host by 
moderating their immunogenicity[579]. 
 
1.3.2.6 Dendrimes. Dendrimers (also called star polymers) are a unique class of 
repeatedly branched polymeric macromolecules with numerous arms radially extending 
from the center, resulting in a nearly perfect 3D geometric pattern[580]. They comprise a 
series of branches around an inner core, the size and shape of which can be modulated as 
per the requirement. In particular, their surfaces are designed with functional groups to 
increase or resist biopermeability and to optimize biodistribution, receptor-mediated 
targeting, therapy dosage, or controlled release of drug, as well their interior void space 
may be used to encapsulate small-molecules metals or labeled imaging probes.  
Production of dendrimers can be customized accordingly to need for shape, dimension 
and nature of trapped molecules. Smart materials are increasing their versatilities, as they 
can be selectively sensitive to different specific environments, such those existing within 
different intracellular compartments.  
Those dendrimers used for cancer therapy, such as oligonucleotide-linked dendrimers, 
are designed to improve the therapeutic index of cytotoxic drugs: these polymers have 
been endowed with specific chemical moieties to direct delivery to cancerous cells and in 
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some cases are able to overcome multidrug resistance in tumors via bypassing efflux 
pumps[581]. 
 
1.3.2.7 Micelles. Micelles formed by self-assembly of amphiphilic block copolymers (5-
50nm) in aqueous solutions are of great interest for drug delivery applications. The drugs 
can be physically entrapped in the core of block copolymer micelles and transported at 
concentrations that can exceed their intrinsic water-solubility. Moreover, the hydrophilic 
blocks can form hydrogen bonds with the aqueous surroundings and form a tight shell 
around the micellar core. As a result, the contents of the hydrophobic core are effectively 
protected against hydrolysis and enzymatic degradation. In addition, the corona may 
prevent recognition by the reticulo-endothelial system (RES) and therefore preliminary 
elimination of the micelles from the bloodstream. The fact that their chemical 
composition, total molecular weight and block length ratios can be easily changed, 
allows control of the size and morphology of the micelles. Functionalization of block 
copolymers with cross linkable groups can increase the stability of the corresponding 
micelles and improve their temporal control[582]. 
 
1.3.2.8 Liposomes. Alec Bangham first produced liposomes in England in 1961. They 
are colloidal carriers, formed spontaneously when certain lipids are hydrated in aqueous 
media and consist of an aqueous volume entrapped by one or concentric bilayers of 
natural and/or synthetic lipids. They are made of amphipathic phospholipids where one 
end of each molecule is water soluble, while the opposite end is water insoluble. 
Accordingly, with their different lipid nature drugs can be encapsulated in liposomes, 
either in the phospholipid bilayer, in the entrapped aqueous volume, or at the bilayer 
interface. Liposomes are stable, biocompatible, biodegradable, self-assembled 
phospholipid membranes. Accordingly, with their structure and production design, they 
are classified as multilamellar, small unilamellar, or large unilamellar, and they range in 
size from 25nm to 10μm in diameter. The size and morphology of liposomes can be 
customized using different method of preparation and composition and serve delivery of 
drugs, vaccines, and genes for a variety of disorders, including cancer[583]. Liposomes 
have been clinically tested as carriers of antineoplastic and antimicrobial drugs, chelating 
agents, steroids, vaccines, and genetic materials[584-585]. Their surface characteristics 
allow liposomes to targeted delivery hydrophobic drugs without eliciting an immune 
response[586] and undergo an enhanced permeability and retention effect for preferential 
extravasation from tumor[587]. In some cases, liposomes attach to cellular membranes and 
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appear to fuse with them, releasing their drugs into the cell. Liposomes eventually 
become subject to enzymatic degradation and/or phagocytic attack, leading to release of 
drug for subsequent diffusion to tumor cells: in this case liposomes are taken up, the 
phospholipid walls are acted upon by organelles called lysosomes, and the medication is 
released.  
Liposomal nanomedicines represent one of the most advanced classes of drug-delivery 
systems, with several currently in the market and many more in clinical trials[588]. There 
are several examples of liposomal formulations for conventional small-molecule 
drugs[589] and some of those have been FDA approved, including liposomal doxorubicin, 
PEGylated liposomal doxorubicin, PEGylated liposomal daunorubicin[590]. Accordingly 
to their nature, they show different mechanisms of action for achieving drug release at 
target, for example cationic liposomes are reported to bind by electrostatic interactions to 
negatively charged phospholipid head groups, preferentially expressed on tumor 
endothelial cells[591].  
The surface features of the different liposomes also drive the choice for the route of 
administration and the more suitable pharmaceutical preparation. Mesophasic 
proliposomal system may be used for transdermal delivery[555] where the liposomal 
suspension might be incorporated into an ointment and gel base. The proliposomes 
system was found to be superior to PEG-based ointment system and it was developed for 
controlled, prolonged and localized delivery via topical route. The prolonged 
pharmacodynamic effect of novel proliposomal ropivacaine oil, together with its delayed 
elimination and prolonged redistribution to plasma, is compatible to depot-related slow-
release and similar to the performance of other liposomal local anesthetics. The 
advantage of the proliposomal oil lies in its ease of preparation and its extended shelf-
stability (>2 years) at room temperature[592-593]. 
 
The next generation of DDS represents a strategy for molecular targeting the drug to 
cancer cells and via antibody-mediated or other ligand-mediated interactions and it 
includes immuno-liposomes, in which mAb fragments are conjugated to liposomes. They 
are an integration of biological components capable of tumor-cell recognition with 
delivery technologies[594]. The immuno-liposomes offer a number of theoretical 
advantages as compared with other antibody-based anticancer strategies and appear to be 
non-immunogenic and capable of long circulation in the blood stream even with repeated 
administration [595]. Similarly, ligand-based targeting using growth factors, hormones, 
vitamins (e.g., folate), peptides or other specific ligands is being pursued in conjunction 
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with liposomes. As well, artificially engineered antibodies have been used as a conjugate 
to thermosensitive liposomes (affisomes) for the delivery of paclitaxel[596]. 
 
Furthermore, liposomes have also been investigated for the delivery of gene therapy, 
transferring nucleic acid-based gene-silencing molecules to tumor cells, in order to 
ensure a targeted molecular intervention and achieve a higher level of specific action than 
conventional cytotoxic chemotherapy.  
 
1.3.2.9 Nanoparticles. Nanoparticles (NPs) may vary in size and nature. They are 
typically metal based or polymer-based and span from few to several hundred 
nanometers. They can be engineered as nanoplatforms for effective and targeted delivery 
of drugs, and imaging labels, as they are able to overcome many biological, biophysical, 
and biomedical barriers. Targeting strategy can vary according to their nature, for 
example, iron-based system can be directed by magnetic field exposure. However, the 
most common targeting strategy is ligand-mediated where a specific interaction between 
NPs and cancer cell surface is desired. In cancer therapy, the ligand-targeted NPs are 
expected to deliver cytotoxic agents selectively and specifically to tumor cells via 
receptor-mediated endocytosis, thereby enhancing intracellular drug accumulation. A 
variety of tumor-targeting ligands, such as antibodies, folate or growth factors and 
cytokines has been used to facilitate the uptake of carriers into target cells[597]. Their 
properties could be attributed to their small sizes; lower toxicity, maximized 
bioavailability and they could be used to deliver small-molecule drugs, peptides, proteins 
and nucleic acids, either alone or in combinations. 
Despite extensive research on NP systems for cancer therapeutics, there are only a few 
tumor-targeted nanotechnology-based drug-delivery systems approved by FDA and 
European Medicines Agency[590,598].  
Recent advances in diagnostic technology led to development of bioaffinity NP probes 
for molecular and cellular imaging, targeted NP drugs for cancer therapy, and integrated 
nanodevices for early screening and detection of cancer. These developments raise 
exciting opportunities for personalized oncology in which genetic and protein biomarkers 
are used to diagnose and treat cancer, based on the molecular profiles of individual 
patients[586].  
NP-based DDS present several advantages, including the possibilities to reduce the lack 
of selectivity of anticancer drugs, targeting the chemotherapeutics to specific sites, either 
actively or passively[558]; to overcome multidrug primary or acquired resistance[576], 
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which is mostly due to increased efflux pumps in the tumor cell membrane; to defeat low 
aqueous solubility of anticancer drugs, increasing their bioavailability[599]. Moreover, NP 
systems have not only the ability to carry loaded active drugs to cancer cells presenting 
high efficacy and less side effects, but also, if combined with existing optical imaging 
technologies, to increase the resolution of tumor imaging[600].  
 
A wide variety of nanoparticles, including magnetic or gold-based, are used for 
diagnosis-cum-therapy of different cancer types, by visualizing tumors and carrying out 
targeted delivery of drugs with reduced toxic side effects[601]. Hence, they allow a 
theranostic approach towards cancer treatments, combining therapy and diagnosis into a 
single procedure or molecule[602]. They also can deliver genetic materials to both primary 
and metastatic cells for genetic therapy. NP formulations appear quite stable with high 
carrier capacity, have longer shelf life and improvement in biodistribution of cancer 
drugs, as well they are suitable for administration of both hydrophilic and hydrophobic 
substances through oral, nasal, parenteral and intraocular routes[603]. 
 
Magnetic NPs are very commonly used and based on the ferromagnetic elements Co, Ni, 
and Fe[604]. They can be also exploited to mediate a hyperthermic adjuvant effect in 
conjunction to deliver drugs in order to achieve high intra-tumoral concentration. 
Magnetic NPs are indeed in use during thermal ablation for cancer treatment, and can be 
considered as a minimally invasive option to exploit together with conventional 
therapies[605]. During thermoablation, cells heated to temperatures ranging 41-47°C begin 
to show signs of apoptosis[606], while temperatures above 50°C are associated with less 
apoptosis and more necrosis[607]. Thus, iron oxide NPs have been used as both diagnostic 
and therapeutic nanoscale materials to treat deep tissue tumors. With minimal drawbacks, 
they continue to be actively investigated because of their minimal toxicity and potential 
for rapid heating[608].  
Similarly, nickel-based NPs can be used for tumor targeting by serving either as inducers 
of hyperthermia in response to an externally applied magnetic field (as drug-delivery 
platforms)[609] or directly as pro-apoptotic oxidant agents[610].  
 
Gold-based nanoparticles (GNPs) are classically used as DDS for cancer therapy[611]. 
They are highly stable nanometer-sized colloidal suspensions, presenting versatile 
scaffolds for drug delivery[612], and they can be functionalized obtaining multiple 
receptor targeting, multimodality imaging and multiple therapeutic actions against 
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cancer. Different subtypes of GNPs such as gold nanospheres, nanorods and nanocages 
have been reported based on shape and physical properties[613]. Colloidal GNPs have 
great potential to overcome delivery limitations because of their biocompatibility and low 
toxicity. In cancer cell lines, surface properties of GNP have been shown to regulate their 
cellular uptake, intracellular release, and distribution in subcellular compartments[614]. 
In addition, GNPs could be heated with shortwave radio-frequency fields. By labeling 
GNPs with antibodies against particular cancer cells, higher concentrations of GNPs 
could be achieved within the target. Once the particles are internalized, radio-frequency 
fields applied to cells result in localized heat leading to cell death[607]. 
 
Polymeric NPs may deliver chemotherapeutic drugs with less interaction with healthy 
cells, resulting in enhanced efficacy, reduced toxicity, controlled and long-term release 
rates, prolonged bioactivity, increased patient compliance due to less administration 
frequency, and the ability to co-deliver multiple drugs with synergistic effects at the same 
site[615]. PNPs are available in different types, such as nanospheres and nanocapsules, 
depending on their particular application[616] and their versatility has been increased with 
the use of smart materials for their production. Smart materials in fact react to 
environmental stimuli such as temperature, pH to suit delivery purposes. Moreover, 
through chemical surface functionalization, NPs have been designed to enhance drug 
targeting specificity, lowering systemic drug toxicity, improving treatment absorption 
rates, and providing protection for pharmaceuticals against biochemical degradation. For 
instance, PNPs coupled with ligands and aptamers have been reported as a way to 
actively target cancerous cells that further induce receptor-mediated endocytosis for 
intracellular delivery. 
 
Quantum-dots (QDs). Among the different NPs, quantum may be considered as the most 
suitable for diagnostic purposes. They are spherical light-emitting NPs composed of a 
semiconductor material, mostly containing selenium metal compounds, with dimensions 
that range from few nanometers to microns. Different sized quantum dots colloid 
solutions once excited with electricity or light emit a constant wavelength fluorescent 
signal that can be exploited for medical purposes. It is easy to imagine the wide 
application that this might have in cancer screening, for marker detection in biological 
fluids, classification of tumor from biopsies, and for high-resolution biomolecular and 
cellular imaging[617]. Moreover, novel functionalized and fluorescent QDs were 
developed with high drug-loading efficiency, low cytotoxicity, and favorable cell 
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compatibility and they are promising candidates for drug delivery and cellular 
imaging[618]. These multifunctional QDs are promising vehicles for the co-delivery of 
nucleic acids and chemotherapeutics, and for real-time tracking during cancer 
treatment[619].  
QDs also have great potential in photodynamic therapy, where they act either as 
photosensitizers themselves or as a carrier[620]. 
 
1.3.2.10 Cell-based carriers. The delivery systems that we have briefly described might, 
in different ways hold some features that limit their application, including the reduced 
amount and/or dimensions of molecules that can be delivered, the restricted carrying 
capacity and the possibility of altering the drugs release[621-622]. Alternatively, the 
different cell-based carriers might be in theory considered as a very effective and reliable 
DDS, almost ideal, for the attractive possibilities to deliver therapeutic compounds, 
especially those that have reduced half-lives and are rapidly inactivated in vivo following 
administration[623]. Cell based carriers have been introduced since the seventies, however 
in the last few years, some have been widely developed and optimized, as possible 
vehicles for therapeutic compounds. They could be identified in two main categories:  
 
Transduced cells that are capable of expressing pharmaceutically relevant agents. These 
cells have been transduced with selected genes and with different vectors. Usually gene 
transfer is performed to endow the cell with a specific feature, for example to express a 
fluorescent protein to track the behavior of the cell in vivo or to correct a genetic defect 
as well as to make the target cell susceptible to the action of a selected drug[624]. They 
include myeloid precursors, fibroblasts, mesenchymal stem cells, neural progenitor cells, 
epidermal stem cells, hematopoietic stem cells, platelets, muscle progenitor and muscle 
stem cells. In addition, cell carriers have been reported as capable of delivering 
immunomodulatory molecules at sites of interest[625]. The main problems associated with 
the use of this technology is to regulate the duration of the effect of the transduced cells, 
the safety of the construct and their distribution in the body as it is difficult to control. 
However, the possibility of engineering stem cells for the in vivo production and release 
of selected therapeutics appear promising and this area will certainly enjoy new 
applications hopefully up to the clinic[626].  
 
Cell carriers. In general, carrier cells can be loaded with drugs or therapeutics. They can 
be transplanted in tissue compartment or enter the blood stream, therefore they be 
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designed to release their content either systemically or at site of action, where the target 
might be other cells or a tissue following a controlled release rate. They can be used to 
provide delivery for example of missing enzymes and hormones that might in turn affect 
the metabolism and function of neighboring cells and tissues[627].  
Cell carriers investigated so far include both bacterial cells and animal cells. Bacterial 
cells have been used as non-living cell envelope preparations from gram-negative cells, 
devoid of cytoplasmic content, while preserving morphology and surface antigenic 
structures[628]. These ghosts have been successfully investigated mainly as adjuvant 
particles to improve an immune response against the ghost-derived target antigens.  
Animal cells can include macrophages, erythrocytes, leukocytes, platelets, islets, 
hepatocytes and fibroblasts and they have been suggested as possible vehicles for 
therapeutic compounds[629]. In particular, macrophages could be loaded with drugs by 
way of ingested nanoparticles. This approach requires that macrophages are adoptively 
transferred to the recipient after ex vivo loading with nanoparticles conjugated with drugs 
and/or contrasting agents[630]. The majority of them are immediately sequestered in the 
liver and in the spleen[631].  
In the majority of cases the carriers are actual endogenous cells, they produce little or no 
antigenic response, and upon aging or being damaged can be removed from the 
circulation following a physiological route. 
 
 
1.3.3 Erythrocyte-based carriers  
 
Since the mid-seventies, the use of erythrocytes (also called Red Blood Cells RBCs) as 
drug carriers has been originally proposed to improve drug delivery. Here below I listed 
only few of the biological features that erythrocytes hold and that are pivotal for their use 
as carriers.  
Erythrocytes are naturally designed to constitute potential biocompatible cellular carriers 
for the delivery of molecules through the blood stream. They are the most common cells 
of blood, responsible for oxygen transport and normal human RBCs are discocytes, with 
a typical biconcave shape and an ellipsoidal disc with depressions located in the center 
on both sides. The process of erythrocyte formation within the body is known as 
erythropoiesis. In a mature human being, erythrocytes are produced in red bone marrow 
under the regulation of a hemopoietic hormone called erythropoietin[632]. The average 
human erythrocyte is 8.6μm in diameter and 1.9μm in thickness (2.5μm in periphery and 
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1μm in the center) and it has a mean volume and surface area of 86μm3 and 145μm2, 
respectively[633]. In mammals, RBCs are anucleated and lose their organelles during 
maturation. They also appear yellowish with a central pallor. The elastic, biconcave disk 
provides a large surface-to-volume ratio for oxygen delivery and better flexibility to 
squeeze through narrow capillaries, of 2-3μm in diameter[634].  
The blood volume of a normal adult human male is about 7% of body weight and about 
6.5% in a female and therefore, the average content of erythrocytes in healthy men and 
women is 5.4x106 and 4.8x106 per μl, respectively. A human body is commonly endowed 
with 2.5x1013 RBCs continuously produced by stem cells in the bone marrow, at a rate of 
2 million per second. As they mature, the erythrocytes appear quite simple in structure, 
they lose their nuclei, and organelles, become disk-shaped, and begin to produce 
hemoglobin. This molecule is a tetramer composed of four monomers held together by 
weak bonds. It consists of two pairs of polypeptide chains, the globins, each having an 
attached heme-molecule composed of iron and a protoporphyrin molecule. The iron atom 
has a free valence and can bind one molecule of oxygen. Thus, each heme-containing 
protein can reversible hold one molecule of oxygen and thus, it is responsible for O2-CO2 
binding inside the erythrocytes. The main role of erythrocytes is in fact the transport of 
O2 from the lungs to tissues and the CO2 produced in tissues back to lungs. Thus, 
erythrocytes are a highly specialized O2 carrier system in the body. Because a nucleus is 
absent, all the intracellular space is available for O2 transport that is guaranteed by about 
270 million hemoglobin molecules per RBC. In addition, because mitochondria are 
absent and because energy is generated anaerobically in erythrocytes, these cells do not 
consume any of the oxygen they are carrying. Erythrocytes have a life span of around 
100-120 days travelling the circulatory system before degenerate and being selectively 
removed and destroyed by macrophages in the reticulo-endothelial system (RES), also 
known as the monocyte-macrophage system, especially in the spleen and liver[638]. The 
breakdown products are recycled; hemoglobin is break down into globin and heme. 
Globin degraded to amino-acids, while iron reused in hemoglobin synthesis[635]. 
Their membrane is dynamic, semi-permeable components of the cell, associated with 
energy metabolism in the maintenance of the permeability characteristic of the cell of 
various cations and anions[633]. The surface area of mature RBCs is about 136μm2 but can 
swell to a sphere of approx. 150μm3. Their membrane is strictly connected with the 
membrane skeletal proteins that are organized in a uniform shell and their shape can 
undergo a number of reversible transformations. An important determinant of RBC 
survival is its deformability, which is affected by the internal viscosity, the 
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surface/volume of the cell and the intrinsic deformability of the membrane. The RBCs 
act as an osmometer since they shrink when placed into a hypertonic solution or swell 
when placed into a hypotonic solution. Thus, they can reach a critical hemolytic volume, 
giving rise to holes on the membrane ranging from 10nm up to 500nm. These processes 
are usually reversible and following hemolysis the holes close and the cell resumes its 
biconcave shape[626].  
The presence or absence of antibodies in plasma and of certain inherited antigens (A, B 
and Rh factor) on the surface of RBCs determines in part the different blood types. These 
antigens are proteins, carbohydrates, glycoproteins or glycolipids that can trigger an 
immune response if they are foreign to the body. The two most important human blood 
group systems are ABO and the RhD antigen and a safe blood transfusion or re-injection 
depends on careful blood typing and cross matching. For instance, blood group AB 
individuals have both A and B antigens on the surface of their RBCs, and their blood 
does not contain any antibodies against either A or B antigen. Therefore, an individual 
with type AB blood can receive blood from any group (with AB being preferable), but 
cannot donate blood to any group other than AB. They are known as universal recipients. 
At the contrary, blood group O (also called blood group zero in some countries) 
individuals do not have either A or B antigens on the surface of their RBCs, and their 
serum contains IgM anti-A and anti-B antibodies. Therefore, a group O individual can 
receive blood only from a group O individual, but can donate blood to individuals of any 
ABO blood group (i.e., A, B, O or AB). Because it is compatible with anyone, O 
negative blood is often overused and consequently is always in short supply.   
Indeed one of the most important features is the possibility of increasing the membrane 
permeability. This allows external content to enter the RBCs during favorable conditions 
and then to be trapped inside when condition regress to normal. Resealed red blood cells 
have been exploited extensively for both temporally and spatially controlled delivery of a 
wide variety of drugs, bioactive and therapeutic Once are loaded with active agents, 
erythrocytes still retain morphological, immunological and biochemical properties 
similar to those of native cells. Moreover, they are completely biodegradable without 
generation of toxic products and show high biocompatibility especially when autologous 
erythrocytes are employed. In comparison to other carriers, RBCs have a prolonged 
lifetime in circulation and can be safely eliminated through fixation of complement and 
uptaken by macrophages[636]. 
Potentially, a wide variety of chemicals can be encapsulated or coupled to the membrane, 
including biopharmaceuticals, therapeutically active peptides and proteins, nucleic acid-
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based biologicals, antigens and vaccines, that all are widely exploited candidates for 
target therapy. Erythrocytes are also suitable for the delivery of therapeutic agents that 
have reduced half-lives and limited tissue penetration[629,637-640]. Moreover, carrier 
erythrocytes can be employed as circulating bioreactors due to the presence of several 
enzymatic activities that can directly affect the loaded molecules and, in the case of 
loaded prodrugs, give rise to the active drug itself[463].  
Upon infusion into the compatible organism, drug-loaded RBCs can serve as the 
intravenous slow-release carriers and/or targeted drug delivery systems especially to 
target the drug to the RES[629], until they become aged due to the gradual inactivation of 
their metabolic pathways. After their natural life span in systemic blood stream, the cell 
membrane loses its natural integrity, flexibility and chemical composition. These changes 
will in turn result in the destruction of the senescent RBCs upon passage through the 
spleen trabecules[641]. In fact, when erythrocytes become old, certain catabolic changes 
occur leading a loss of both plasticity and resistance to osmotic and mechanical damage. 
These changes hinder the passage of the red cells through the microvasculature, which 
may convey to either lysis of the cell in circulation or phagocytosis in RES. In the first 
scenario, erythrocyte opsonization (coating by compounds appetizing phagocytes) by 
immunoglobulins and complement promoting phagocytosis give rise to direct destruction 
of carrier erythrocytes, lysis, aggregation, immune reactions, cellular uptake, adhesion to 
vascular endothelium and rapid elimination via phagocytosis and entrapment in the 
microvasculature[642]. Once in the reticulo-endothelial system, the erythrocyte is attacked 
by lysosomal enzymes that cause the breakage of the cellular membrane and the 
degradation of the hemoglobin by the heme-oxygenase enzyme. Aged or abnormal 
erythrocytes could be then destroyed by the phagocyting macrophages of the RES, 
including peritoneal macrophages, hepatic Kupffer cells, alveolar macrophages of the 
lung, peripheral blood monocytes[643] and vascular endothelial cells[644] that recognize the 
cells and remove them from circulation.  
It is noteworthy that the possibility exists to engineering modifying the RBC surface and 
loading capacity to benefit delivery efficacy and improve their application as drug release 
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1.3.3.1 Drug-erythrocyte associations. There are two major approaches for establishing 
a physical association between the therapeutic compound and erythrocyte carriers. The 
most widely used formulation is drug encapsulation in erythrocytes using several loading 
procedures, while the second approach occurs through the attachment of the ligand to 
RBC membrane. During all these procedures, blood group antigens on RBCs surface are 
not destroyed and blood typing is retained after drug loading or membrane binding[646-
647].  
 
Encapsulation of drug or other bioactive agents in resealed erythrocyte carriers can be 
performed by several procedures. Some of these methods have a physical nature whereas 
the others are chemically based and they all provide encapsulation of diverse agents 
including antibiotics, steroids, antimicrobial agents, proteins and genetic materials into 
RBCs. The optimal characteristics for a compound to be successfully encapsulated in 
erythrocytes include a considerable degree of water solubility, resistance against 
inactivation within the erythrocytes, the lack of physical and/or chemical interaction with 
erythrocyte membrane or the other cell constituents, and well-defined pharmacokinetic 
and -dynamic properties[648]. At the end of procedures, they reserve most of their volume 
available for the encapsulated substance and once in the stream, the drug-loaded 
erythrocytes serve as slow circulating depots[649] and target the drugs to the RES[650]. 
Moreover, erythrocytes provide a two-ways shelter action preventing drug premature 
inactivation and degradation by endogenous factors and, at the same time, protecting the 
organism against the toxic effects of the drugs thus avoiding immunological reactions.  
 
Drug loading in erythrocytes include several osmotic-based methods, chemical 
perturbation of the membrane, electroporation, entrapment by endocytosis, loading by 
electric cell fusion and by lipid fusion. 
 
Osmotic-based methods constitute the benchmark methods for the encapsulation of 
substances in erythrocytes, developed during the 1970s. Erythrocytes have the ability to 
undergo reversible swelling and shape changes in a hypotonic solution or under stress, 
accompanied by an increase in the permeability of the membrane. RBCs can increase in 
volume by 25-50% leading to an initial change in the shape from biconcave to spherical 
adapting additional volume while keeping the surface area constant[651]. Therefore, the 
cells can maintain their integrity up to a tonicity of 150 mosM/kg, above which the 
membrane ruptures, releasing the cellular contents. Exposure of erythrocytes to a 
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hypotonic solution creates transient pores of 200-500 Å in the erythrocyte membrane, 
and allows drugs to enter and become permanently entrapped after the cells have been 
resealed with a specific isotonic buffer solution. Osmotic stress can alter erythrocyte 
morphology thereby accelerating their removal from the circulation by the RES[652].  
Erythrocyte ghosts are what remains after cell lysis and depletion of cellular contents and 
can be resealed by restoring isotonic conditions, having the drug inside. Upon incubation, 
the cells are able to resume their original biconcave shape and recover original 
impermeability[653]. This methodology has been widely used and customized, applying 
some variations including hypotonic dilution, or dialysis and they have been applied in 
the encapsulation of various compounds, such as lipids, enzymes and other drugs. 
 
Hypotonic dilution was the first method studied and developed for the encapsulation of 
chemicals into erythrocytes and is the simplest and fastest way to include[654], low 
molecular weight drugs. According to this method, a volume of packed erythrocytes is 
diluted 2-20 times with aqueous solution containing the selected drug obtaining a hypo-
osmotic environment. The solution tonicit7 is then restored adding a hypertonic buffer 
and the loaded cells collected by centrifuge separation[655].  
The major drawbacks of this method include low entrapment efficiency[656] and a 
considerable loss of hemoglobin and other cell components. This reduces the circulation 
half-life of the loaded cells that are readily phagocytosed by RES macrophages[654]. This 
method is used for loading several chemical compounds, including enzymes, 
bronchodilators and anticancer drugs[651]. 
 
A more severe version of hypotonic dilution is the hypotonic hemolysis. The cells can 
maintain their integrity in an isotonic environment. Reduction of solute concentration in 
the external fluids   leads to membrane ruptures. At peri-lysis point, some transient pores 
are generated on the membrane that lead to cell lysis and loss of cellular contents. The 
rational for using these ruptured erythrocytes to reconstruct drug carriers is because 
ruptured membranes can be resealed by restoring isotonic conditions. Upon incubation, 
the cells resume their original biconcave shape and recover original impermeability[654]. 
This method also hold an historical value as it was used in 1986 by Leslie McEvoy and 
colleagues to evaluate the role of trans bilayer phospholipid distribution in the 
recognition and phagocytosis of erythrocytes by macrophages, finding that the 
asymmetrical distribution of phospholipid is the physiological feature that prevents RBC 
interaction with RES[658]. 
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As a optimization of this process, hypotonic hemolysis was later adapted for the 
standardization of production of a novel carrier by the Italian National Council of 
Research (CNR) which filed a patent, identified as WO2010/070620 for a engineered 
erythrocyte-based drug delivery system, referred to Erythrocyte-Magneto-FHA-
Virosomes (EMHVs) developed to improved ability of erythrocytes to release therapeutic 
compounds to specific target cells[639]. This system is currently in use in our lab and 
constitutes the base of the majority of our experimental activities, as we focus on the 
development and implementation of new anticancer therapeutics for personalized 
medicine[463,639-340,645]. Various modified version of similar process can be exploited to 
develop automatized systems: "Red cell loader" is a new procedure for the encapsulation 
of non-diffusible drugs into human erythrocytes, developed by Magnani and 
colleagues[636]. 
 
To optimize loading, several procedures were coupled: for example, hypotonic stress was 
associated with dialysis, another widely used method for concentration/size 
separation[659]. Semi-permeable dialysis membrane maximizes the 
intracellular/extracellular volume ratio for macromolecules during lysis and resealing. In 
the process, an isotonic and buffered suspension of erythrocytes with a suitable 
hematocrit is placed in a conventional dialysis tube immersed in 10-20 volumes of a 
hypotonic buffer at 4°C. The tonicity of the dialysis tube and, as a consequence, the 
resealing of loaded erythrocytes, are then restored at 37°C by directly adding a calculated 
amount of a hypertonic buffer (usually containing adenosine, glucose and magnesium 
chloride) to the surrounding medium or by replacing the surrounding medium by isotonic 
buffer. The drug to be loaded can be added by either dissolving the drug in isotonic cell 
suspending buffer inside a dialysis bag at the beginning of the experiment or by adding 
the drug to a dialysis bag after the stirring is complete. 
Hypotonic dialysis has high entrapment efficiency, in vivo survival and integrity of RBCs 
and loading capacity. Conversely, the drawbacks include a long processing time, 
heterogeneous size and the need for special equipment.  
 
Chemical perturbation of the membrane is based on the increase in membrane 
permeability of erythrocytes when the cells are exposed to certain chemicals. In 1973, 
Deuticke and colleagues showed that the permeability of erythrocyte membrane increases 
upon exposure to polyeneantibiotic such as amphotericin B[660]. Later, this method was 
successfully used to entrap the antineoplastic drugs in human and mouse 
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erythrocytes[661]. However, these methods induce irreversible destructive changes in the 
cell membrane and hence are not very popular[554]. 
 
Electroporation, also known as electro-insertion or electro-encapsulation, is performed 
using an electrical pulse to encapsulate bioactive molecules[662-663]. A strong external 
electrical field brings about irreversible changes in an erythrocyte membrane and thus, 
transient electrolysis has been used to generate desirable membrane permeability for drug 
loading[664]. The erythrocyte membrane is opened by a dielectric breakdown and 
subsequently, the pores are able to admit molecules of different size. The procedure 
involves suspending erythrocytes in an isotonic buffer in an electrical discharge chamber. 
This method of encapsulation is a good alternative to other commonly employed 
techniques and its entrapment efficiency is about 35%, as well the life span of the 
resealed cells in circulation is comparable with that of normal cells. Various compounds 
such as enzymes, drugs and latex particles of diameter 0.2μm[665] can be entrapped within 
erythrocytes by this method.  
 
Entrapment by endocytosis involves the dilution of 1:10 of packed erythrocytes with a 
particular buffer, followed by incubation. The various candidates entrapped by 
endocytosis include primaquine, vinblastine, hydrocortisone and chlorpromazine, which 
are known to induce uniconcave shapes called stomatocytes in the cell membrane. The 
pores created by this method are then resealed and the vesicle membrane separates 
endocytosed material from cytoplasm, thus protecting it from the erythrocytes and vice-
versa[666-667]. 
 
Loading by electric cell fusion involves the initial encapsulation of drug molecules into 
erythrocyte ghosts followed by adhesion of these cells to target cells. The fusion is 
accentuated by the application of an electric pulse, which causes the release of an 
entrapped molecule. An example of this method is loading a cell-specific monoclonal 
antibody into an erythrocyte ghost[668]. An antibody against a specific surface protein of 
target cells can be chemically cross-linked to drug-loaded cells that would direct these 
cells to desired cells[669]. 
 
Loading by lipid fusion is another method to encapsulate drug into erythrocytes. Lipid 
vesicles containing a drug can be directly fused to human erythrocytes, which lead to an 
exchange with a lipid-entrapped drug. This technique was used for entrapping inositol 
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monophosphate to improve the oxygen carrying capacity of cells[670], even though its 
entrapment efficiency is very low.  
 
Membrane binding of ligand to RBC membrane represents an alternative to 
encapsulation strategy to achieve RBC loading of active molecules. As for encapsulation, 
it could be reversible or irreversible. Drugs can be coupled to erythrocyte surface using 
variety of covalent and non-covalent cross-linkers, as well as anchored onto circulating 
naïve RBCs using recombinant fusion proteins with specific affinity to them. Erythrocyte 
membrane has the potential to provide an extended surface area that may be used for the 
attachment of multiple copies of protein or other therapeutic molecules. Lack of isolation 
of a drug from blood en route to the therapeutic site would represent an obvious 
downside of surface coupling vs encapsulation. However, the problem of premature 
inactivation and side effects can be partially avoided using pro-drug formulations 
resistant to plasma inhibitors[671]. On the other hand, surface coupling strategies avoid 
damaging encapsulation procedures and therefore offer theoretical advantages of drug 
loading without compromising RBC biocompatibility. In addition, binding therapeutic 
drugs to erythrocyte surface circumvents issues related to drug release[672]. Notably, 
coupling to RBC surface resolves diffusional limitations: even enzymes that react with 
small, membrane permeable substrate are more active when bound to the RBC surface 
than when incorporated within the cell[673].  
Techniques for coupling different molecules to RBC membranes have been designed 
during past decades, in the process of development of reagents for immunological 
reactions of agglutination. Numerous cross-linking agents and procedures have been 
applied to conjugate proteins and other antigens and biological molecules to RBCs of 
different animal species. However, subsequent studies revealed that these conjugation 
methods grossly damage erythrocyte membrane, reducing their plasticity, resistance to 
lytic agents and biocompatibility.  
Several practical strategies for coupling therapeutics to carrier RBC surface have evolved 
and have been tested in vitro and in vivo in last two decades. These strategies can 
involve: 1) chemical coupling of agents directly to RBC surface 2) coupling of a receptor 
that binds a therapeutic agent to erythrocyte membrane 3) conjugation of therapeutics 
with affinity ligands that bind to erythrocytes thereby anchoring cargoes on them. 
Binding can be achieved with antibodies, antigens, enzymes, cytokines and other 
biologically active compounds explored for systemic delivery.  
Animal studies showed that surface coupling to RBC could be used for improvement of 
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antigen delivery, masking of RBC antigens, clearance of pathogens from blood and 
intravascular delivery of therapeutics that supposed to act within the vascular lumen[671]. 
The most widely used strategy for membrane binding of ligands to erythrocyte carriers is 
the "avidin-biotin" approach with  several applications in drug delivery during the last 
two decades[674]. Biotinylation of intact mammalian erythrocytes could be performed 
either by attachment to the amino groups by means of biotin N-hydrosuccinimide ester 
(NHS-biotin) or by oxidation of the induced aldehyde groups of the erythrocyte 
membrane by biotin hydrazide. Avidin-biotin bridges have been used for reversible 
membrane binding of several bioactive agents, such as bovine serum albumin (BSA)[675] 
and HIV-1 tat protein[676]. 
 
1.3.3.2 Delivery strategies. According to the preferred therapeutic approach, circulating 
erythrocytes are used as either carriers for the sustained release of the drugs or to target 
the drugs to specific organs[677], using two major strategies in the delivery of the chemical 
compounds. 
 
Drug release strategy  involved the release of the therapeutics and/or imaging agents 
encapsulated into carrier erythrocytes. Releasing can occur either slowly, for example via 
diffusion through RBC plasma membrane[678] and/or its eventual degradation[679], or 
rapidly, e.g. via lysis of carrier RBC by plasma complement[672]. 
The maintenance of the normal oxidant/antioxidant balance in erythrocytes during drug 
encapsulation may help to produce loaded cells with characteristics similar to those of 
normal erythrocytes[680], without RES involvement and, in this case, the drug-loaded cells 
can be used as slow-release carriers for the entrapped drugs. Dosage is designed to obtain 
a prolonged therapeutic effect by continuously releasing medication over an extended 
period after administration of a single bolus[681]. Several mechanisms can contribute to 
this purpose including passive diffusion out of the loaded cells into circulation, 
specialized membrane-associated carriers[682], accumulation of the loaded erythrocytes 
into the lymphatic nodes, and drug release upon hemolysis in this sites and hemolysis in 
the injection sites[683]. 
 
Targeted drug delivery, involving RES or not, is an important physiological strategy 
using erythrocytes as carriers in drug delivery and it is among their mostly attractive 
applications in the recent decades. Accelerated removal and RES targeting occur when a 
considerable fraction of carrier is be trapped by the RES organs within a short time 
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period after re-injection. Once RES macrophages and other phagocytes naturally 
recognize loaded RBCs their fate is to be processed by these sites, which are the intended 
site of action of the drug[684-685]. Therefore, targeting outside these sites is minimal with a 
consequent reduction of  side effects and effective dose[686].  
The delivery strategy results appropriate for the treatment of specific disease states[687]. 
Biotechnological modification has been prompted to increase RES sequestration of 
loaded RBC and to increase selectivity towards certain organs such as the liver and the 
spleen. For instance, exposure of loaded carriers to membrane stabilizing agents 
increases the targeting index of the erythrocytes to RES via decreasing the deformability 
of these cells[688].  
As well coating the carrier cells by anti-Rh or other types of antibodies may be another 
method that makes the erythrocytes more recognizable by RES macrophages. Pre-
exposing the carrier erythrocytes to thermal shock, oxidant compounds, the agents 
reactive to the sulfidryl group-containing portions of the cell membrane, the enzyme 
neuraminidase and the proteolytic enzymes also have been exploited to improve RES 
targeting of carrier erythrocytes with some degree of success[554]. On the other hand, 
treatment of loaded RBCs with glutaraldehyde enhances their stability and, consequently, 
the release of the encapsulated substance is reduced[689-690]. 
 
It is possible to direct loaded erythrocytes to target organs other that those belonging to 
RES system. The various approaches may include the co-encapsulation of elements that 
help specific localization. For example, localized disruption and release can be achieved 
with application of ultrasound waves and consequently microvessel ruptures due to 
targeted microbubble destruction[691]. As well, wheat lectin extracted pre-treating the 
erythrocytes loaded with anticancer drugs improves their targeting index to neoplastic 
cells[692]. 
 
1.3.3.3 Advantages and disadvantages. At this point, and for the purpose of this thesis, 
a clear summary of the most important features of erythrocyte-based DDS is necessary to 
emphasize their beneficial aspect encouraging their use in drug delivery, as well as to 
stress some  drawbacks that might jeopardies our research. These in fact must be the 
focus of future effort for therapeutic optimization[693].  
Here is the list of some of the beneficial feature that enable their use as system of choice 
in certain situations as drug delivery system preferred to other widely used carrier 
systems (Table 3). 
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High degree of uniform size and shape of the 
carrier (monodispersion)[694-695].  
Complete biodegradability[682,696-697].  
Ability to circulate throughout the body 
(physiological role) reaching all 
compartments[638] 
Safe elimination mechanisms, including 
fixation of complement and uptake by 
macrophages[636]. 
For human erythrocytes, only autologous, 
Compatible or O negative blood can be 
used[699]. 




High performance of encapsulation[700]. 
High amount of loaded drug within a small 
cell volume (quantum delivery)[696]. 
Long life span in circulation[682,701]. 
Versatile carriers used to deliver a wide 
variety of compounds[640,702]. 
Possible leakage of certain encapsulated 
substances from the loaded 
erythrocytes[699,703]. 
Altered erythrocyte physiology due to the 
loaded molecules[699]. 
Difficulty to storage loaded viable 
erythrocytes prior to re-entry the host 
body[699].  
The need of using of conditioning agents 
(isotonic buffers with essential nutrients, 
nucleosides or chelators, lyophilization) as 
well as low temperature to stabilize 
products[699]. 




Possibility of localized concentration of the 
therapeutic agent to the target tissue, 
magnetic driven concentration[463,639,645,704-
706]. 
Targeting the RES organs towards the  
physiological route[682,698,707].  
Limited carrier activity in non-RES 
organs[708].  
Therapy release 
Improving of drug pharmacokinetic and -
dynamic parameters (increasing therapeutic 
window)[463,645,699,704]. 
Sustained release into the circulatory system 
acting as a reservoir for the loaded drug[696]. 
Ideal zero-order drug-released kinetics[709]. 
Systemic drug clearance and activity in blood 
are prolonged[698,699,709-710].  
Prevention of drug degradation and 
inactivation by host agents[463,682,701,709]. 
Prevention of any undesired immune 
response against the loaded drug[711].  
Considerable increase in drug dosing interval 
in chronic therapy[710,712]. 
Bioreactor activity that converts loaded pro-
drugs by RBC endogenous enzymes[463,713].  
Limited drug half-life due to easy uptake and 
accelerated in vivo removal by the RES (as 




Targeting the RES organs (physiological 
route[682,698,707].  
Protection of the organism against toxic 
effects of drugs[704]. 
High biocompatibility as the use of 
autologous cells, minimize the possibility of 
triggered immune response[682,696,698-699]. 
Decrease drug side effects[712,716]. 
Possible contamination due to the blood 
source, the equipment used and the loading 
environment[714-715].  
Intravascular hemolysis, including acute 
vascular, renal and immune reactions to free 
hemoglobin and hypoxia[708]. 
Off target drug leakage[699,703]. 
 
The success of blood derivatives technology highly depends on the reliability of the 
products. In the case of erythrocyte carrier production, good laboratory practices are 
applied and guidelines are set for the standardization of important product features. 
Indeed, the success of resealed erythrocytes products as a drug delivery system depends 
equally on final chemo-physical conditions as well as on their shelf-life duration. The 
most common storage media include oxygenated Hank's balanced salt solution (HBSS) 
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containing 1% soft gelatin, and acid-citrate-dextrose at 4°C. The cells are well recovered 
after liquefying the gel by placing the tube in water bath at 37°C followed by 
centrifugation. In this environment, erythrocytes remain viable in terms of their 
physiologic and carrier characteristics for at least 2 weeks at this temperature. The 
addition of calcium-chelating agents or the purine nucleosides improve circulation 
survival time of cells upon re-injection. Exposure of resealed erythrocytes to membrane 
stabilizing agents, such as dimethyl sulfoxide (DMSO), followed by lyophilization or 
glass filtration has been reported to enhance their stability upon storage. The resultant 
powder was stable for at least one month without any detectable changes. The major 
disadvantage of this method is the presence of appreciable amount of membrane 
stabilizers in bound form that remarkably reduces circulation survival time. 
Alternatively, another method utilized for storage has been cryo-preservation of RBCs in 
liquid nitrogen. Another strategy to increase storage stability includes encapsulation of a 
prodrug that undergoes conversion to the active drug only at body temperature in a way 
that therapeutic activity is maintained up to administration.  
 
Once administered into the blood stream, efficacy of resealed erythrocytes is related to 
their life- span that depends upon their size, shape, and surface electrical charge as well 
as the extent of hemoglobin and other cell constituents lost during the loading process. 
There are standard methods used to determine in vivo survival time, for example labeling 
of cells by fluorescent markers such as fluorescin isothiocyanate or entrapment of 14C 
sucrose or gentamicin. These methods are necessary also to describe the circulation 
survival kinetics of resealed erythrocytes that usually shows a typical bimodal behavior 
with a rapid loss of cells during the first 24 hrs. after injection, followed by a slow 
decline phase with a half-life about days or weeks[717].  
 
1.3.3.4 Characterization. After loading of therapeutic agent on RBCs, the carrier cells 
may be exposed to physical, cellular as well as biological evaluations. Physical 
characterizations include shape and surface morphology, cell size and volume, energy 
metabolism, deformability, surface pH, density gradient separation, stability, drug release 
and drug content. Cellular investigations involve hemoglobin content, cell volume and 
cell recovery, osmotic shock and fragility, turbulence shock and erythrocyte 
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Shape and surface morphology decide their life span after administration. The 
morphological characterization of erythrocytes is undertaken by comparison with 
untreated erythrocytes using microscopy imaging[718]. In the majority of cases, light 
microscopy reveals no change in resealed cells apart from the presence of few spherical 
erythrocytes (spherocytosis). Electron and phase contrast microscopy are normally used 
to check for morphological changes induced by osmosis-based encapsulation 
methods[719]. This analysis may reveal few stomatocytes, a form of spherocytosis with an 
invagination in one point of the disk and some cells of smaller size (microcyte)[693] while 
the majority of the cells maintain their biconcave discoid does not change shape after the 
loading procedure.  
 
Deformability affects the life span of the cells and the ease of passage through narrow 
capillaries and RES. This parameter determines the rheological behavior of the cells and 
depends on the visco-elasticity of the cell membrane, viscosity of the cell contents, and 
the cellular surface-to-volume ratio. The deformability is measured by passage time of 
definite volume of cells through capillary or polycarbonate filters[693]. 
 
Stability is assessed by means of the incubation of the cells in the autologous plasma or 
in an iso-osmotic buffer, setting hematocrit between 0.5% and 5% at temperatures of 4°C 
and 37°C[720]. To improve stability and prolong shelf life of carrier, erythrocytes are 
stored as lyophilized powder cells in an amber color vial to minimize light 
interaction[668]. 
 
Drug release rate is the most important parameter for evaluation of the state of resealed 
erythrocytes. In fact, this parameter regulates their pharmacokinetic behavior in vivo.  
Normally hemoglobin is released at the same time of because drug release as it involves 
the loss of cell membrane integrity (hemolysis). The drug release is controlled by 
molecular weight and liposolubility of the drug. The ratio between the rate of 
hemoglobin and the rate of drug release depend on the mechanisms involved in the 
release of the substance encapsulated within the erythrocytes[638]. There are mainly three 
ways for a drug to efflux out from the erythrocyte carriers: phagocytosis, diffusion 
through the membrane of the cells and activation of a specific transport system.  
RBCs are normally removed from circulation by the process of phagocytosis. The 
membrane surface state (rigidity or presence of antibodies) determines degree of cross-
linking determines whether liver or spleen will preferentially remove the cells. In this 
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case, a quick delivery of drug to RES compartment occurs.  
The rate of diffusion of the drugs out of RBC depends upon the rate at which a particular 
molecule penetrates through a lipid bilayer and it is great for a molecule with high lipid 
solubility[721]. Therefore, when the release rate of lipophilic drug is considerably higher 
than that of hemoglobin as the drug may diffuse readily thanks to passive diffusion. 
When the rate of drug release is instead comparable to that of hemoglobin, drug release 
occurs thanks to cell lysis, as the drug cannot be released by mere diffusion mechanism. 
Hence, hydrophilic drugs may become attached to cell structures requiring the lysis of 
the cell for drug release[722]. Moreover, most of the drug molecules enter cells by a 
specific membrane transport system that also ensures the drug release[554].  
Measurement of the internalized drug is performed to verify efficacy of the chosen 
encapsulating method, at the end of the process on isolated loaded erythrocytes. The 
process involves the deproteinization of packed, loaded cells with acetonitrile, followed 
by complete lysis and centrifugation. The clear supernatant is analyzed for the drug 
content using spectrophotometer or HPLC[682]. 
 
Hemoglobin content may be impaired by the alterations in the permeability of the 
membrane of  RBCs during the encapsulation procedure[723]. The process involves the 
deproteinization of cell membrane, followed by hemoglobin assay using a cell 
suspension by recording the absorbance of supernatant at 540nm on a 
spectrophotometer[724].  
 
Percent cell recovery involves counting the number of intact cells per unit volume of 
packed erythrocyte before and after loading the drug. The goal is to minimize the loss 
during the encapsulation procedure to maximize cell recovery[724]. 
 
Osmotic fragility detects the effect of loading process on the RBCs to check the possible 
changes in cell membrane integrity and the resistance of these cells to osmotic pressure 
of the suspension medium. The test is carried out by suspending cells in media of varying 
sodium chloride concentration and determining the hemoglobin released. In most cases, 
osmotic fragility of resealed cells is higher than that of the normal cells because of 
increased intracellular osmotic pressure[635].  
 
Turbulence fragility depends upon changes in the integrity of cellular membrane and 
reflects resistance of loaded cells against hemolysis resulting from turbulent flow within 
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circulation[725]. It is determined by repetitive passages of cell suspension through 30-
gauge hypodermic needle at 10 ml/min flow or vigorously shaking the cell suspension 
using a multiple test tubes orbital shaker. In both cases, hemoglobin and drug released 
after the procedure are determined[726]. The turbulent fragility of resealed cells is found to 
be higher. Moreover, the turbulence fragility index is defined as the shaking time 
producing 20% hemoglobin release from erythrocytes. 
 
Erythrocyte sedimentation rate (ESR) is an estimate of the suspension stability of RBCs 
in plasma and is related to the number and size of the red cells and to relative 
concentration of plasma protein, especially fibrinogen and α, β globulins. This test is 
performed by determining the rate of sedimentation of blood cells in a standard tube[727].  
 
The potential of erythrocytes based carriers are better exploited in  in vivo applications as 
this drug delivery system can reach a wide spectrum of pharmacological and therapeutic 
targets: they can be used for liver-deficiency/therapy[728], delivery of antiviral agents[678], 
enzymes and NPs, treatment of hepatic tumor[649] and for parasitic disease[682], removal of 
RES iron overloads and toxic agents[729]. They also may function as circulating 
bioreactors, improving oxygen delivery to tissue. 
 
1.3.3.5 Erythrocyte carriers in cancer. Over the last decades, erythrocytes have been 
studied as carriers of chemotherapeutic agents for targeting the RES[708]. However, to 
date the majority of the drug delivery studies based on drug-loaded erythrocytes that are 
in the preclinical phase are focused on the delivery of anticancer 
molecules[463,639,645,690,730].  
 
Loading anti-cancer drugs into carrier erythrocytes reduced drug toxicity towards the 
body and improves their delivery to tumors via several mechanisms: for example, some 
study exploit antibody specific recognition of tumor cells, while other are relying on an 
unspecific mechanisms called Enhanced Permeation and Retention (EPR) proper of the 
solid tumor microenvironment[679,731].  
Liposomes, linear polymers and polymer micelles represent the most popular carriers for 
anti-cancer drugs. However, RBC carriers may find a niche in tumor treatment, providing 
a wide range of anti-cancer encapsulated drugs and formulations with prolonged 
circulation. Carrier erythrocytes are also expected to improve drug and detection probe 
delivery, to have less adverse effects, and thus result in improved detection and treatment 
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of tumors[732]. For instance, loading the hydrophobic anti-tumor agent dequalinium into 
mouse RBCs supplied much longer half-life in circulation than PEG-liposomal 
formulation[733].  
The treatment of carrier erythrocytes with certain substances gives rise to alterations in 
the properties of the loaded RBCs and, especially, to a greater receptiveness of the RES 
in the macrophages. In particular, their cross-linking treatment with glutaraldehyde 
enhances the properties as a carrier system, and the carrier erythrocytes appear more 
stable and resistant to turbulences. The output of the encapsulated substance from these 
erythrocytes into the circulatory flow is reduced[696]. However, the treatment with 
glutaraldehyde increases the selectivity of the erythrocytes towards the RES[734], 
increasing their uptake by macrophages and other cells exerting active phagocytosis[735].  
Few encouraging examples of using loaded erythrocyte based therapy support the effort 
to optimize and advance erythrocyte carrier technology. For example, doxorubicin-
loaded RBC delivered the cargo into macrophages[736] and accumulated in the liver after 
intravenous injection in animal models[737]. This treatment was used against lymphoid 
tumors in dogs. In this case, doxorubicin inflicted unexpected substantial chronic 
suppression of myeloid cells however did not result in marked cardiac toxicity, a 
hallmark adverse effect[738]. Notably, a formulation of human autologous or blood typing 
and cross-matching compatible erythrocytes encapsulated with a related anthracycline 
antibiotic daunorubicin has been tested in patients with acute leukemia and showed a 
more prolonged drug level in plasma and lesser side effects than after injection of free 
drug[739]. Similarly, doxorubicin-loaded autologous erythrocytes re-infused in patients 
with lymphomas, provided reduction of peak level and extension of drug level in plasma 
of patients resulting in significant elevation of the area under the curve and reduction of 
side effects comparing with free drug[740]. 
 
Delivery of drug carriers to solid tumors relies in major part on the EPR effect mediated 
by abnormally high permeability of tumor vasculature and lack of effective lymphatic 
drainage. In the context of vascular permeability and tumor extravasation via EPR effect, 
large RBCs represent less effective delivery platform than sub-micron carriers such as 
liposomes.  
 
Erythro-Magneto-FHA-Virosomes® (EMHV). Delivery of drug carriers to solid tumors 
relies in major part on the EPR effect mediated by abnormally high permeability of 
tumor vasculature and lack of effective lymphatic drainage. In the context of vascular 
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permeability and tumor extravasation via EPR effect, RBCs represent an effective 
delivery carrier platform.  
Recently, in the laboratory the Institute of Clinical Physiology (IFC) of Consiglio 
Nazionale delle Ricerche (CNR) in Siena, an engineered modified erythrocyte-based 
delivery system was developed and patented. The Erythro-Magneto-FHA-Virosomes® 
(EMHV) represents a versatile carrier suitable for the delivery of active molecules of 
different chemical nature. For the production of EMHVs, erythrocytes are enriched with 
Fe2O3 paramagnetic nanoparticles, normally used in diagnostics. Once in the blood 
stream, the application of a biocompatible external magnetic field concentrates the carrier 
in selected areas of the body. Moreover, the erythrocyte membrane is decorated with the 
fusogenic glycoprotein filamentous hemaglutinin (FHA). EMHVs are therefore endowed 
with "virosome" properties that enhance their ability to attach and fuse with the host cell 
membrane. Once the EMHV is anchored to the target cell, a complete EMHV-target 
membrane fusion occurs within thirty minutes, with the complete release of the EMHV 
contents inside the host cells[639].  
EMHVs have been extensively characterized[463] and have been used as an effective 
DDS, which reliably conveys drugs to site of action sparing the normal tissue from toxic 
effects. EMHVs were used to deliver gene therapy, based on the use of synthetic DNA 
Elk-1 decoy in a model of syngenic porcine vascular smooth muscle cells in vitro, 
preventing cell migration and proliferation[640]. More relevantly, a preclinical 
investigation on the use of epigenetic therapy with DAC was successfully carried out, 
demonstrating the feasibility of drug delivery to a selected cancer site in vivo. Moreover, 
these experiments also indicated that the use of EMHV to deliver DAC increases its 
effectiveness as an anticancer age in a xenograft model of responsive human prostate 
cancer. Interestingly, EMHVs conveyed DAC therapy resulted in an anti-proliferative 
effect also in human non-responsive human prostate cancer model[645]. Currently, our 
effort continues to investigate the possibility of using EMHVs for combinatory therapy 
with different chemotherapeutics or molecule of different chemical nature.   
Following in the footsteps of these early successes, optimization of encapsulation of 
different pharmaceutical agents is pivotal for the development of novel therapeutic 
strategies. Erythrocytes as carrier may be suitable to convey different types of molecules 
in high concentration, however the choice of the active agent might require adaptation of 
the encapsulation procedures. Here I have reported a briefly list of the possible drugs that 
could be delivered by these carrier. The list is based mostly on the need encountered in 
our research for innovative anticancer therapy, under ongoing development in our lab.  
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Inhibitors of epigenetic enzymes have demonstrated promising results for the treatment 
of several tumors, although some reports emphasized the need to improve drug stability 
in solution as well as maximize delivery efficacy, reducing toxic side effects and prolong 
epigenetic outcomes. For instance, the remarkable therapeutic potential of free DAC is 
dramatically hampered by its systemic instability once free circulating into the blood 
stream. Many formulations have been designed to protect it from rapid degradation, 
using  different carriers  such as liposomes, polymer based system and NPs linking[741] in 
the attempt of improving  the pharmacokinetic and -dynamic principles that govern the 
action and disposition of demethylating agents[629].  
The main body of the successful results from this thesis will relate to the characterization 
and the use of DAC included into our EMHV delivery system to treat solid tumors in 
animal models.  
 
Biodrugs include peptides, RNA- and DNA-based therapeutics and can target cancer 
cells, interfering with the expression of specific protein and promoters of gene involved 
in tumor growth and progression. In general, biodrugs are inherently unstable, potentially 
immunogenic and typically require a delivery vehicle for efficient transport to the 
targeted cells.  
 
Molecular beacons (MB) may be peptide-, RNA- or DNA-based molecules. Peptide-
based MBs are Förster resonance energy transfer (FRET)-based target-responsive probes, 
which offer control of fluorescence emission in response to specific cancer targets and 
thus are emerging as promising tools for in vivo cancer diagnostics, image guidance and 
therapy. They show great potential due to their theranostic proprieties, although present 
selective delivery, specific activation and detection sensitivity and thus, the need to be 
targeted by DDS[742]. RNA-based molecular beacons (MB) against cancer protein have 
been designed and DNA-based MBs could be also custom synthesized, against an 
intracellular target homologues nucleic acid sequence that is recognized and reported.  
MBs are hairpin-shaped and present an internally quenched fluorophore, whose light 
emission is restored when they bind to their targets nucleic-acid sequence and undergo a 
spontaneous conformational change[743]. Therefore, if the target nucleic acid is present, 
the event of MB-target hybridization can occur, causing the activation of the fluorophore 
with fluorescent light emission. The probes are particularly suited for tracing specific 
sequences of nucleic acids and they can be also used as novel theranostic tools as the 
protein sequence hybridization will impede transcription.   
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Among cancer regulatory targets, BIRC5(Survivin) is a member of the inhibitor of 
apoptosis family (IAPs)[744-745]. Besides its inhibitory action on apoptosis, Survinin is also 
involved in the regulation of cell division. Its protein expression is up regulated in several 
cancers as it regulates tumor progression and evasion of apoptosis. In line with its 
physiological roles, it is expressed also in several healthy tissues. The high expression of 
Survivin in cancer cells correlates to poor prognosis and resistance to chemotherapeutic 
treatment, thus making this protein an attractive target in anticancer therapy. The dual 
role of Survivin in cells, regulation of cell division and inhibition of apoptosis, combined 
with controversial data concerning the expression in normal tissues, emphasize the need 
to have an appropriate control release for selected inhibitors to test both in vitro and in 
vivo studies. Recently, various biological drugs have been developed, targeting Survinin 
expression. Among them, MB against mRNA-Survivin (SURV-MB) has become one of 
the agents used for the development of our EMHV-mediated anticancer therapy. To 
overcome limitation of the instability and to allow better permeability, we successfully 
used SURV-MB-loaded EMHVs to investigate Survivin role in retinoblastoma.  
 
RNA-based therapeutics can be classified by the mechanism of activity and include 
inhibitors of mRNA translation (antisense), agents of RNA interference (RNAi), 
catalytically active RNA molecules (ribozymes), and RNAs that bind and block targeted 
proteins and other molecular ligands (aptamers).  
RNA interference, also known as post-transcriptional gene silencing (PTGS) pathway, is 
a biological process in which endogenous microRNAs (miRNAs) and double-stranded 
exogenous small interfering RNAs (siRNAs) molecules inhibit gene expression, typically 
causing degradation of specific target mRNAs, translational repression and sequence-
specific cleavage of complementary mRNA. At present, many RNA-based therapeutics 
have reached clinical testing[746]. Challenges with their delivery, specificity, stability, and 
immune activation have spawned improvements in nucleic acid carriers and the 
development of chemically modified oligonucleotides[747].  
 
Ribozymes are catalytic RNAs that function as enzymes and do not require proteins for 
catalysis. They are self-processing RNAs that cleave mRNA transcripts[746]. However, 
the substrate recognition domain of ribozymes can be artificially engineered to stimulate 
site-specific cleavage and to be allosterically activated by effector molecules, which has 
led to the development of artificial "riboswitches" as biosensors and synthetic biological 
tools[748].  
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Ribozymes require chemical stabilization before the delivery to the target cells and some 
of them have shown encouraging results[749-750], although presenting some severe side 
effects. For example, Survivin (BIRC5)-ribozyme was able to catalyze Survivin(BIRC5)-
mRNA degradation. 
 
Aptamers are single-stranded nucleic acids that bind and block targeted proteins with 
high affinity and specificity due to their stable-three dimensional shapes[751]. Many RNA 
aptamers exist as hairpin-like monomers that bind targets via unpaired nucleotides, but 
some others function as multiplexes. They are often modified during chemical synthesis 
to increase their resistance to nucleases and improve pharmacological properties[746]. 
 
DNA-based biodrugs are also available: Decoys (hijacker molecules) are short synthetic 
double-stranded (DNA) oligodeoxynucleotides that compete with promoters and can 
sequester and block related transcription factors, preventing their binding at target 
promoters. There are few encouraging reports of anticancer activity due to decoys used 
against the regulation pathways  for HSF1 and NFkB, two key role proteins in cancer 
development. Although they are intended for potential therapeutic applications however, 
they might be better suitable as combinatory strategy for multi-transcription factor-




1.3.4 Ocular DDS 
 
In the attempt to develop a therapeutic strategy for retinoblastoma, one of the most 
important features to consider is how to deliver the treatment to the cancer lesion. In this 
effort, one must consider that the eye is a close system, however highly supplied by 
major blood vessels. Moreover, the eye, for anatomic and functional classification, 
belongs to the central nervous system, and similarly to the brain is protected by 
biophysical barriers. For this, topical and systemic administration of drugs to the eye is 
highly inefficient and, consequently, ocular drug delivery is an extremely challenging 
endeavor[753]. The main drawbacks are bioavailability and uncontrollable targeting of 
conventional ophthalmic preparations. Different drug delivery systems have been 
investigated for these purposes, including a controlled-release of the drug, drug targeting 
and penetration enhancement of the drug[754]. 
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Topical eye drop is the most convenient and suits patient compliance[755] as it is a non-
invasive route of administration, even though delivery of therapeutic drug levels to the 
targeted ocular tissues is partially achieved and maintained for short time. 
In the treatment of ocular diseases, topical application has been therefore the main route 
of drug administration, especially to the anterior segment of the eye. Advances are 
established by modulation of conventional topical solutions with permeation and 
viscosity enhancers. However, rapid clearance from the eye often results in short 
intraocular residence times and therapeutic effect can only be achieved with frequent 
administrations. On the other hand, for posterior segment of the eye, drug can be 
delivered by using different routes, although the presence of blood retinal barriers hinders 
the systemic disposal. In these cases, repeated intravitreal injections represent the most 
common and widely recommended route of drug administration however, they cause 
several side effects and poor patient tolerance[756]. Periocular injections are less invasive 
and better accepted, however they lead to compromised drug permeation, due to the 
ocular barriers. To overcome these limitations there is the need for controlled and 
sustained release of the drug in these compartments and research has been focused 
towards development of drug releasing devices and nanoformulations for treating chronic 
vitreoretinal diseases. These novel devices and/or formulations must hold some 
requirement such as an easy formulation, no/negligibly irritating action, high precorneal 
residence time, sustained drug release rate, and enhanced ocular bioavailability of 
therapeutics[1]. To date, several ocular drug delivery systems, such as emulsion, 
ointments, suspensions, aqueous gels as well novel ocular DDS, like nanotechnology-
based drug delivery, implants, contact lenses, microneedles and in situ thermosensitive 
gels have been developed. 
 
Hydrogels have been investigated since 1965 as ocular drug delivery systems and 
increase of their loading capacity, optimization of drug residence time on the ocular 
surface and biocompatibility with the eye tissue have been the main focus of previous 
studies[757]. Then, the development of new therapies for treating various eye conditions 
has led to a demand for extended release delivery systems, which would reduce frequent 
ocular instillation while still achieving therapeutic drug levels in the target tissues for a 
specific length of time.  
 
Investigation led to the use of conventional drug delivery systems as potential intraocular 
carriers. NP-based systems designed for retinoblastoma therapy have improved rates of 
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drug delivery to the posterior segment of the eye and have increased the intravitreal half-
life of chemotherapy agents, thus highlighting their potential in treatment of this 
cancer[758]. The intravitreal delivery of biodegradable drug-loaded polyester-based 
microspheres in the ocular tissue exhibited reduced rates of toxicity to surrounding 
normal structures[759], as well dendrimers or gold-tethered liposomes containing 
chemotherapeutic agents significantly decreased tumor volume in retinoblastoma 
preclinical models[760-761]. Even in the case of ocular delivery, gold-based NPs conjugated 
with chemotherapeutics can strongly absorb near infrared light, which enables the 
subsequent drug release and the photo-thermal destruction of cancer cells[762]. The light-
responsiveness of gold and other photosensitive nanocarriers infers considerable potential 
for Rb because of the regular use of lasers in the treatment of retinal disease. 
As bioengineering advances, various non-implantable and implantable drug delivery 
devices have been also developed. Colloidal carriers may allow targeted drug delivery 
and provide protection to substances that are sensitive to degradation. To improve 
bioavailability and delivery rate, several biodegradable polymers have been used as 
ocular drug carrier for controlled-release systems. They release the drug at time of self-
degradation and are finally absorbed by the body[754]. Furthermore, novel natural 
polymers, like arabinogalactan, xyloglucan, gum cordia, locust bean gum and 
carrageenan have demonstrated the possibility to safely deliver drugs at a controlled rate 
in different ophthalmic formulations[763]. 
 
Numerous novel treatment options have been as well explored and include molecularly 
targeted or gene therapies and systemic or local drug delivery systems. In particular, 
molecularly imprinted soft contact lenses (SCLs) hold high potentials as novel drug 
delivery systems for the treatment of eye disorders. This technique is used for the 
preparation of polymers with specific binding sites for a template molecule; it is a 
versatile and effective method in optimizing the drug release behavior and enhancing the 
loading capacity of SCLs.  
 
It is undoubtable that the applicability of these novel different ophthalmic formulations is 
increasing, however, to date tremendous effort is still required to establish them on a 
commercial scale. Consequently, there is a need for designing new delivery strategy and 
optimize eye treatment. In this project, we focused on the necessity to develop the 
engineered erythrocyte-bases DDS that could recapitulate all the beneficial 
characteristics of the erythrocyte carriers and that could be locally and safely concentrate 
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in the eye. More specifically, we investigated the potential of the  magnetically driven 
EMHVs to deliver novel therapies against Rb. The application of the external 
biocompatible magnetic field ensured carrier localization. EMHV would favor drug 
release and concentration at site of cancer lesion, sparing adjacent healthy ocular tissues 
in an orthotopic mouse model, generated by using Weri-Rb1 human retinoblastoma cells, 
where both epigenetic therapies and newly synthesized biodrug against deferentially 
expressed gene markers of Rb were tested. Therefore, carrier erythrocytes could be 
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2 AIMS 
 
Retinoblastoma is a devastating solid tumor that affects children and youngsters, for 
which treatment is still mostly confined to surgery and chemotherapy.  The main aim of 
this work was to characterize and develop an innovative strategy for the local delivery of 
new therapies to treat retinoblastoma. Moreover, our activity has been focused on 
standardizing a preclinical investigation set developing an orthotopic model that could be 
versatile for the study of a novel DDS  for the delivery of newly synthesized biodrugs of 
different chemical nature.   
 
As retinoblastoma is known to arise from epigenetic alterations, besides RB1 inactivation 
and/or silencing, the work aimed at targeting reversible epigenetic gene silencing that 
sustain cancer development. To identify key genetic actors that mediate cancer 
phenotype in retinoblastoma cells a step-wise experimental design was set, that started by 
proving the anti-proliferative effect of DAC on Weri-Rb1 in vitro and in vivo. We aim at 
studying, by microarray analysis, the time course of differential gene expression to 
identifying potential key genes and pathways mostly affected by the epigenetic treatment. 
Methylation analysis of the selected gene panorama will give indication on the 
mechanism of action of DAC that could have either a direct effect on methylation of 
genes, or a more blunt effect on cell survival. We will use computational analysis of 
predictive gene-gene co-expression network of interaction and we will perform 
validation of the predictive investigation by means of qPCR. 
 
While confirming DAC demethylating activity and anti-proliferative effect on Weri-Rb1, 
a comparison between single DAC treatment and combination of treatment with other 
epigenetic drug, namely trichostatin A, a HDAC inhibitor will be also performed as part 
of the optimization of the new therapeutic approach to identify the most effective and 
less toxic epigenetic treatment in Rb. This set of experiment will shed light on the 
epigenetic regulation of Weri-Rb1 and also indicate which one, between DAC alone and 
the combination of the two drugs, could be the best treatment worthy of further 
experimental investigation. 
 
The development of a localized delivery strategy is in fact a major goal of my research, 
therefore I implemented and optimize the inclusion of only DAC into a cell-based carrier. 
The erythrocyte based engineered DDS named the Erythro-Magneto-FHA-Virosome® 
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(EMHV), was patented by the CNR laboratory in which I carried out the whole 
experimental work. EMHVs provide a magnetically driven mean to concentrate drug 
delivery at site of cancer lesion. My project aims at describing the localized activity of 
EMHV-loaded DAC both in xenograft and in orthotopic models. It is expected that the 
use of the carrier will highly improve the efficacy of DAC, opening the therapeutic 
window of this FDA approved anticancer agent. These experiments are mandatory for the 
further development of the therapy in clinical set.  
 
Furthermore, in accordance with our analysis of microarray and gene expression in vitro 
and ex vivo indicating Survivin as a major role-play gene in Rb, I decided to investigate 
for the first time a newly synthesized biodrug, a molecular beacon (MB) against 
Survivin-mRNA (SURV-MB) to prevent expression of this widely expressed pro-
survival effector Rb in cancer cells. Moreover, the use of a MB to impede gene/protein 
expression could result in both therapeutic and diagnostic effect. I aimed at describing 
the internalization of MB within Weri-Rb1 and to preliminary verify their potential as 
diagnostic tool. To test their potential anti-proliferative effect, MB will be used both as 
free agent as well as loaded into the EMHV. For this a characterization of MB inside 
EMHV is also due. 
  
Overall, this could be considered as a forerunner project to identify new genetic 
biomarkers for retinoblastoma and to describe relevant genetic networks sensitive to 
epigenetic regulation to exploit as therapeutic targets. This project is also set to develop 
new therapeutic strategy based on the use of an innovative carrier for minimally invasive 
localized treatment of Rb that holds potential for clinical application. The combination of 
our results from computational prediction, network interaction and carrier optimization 
could provide the basis for innovative tools in personalized medicine.  
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Superparamagnetic NPs were purchased from nanoscreenMAG, Chemicell, Berlin, 
Germany. Filamentous Hemagglutinin from Bordetella pertussis (FHA), 5-aza-2'-
deoxicytitidine (DAC) and Trichostatin A (TSA) were purchased from Sigma-Aldrich, 
Milan, Italy. TurboFect Transfection Reagent was purchased from Thermo Scientific, 
Waltham, Massachusetts, USA. Molecular Beacon (MB) for Survivin-mRNA[764] has 
been modified by the laboratory of IFAC CNR in Florence, immobilizing the 
fluorophore/quencher pair at the extremities: 5'(ATTO647N)-
CGACGGAGAAAGGGCTGCCACGXCG(BBQ)-3' X=C6-dT Thio, and then kindly 




For all the experiment, the human derived Weri-Rb1 retinoblastoma cell line was used, as 
it represent a widely accepted model for the study of retinoblastoma. Weri-Rb1 
retinoblastoma cell line was obtained from American Type Culture Collection (ATCC, 
Rockville, MD) and maintained in culture medium RPMI 1640 supplemented with 10% 
Fetal Bovine Serum, 2mM L-glutamine, in presence of 100U/ml penicillin-streptomycin, 
at split ratio of 1:2 twice a week. Weri-Rb1 cells were used both for in vitro study and for 
xenograft and orthotopic implantation.  
 
Confocal Laser Scanning Microscopy (CLSM) analysis  
 
After 24 hours of incubation, Weri-Rb1 cells at a density of 5x105 were seeded in 6-well 
microtiter plates. This cell line grows in suspension and recapitulates all the feature of 
human cancer. The culture medium could contain MB against Survivin-mRNA, either 
administered in free form or loaded inside the erythrocyte-based delivery system 
EMHVs. Free biodrug was internalized inside cells using the transfection reagent, 
following manufacturer's instructions, meanwhile the loading inside EMHVs was 
performed following the CNR patented method, described below. 
In a sample, fresh medium was replaced with no adding of Survivin-MB-EMHVs to 
visualize naïve cell structure (control). For microscopy investigation of drug inclusion, 
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cells were let adhere on the coverslip using a mix of ice-frozen acetic acid and ethanol 
100%. Cells were washed in 1X PBS buffer, fixed with cold ethanol and then transferred 
on a slide. Nuclei were counter stained with DAPI. Cells were washed twice with 1X 
PBS and a coverslip is mounted on the slide, using an anti-fade medium. Fluorescence 
and bright-field images were captured by CSLM, Leica TCS SP5 inverted microscope 
system, equipped with sources emitting from the UV to the visible. DAPI fluorescence 
was detected using excitation at 405nm and recording emission at 454nm while the 
fluorescence of Survivin-MB was detected using excitation at 635nm and recording 
emission at 670nm. 
 
Cytofluorimetric (FACS) analysis 
 
Weri-Rb1 cells at a density of 5x105 were seeded in 6-well microtiter plates for cell cycle 
assays. The culture medium in which cells were re-suspended might be the same [CTRL] 
or contain free DAC at the concentration of 2.5μM (corresponding to the therapeutic 
dose of 1.7μg), in order to confirm the previous data [DAC 1.7μg]. This treatment was 
also delivered towards the CNR patented erythrocyte-based delivery system named 
EMHV and so 1μg DAC loaded-EMHVs could be tested on Weri-Rb1 [DAC 1μg - 
EMHV]. Cells could be also treated with free TSA at increasing doses of 75, 150 and 
300ng [TSA 75ng, TSA 150ng, TSA 300ng] to detect the most effective anti-
proliferative condition, and then a combined therapy involving free therapeutic DAC and 
free TSA at different doses after 24 hours incubation might be detected [DAC 1.7μg - 
TSA 75ng (24h); DAC 1.7μg - TSA 150ng (24h); DAC 1.7μg - TSA 300ng (24h)]. 
Moreover, Survivin-MB loaded-EMHVs were used on Weri-Rb1 cells, to detect its 
activity for cell cycle arrest.  
After 24, 48 and 72 hours of incubation, control and epigenetic treated cells were 
harvested and analyzed by FACS. Weri-Rb1 cells treated with loaded Survivin-MB were 
instead analyzed after 6 and 24 hours incubation. Nuclei were stained with 10μg/ml 
propidium iodide (PI) in hypotonic solution (1X PBS containing 0.1% sodium citrate and 
0.1% Triton X-100) for 30 minutes at 4°C in the dark for assessment of cell cycle phases.  
Apoptotic cells were detected by Annexin V test (BioVision). The control and treated 
cells, except whose treated with DAC-EMHV, were suspended in 1X binding buffer and 
incubated at room temperature for 15 minutes with Annexin V-FITC, as well Propidium 
Iodide (PI) was added for nuclei staining following manufacturer's instructions. 
Conversely, EMHVs cannot be analyzed using apoptosis kit due to their physical and 
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morphological features.  
Flow-cytometry was carried using Becton-Dickinson FACScan CentroII and data were 
analyzed by FlowJo software. 
 
Quantitative qPCR experiments 
 
QPCR was performed to quantify mRNA levels in some of the relationships evidenced in 
particular by regulatory paths governed by master regulators. Total RNA was extracted 
from Weri-Rb1 cells using NucleoSpin RNA isolation kit (Macherey-Nagel) according to 
the manufacturer's instructions. RNA concentration and purity was determined by 
Picodrop spectrophotometer. For each sample, 1μg of total RNA was reversely 
transcribed using the Maxima H Minus First Strand cDNA Synthesis Kit (Thermo 
Scientific). Gene expression was determined by DyNAmo Flash SYBR Green qPCR Kit 
(Thermo Scientific), using the PikoReal Real-Time PCR System (Thermo Scientific). 
The relative expression of target genes will be evaluated using the comparative cycle 
threshold method and all samples were analyzed in triplicate.  
Amplification conditions were: 7 minutes at 95°C followed by 40 cycles of 10 seconds at 
95°C, 20 seconds at 60°C and 20 seconds at 72°C. The relative expression of target genes 
was evaluated using the comparative cycle threshold method, with b-actin used for 
normalization.  
Primers used: 





































































Methylation specific PCR (MSP) 
 
DNA methylation patterns in the CpG islands of CASP8, FAS and BIK were assessed by 
methylation specific PCR, based on the sequence differences between methylated and 
unmethylated DNA after sodium bisulfite modification. Weri-Rb1 cells were treated for 
48 hrs. with DAC 2.5 uM and successively genomic DNA was extracted from treated and 
untreated cells using QIAamp DNA mini kit. Following the manufacturer's instructions, 
genomic DNA was subjected to bisulfite modification by the Thermo Scientific EpiJET 
Bisulfite Conversion Kit. Successively, modified DNA from control and treated cells was 
used for MSP reactions. Amplification conditions were: 3 minutes at 95°C, 40 cycles of 
30 seconds at 95°C, 60 seconds at primers Tm and 60 seconds at 72°C, followed by a 
final extension of 2 minutes at 72°C. PCR products were separated on a 2.2% agarose gel 
containing ethidium bromide and visualized under ultraviolet illumination. 
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The primer pairs specific for methylated (M) and un-methylated (U) sequences were the 
following: 
Primers used: 
MSP Primer Sequence Tm (°C) 
CASP8[765] 
M-Forward 5'-GTT GGT TTT ATT TAG TTC GGC-3' 
60 
M-Reverse 5'-CCC TAT CGA TAA CAA ATA ATA TAC-3' 
U-Forward 5'-GTT GGT TTT ATT TAG TTT GGT-3' 
55 









M-Forward 5' -GGGAGTCGTGTTTAGGTTTTATC-3' 
48 
M-Reverse 5'-GAACAAAAAAAATACGTTTCGAA-3' 
U-Forward 5' -GGGGAGTTGTGTTT AGGTTTTATT-3' 
52 
U-Reverse 5'-CAAACAAAAAAAATACATTTCAAA-3'  
 
 
Preparation of loaded EMHVs 
 
Human erythrocytes have been prepared accordingly to the previously described 
protocol[463]. Briefly, whole blood was prepared by gradient centrifugation at 400g for 30 
minutes and then washed twice in 1X PBS.  
2x109 erythrocytes were lysed in 250μl lysis buffer for 60 minutes at 0°C and the 
isotonicity was then restored by adding 130μl of resealing buffer, supplemented with 2μg 
of FHA, 0.1mg of 50-70nm super-paramagnetic NPs and the required amount of drug, 
like 0.1mg of DAC or 2μg of Survivin-MB.  
After 45 minutes incubation at 8000g for 15 minutes at 4°C, loaded EMHVs were 
washed twice with 1X PBS, resuspended in 1X PBS and conserved at 4°C until used.  
Using previous HPLC investigation, the drug amount inside the DDS was standardized 
and 2x109  DAC-EMHVs could accommodate about 10μg of total drug. Moreover, the 
active phosphorylated form of DAC represented the 50% of total loaded drug into the 
EMHVs. 
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Animals 
 
According to ministerial guidelines, animals used in preclinical models in "Toscana Life 
Sciences" animal facility were housed in microisolators in autoclaved cages with 
polyester fiber filter covers, under germfree conditions. All food, water, and bedding 
were sterilized and the animals were maintained in an ambient temperature of 23±2°C in 
rooms having a 12 hours light/dark cycle.  
Mice will be anesthetized by 2.5% isoflurane during manipulation.  
 
Xenograft  
Xenograft tumors were established monolaterally in Nude-Foxn1nu/nu female mice 
(Harlan Laboratories, Udine, Italy) by means of a subcutaneous injection into the left 
flank consisting of 5x106 Weri-Rb1 cells suspended in 0.2ml of a 1:1 mixture of ice-cold 
MatrigelTM basement membrane matrix (BD Bioscience, MA, USA) and 1X PBS, using 
a 20-gauge needle syringe. Accordingly to ministerial animal welfare body, the 
experimental protocol used was classified as minimally invasive.  
Once xenografts started growing, their sizes (mm3) were measured twice a week with 
digital caliper and the volume was calculated according to the modified ellipsoid formula 
1/2(Length x Width2). Tumor xenografts were allowed to grow approximately up to 
100mm3 and this volume was selected as the initial stage for beginning the treatment. 
Mice were randomized, anesthetized and prepared for tail vein injection with the selected 
treatment. Before starting the experimental setting, the measurement procedures need to 
be standardized: tumor mass could be in fact evaluated by measuring sizes using either 
digital caliper, or with ultrasound scan system Visualsonic (VEVO2100). Tumor 
volumes have been then compared to the corresponding initial volumes, in order to 
normalize the data (X = 100 x volume1/volume0).  
Two independent experiments were performed with at least six mice assigned to each 
group. Animals were assigned to five different groups in each experimental setting, 
receiving biweekly intravein (I.V.) injections of 300μl treatment, over 3 weeks. They 
might be treated as follow: 1X PBS [CTRL]; 75μg free DAC (corresponding to the 
therapeutic dose of 2.5 mg/kg) [DAC 75μg]; 45μg free TSA [TSA 45μg]; 75μg free DAC 
followed by 45μg free TSA (after 24h) [DAC 75μg - TSA 45μg (24h)]; 2x109 DAC 
loaded-EMHV (containing 10μg) followed by a static magnetic field, in which two 
cylindrical (0.7 cm diameter, 0.5 cm high) earth magnets (52N) were externally applied 
to the xenograft mass not impeding movements for 30 minutes immediately after I.V. 
133 
An innovative epigenetic strategy for retinoblastoma treatment 
injection, to achieve intra-tumor localization and accumulation [DAC 10μg - EMHV - 
MF]. The magnetic field application was repeated at time of each injection. Mice were 
then allowed recovering and monitored for signs of distress. At the end of the treatment 
course or when the tumor volume reached approximately 1300mm3, mice were sacrificed 
by CO2 asphyxiation and the retinoblastoma mass, liver and kidneys were harvested. Half 
of these samples were stored in liquid nitrogen using OCT, whereas the remaining parts 
have been processed using TRIAZOL and store at 4°C until additional analysis. 
 
Orthotopic tumors 
Orthotopic tumors were established monolaterally in the right eye of Nude-Foxn1nu/nu 
female mice (Harlan Laboratories, Udine, Italy) by means of an sub-retinal injection 
consisting of 1x104 Weri-Rb1 cells suspended in 10μl 1X PBS, using a 32-gauge needle 
syringe, modifying the experimental method of Bond and co-workers[769]. In particular, 
the procedure has been carried out using an eco-guided micromanipulator (VEVO2100 
ultrasound system) and the globe was pierced laterally through the conjunctiva and the 
sclera to reach vitreous cavity. The needle will be held steadily in this position, 
depressing the plunger slowly. Accordingly, to ministerial animal welfare body, the 
experimental protocol used was classified as moderate invasive. Once orthotopic tumors 
started growing 2-3 weeks post-injection, they present the classical leukocoria sign of 
retinoblastoma and their sizes (mm3) have been evaluated once a week after 3D imaging 
reconstruction. Tumors were allowed to grow approximately up to 30mm3 and this 
volume was selected as the initial stage for beginning the treatment. Mice were 
randomized, anesthetized and prepared for tail vein injection with the selected treatment. 
Before each injection, tumors were measured using the ultrasound scan system and 
compared to the corresponding initial volumes, in order to normalize the data (X=100x 
volume1/volume0).  
Animals were assigned to two different groups in each experimental setting, receiving 
biweekly I.V. injections of 300μl treatment, over 3 weeks. They might be treated as 
follow: 1X PBS [CTRL] or 75μg free DAC (corresponding to the therapeutic dose of 2.5 
mg/kg) [DAC]. Mice were then allowed recovering and monitored for signs of distress. 
At the end of the treatment course or when the tumor volume reached approximately 
90mm3, mice were sacrificed by CO2 asphyxiation and both eyes (naïve and within the 
orthotopic tumor), liver, kidneys were harvested. Half of these samples were stored in 
liquid nitrogen using OCT, whereas the remaining parts have been processed using 
TRIAZOL and store at 4°C until additional analysis. 
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Morphological analysis of orthotopic tumor 
 
To carry out morphological investigation on the implanted tumor, eye bulbs from 
experimental animals were collected, and put in sucrose 30% overnight. The washed 
bulbs were cryo-protected in OTC, snap-frozen in liquid nitrogen and then store at -80°C 
until required. Each animal donated both eye, as the non-treated eye would serve as an 
internal control. A morphological descriptive investigation was performed on whole eye 




The cell cycle phases are expressed as Mean±SD of at least n=3. Three-Ways ANOVA 
were applied to compare the effect of different treatments on cell cycle phases (sub G1, 
G0-G1, S, G2-M) and One-Way ANOVA was used to compare the effect of DAC-
EMHVs treatment at selected time points (24, 48 and 72 hours). 
The apoptotic cells were expressed as Mean±SD of at least n=3. Statistical analysis was 
performed with One-Way ANOVA independently for early and late apoptosis on log-
transformed data to improve normalization. Pairwise comparisons were tested using 
Tukey’s honestly significant difference criterion. 
For the significance of gene expression values in qPCR validation, the statistical analysis 
of ΔCt values was based on One-sample T-Test and expressed as Mean±SEM.  
The in vivo results are expressed as Mean±SEM of n=6. One-Way ANOVA and One-
Way ANOVA repeated measures when required, were applied to compare the tumor 
mass reduction in the evaluation of the xenograft implant or orthotopic tumor after 




Human red blood cells were obtained from transfusion bags collected from anonymous 
healthy voluntary donors, which have given their written informed consent carried out in 
accordance with Italian Government law. It was not necessary the approval from an 
institutional review board (ethics committee) since neither direct human participation nor 
involvement of human studies have been foreseen in this work. Samples have been 
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The preclinical studies were carried out in strict accordance with the recommendations in 
the Guide for the Care and Use of Laboratory Animals of the International guidelines on 
handling of laboratory animals and applying the 4Rs to experiments (in accordance with 
NIH and European Commission recommendations). The protocols for Animal 
Experiments were approved by the Ethics Committees of the Toscana Life Sciences and 
the Istituto Superiore di Sanità (ISS) on behalf of Italian Minister of Health (Permit 
Number: # CNR-030314 and # CNR-101013).  
Animal well-being was monitored accordingly to Langford and colleagues[770]. 
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The retinoblastoma epigenetic panorama is a growing field of investigation. In this work, 
I focused on the possibility of developing and characterize innovative therapeutic 
approach to treat Rb and reverse gene silencing that induces cancer phenotype. In 
particular, I focused on the characterization of the role of timing the effect of a 
demethylating agent in reverting the silenced tumor-suppressor genes that are inactivated 
in retinoblastoma. This investigation revealed a time-dependent activity of DAC on 
Weri-Rb1 cell viability and proliferation due to a regulation of pivotal gene methylation.  
 
In vitro anti-proliferative effect of therapeutic DAC on Weri-Rb1 
 
The in vitro efficacy of therapeutic DAC was tested on Rb cell line Weri-Rb1. The cell 
cycle profile and apoptosis were both measured by FACS analysis at 24 up to 72 hrs., 
showing that at the latest time point, DAC at the concentration of 2.5μM (corresponding 
to the therapeutic dose of 1.7μg) induced a significant enrichment in sub G1 phase 
comparing to untreated cells, suggesting a possible activation of apoptotic response (Fig. 
4.1a). This increased sub G1 phase reached statistical significance at 72 hours (CTRL 
9.2±2.3 vs DAC 1.7μg 32.8±2.2) (ANOVA *P<0.05).  
Fig. 4.1a: FACS analysis. Cell cycle in Weri-Rb1, using propidium iodide at 24, 48 and 72 hrs. after 
DAC treatment. Mean ± SD. *P<0.05. 
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To assess if the treatment could induce the activation of apoptotic response, Annexin V 
test was also performed. The analysis confirmed that therapeutic DAC exerted an 
apoptotic effect in retinoblastoma cells (Fig. 4.1b). In particular, the epigenetic treatment 
induced a reduction of alive cells and, as a consequence, an enrichment in late apoptosis 
at 72 hours after treatment, reaching statistical significance if compared to control (CTRL 
60.6±0.9 vs DAC 1.7μg 14.4±1.3) (ANOVA *P<0.05). 
Fig. 4.1b: FACS analysis. Apoptosis in Weri-Rb1, using Annexin V-FITC at 24, 48 and 72 hrs. after 
DAC treatment.  Mean ± SD. *P<0.05. 
 
 
With these analyses, we confirmed the previously encouraging results obtained in our 
laboratory at IFC CNR. Comparing this first set of data, still unpublished, with our new 
experiment, we confirmed that the time-dependent gene co-expression distribution in 
Weri-Rb1 after therapeutic DAC treatment induces an epigenetic reprogramming of 
retinoblastoma cells. Through a microarray analysis, the most prominently induced gene 
expression after DAC treatment was investigated, mapping the time-course dependent 
differential gene expression (DGE) profile of both pro- and anti- apoptotic genes[195]. The 
authors also investigated the relevance of methylation regulation for these genes, 
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Here, referring to that same microarray and after a thorough investigation with gene-
pathway association mapping analysis carried out in the laboratory, I decided to expand 
the panel of genes of interest. These genes have been selected based on their molecular 
functions, which might be altered in numerous chronic disorders and especially related to 
cancer (Table 4.1, Fig. 4.2). For these fifteen genes, the differential expression varied 
with a threshold greater or equal to 2 at each of the selected time points. Using a gene-
gene co-expression network, we described their connected representations: GeneMania 
was used to generate the networks, showing co-expression dynamics among the 
connected genes building the interactomes (Fig. 4.3) and the network configurations 











protein binding; identical protein binding; 
kinase binding; enzyme binding; transcription 
activator binding; phosphate binding; 
transcription repressor binding; anion binding 
It is a ubiquitous transcription factor involved in 
several biological processes. Upon degradation of the 
inhibitor, it moves to the nucleus and activates 
transcription of specific genes.  
HSF1 protein binding Its product is a transcription factor rapidly induced 
after temperature stress that is playing a role in the 
regulation of lifespan. Expression of this gene is 
repressed by phosphorylation, which promotes 
binding by heat shock protein.  
CASP8 protein binding; identical protein binding; 
cysteine-type endopeptidase activity; cysteine-
type peptidase activity 
This gene encodes a member Caspase family, 
involved in the extrinsic apoptosis pathway. 
Sequential activation of Caspase plays a central role in 
the execution-phase of cell apoptosis. This protein is 
involved in the programmed cell death induced by 
FAS and various apoptotic stimuli. The N-terminal 
FADD-like death effector domain of this protein 
suggests that it may interact with FAS-interacting 
protein FADD. 
BAX protein binding; BH domain binding; identical 
protein binding; protein heterodimerization 
activity; protein domain specific binding; 
protein dimerization activity; BH3 domain 
binding; death domain binding 
The encoded protein belongs to the BCL2 protein 
family, forming a heterodimer with BCL2, and 
functioning as an apoptotic activator. It interacts with, 
and increases the opening of VDAC, which leads to 
the loss in membrane potential and the release of 
cytochrome C. The expression of this gene is 
regulated by P53. 
TRAP2 
(PSMD2) 
protein binding; enzyme regulator activity It encodes one of the non-ATPase subunits of the 19S 
regulator lid of the proteasome, a multicatalytic 
proteinase complex that can cleave peptides in an 
ATP/ubiquitin-dependent process in a non-lysosomal 




protein binding; identical protein binding; 
protein heterodimerization activity; caspase 
inhibitor activity; caspase regulator activity; 
cysteine-type endopeptidase inhibitor activity; 
protein dimerization activity; enzyme binding; 
cobalt ion binding; enzyme regulator activity; 
endopeptidase inhibitor activity; 
endopeptidase regulator activity; peptidase 
inhibitor activity; Ran GTPase binding; 
peptidase regulator activity 
It is a member of the inhibitor of apoptosis (IAP) gene 
family, which encodes negative regulatory proteins 
that prevent apoptotic cell death. Gene expression is 
high in most tumors.  
RRAD protein binding  Ras related glycolysis inhibitor and calcium channel 
regulator. 
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TRAF2 protein binding; sphingolipid binding The encoded protein is a member of the TNF receptor 
associated factor (TRAF) protein family and it directly 
interacts with TNF receptors and forms a 
heterodimeric complex with TRAF1. The interaction 
of this protein with TRADD ensures the recruitment 
of IAPs for the direct inhibition of caspase activation.  
TOLLIP protein binding; kinase binding; Toll-like 
receptor binding; enzyme binding 
This gene encodes a ubiquitin-binding protein that 
interacts with several Toll-like receptor (TLR) 
signaling cascade components,  regulates 
inflammatory signaling and is involved in interleukin-
1 receptor trafficking and in the turnover of IL1R-
associated kinase.  
P73 
(ARHGAP24) 
protein binding; enzyme regulator activity This gene encodes a member of the p53 family of 
transcription factors involved in cellular responses to 
stress and development.  
DAP3 protein binding; protein domain specific 
binding 
This gene encodes a 28S subunit protein that also 
participates in apoptotic pathways which are initiated 
by tumor necrosis factor-alpha, FASL, gamma INF.  
CASP6 cysteine-type endopeptidase activity; cysteine-
type peptidase activity, protein binding  
This gene encodes a protein member of Caspase 
family that is processed by Caspases 7, 8 and 10, and 
is thought to function as a downstream enzyme in the 
Caspase activation cascade. 
BCL2L1 
(BCL_XL) 
protein binding; identical protein binding; 
protein heterodimerization activity; caspase 
inhibitor activity; BH domain binding; caspase 
regulator activity; protein domain specific 
binding; cysteine-type endopeptidase inhibitor 
activity; protein dimerization activity; enzyme 
regulator activity; endopeptidase inhibitor 
activity; endopeptidase regulator activity; 
peptidase inhibitor activity; peptidase 
regulator activity 
The proteins encoded by this gene belong to the BCL-
2 protein family. These proteins are located at the 
outer mitochondrial membrane and have been shown 
to regulate outer mitochondrial membrane channel 
(VDAC) opening, controlling the production of 
reactive oxygen species and release of cytochrome C 
for the intrinsic apoptosis pathways.  
FAS protein binding; identical protein binding; 
kinase binding; [acyl-carrier-protein] S-
acetyltransferase activity; 3-oxoacyl-[acyl-
carrier-protein] reductase activity; 3-
hydroxypalmitoyl-[acyl-carrier-protein] 
dehydratase activity; enoyl-[acyl-carrier-
protein] reductase activity; 3-hydroxyacyl-
[acyl-carrier-protein] dehydratase activity; 
enoyl-[acyl-carrier-protein] reductase 




protein] hydrolase activity; [acyl-carrier-
protein] S-malonyltransferase activity; 3-
oxoacyl-[acyl-carrier-protein] synthase 
activity; oleoyl-[acyl-carrier-protein] 
hydrolase activity; enzyme binding; 
phosphopantetheine binding; fatty acid 
synthase activity; acyl carrier activity; S-
acyltransferase activity 
The protein encoded by this gene is a member of the 
TNF-receptor superfamily that plays a central role in 
the extrinsic apoptosis pathways, and it has been 
implicated in the pathogenesis of various diseases.  
BIK protein binding; BH domain binding; protein 
heterodimerization activity; protein domain 
specific binding; protein dimerization activity 
The protein encoded by this gene shares a critical BH3 
domain with other death-promoting proteins, such 
BAX, that is required for its pro-apoptotic activity, 
and for interaction with anti-apoptotic members of the 
BCL2 family, and viral survival-promoting proteins. 
Since the activity of this protein is suppressed in the 
presence of survival-promoting proteins, it is 




Table 4.1: 15 selected pro-apoptotic or tumor-suppressor genes showing upregulation (log>2) in the 





























Fig. 4.2: Number of genes involved in molecular functions of interest for cell regulation 
 
 
Fig. 4.3: Interaction network of selected 15 genes obtained from Biogrid database and visualized using 
Cytoscape. 
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In Fig 4.3 the association map of the selected genes generated by Cytoscape is depicted: 
CASP8 interacts with other selected genes namely CASP6, FAS and TRAF2. BIK gene 
with high differential expression interacts with BCL2L1. Remaining eight genes did not 
show any direct interaction among selected genes. Many of these genes were involved in 
similar biological processes (Table 4.1) along with genes constituting connected 
component such as BIK, BIRC5, BAX and BCL2L1. Most relevantly, these genes are 
involved in process related to heterodimerization activity. Dimerization is crucial in 
retinoblastoma as RB protein binds and inhibits E2F family transcription factors 
constituted of E2F and DP protein, as dimerization partner[771-772].  
 
Validation of DGE in Weri-Rb1 after DAC treatment 
 
After computational data reading, the expression profile of the fifteen selected genes was 
monitored after epigenetic treatment at different times and then validated using qPCR. 
Relative quantification of mRNA levels of these genes was evaluated at 48, 72 and 96 
hours after treatment and compared to control. Data were shown as a ratio between 
treated (DAC) and untreated cells and normalized to b-actin (Fig. 4.4). Notably, a 
significant upregulation of pro-apoptotic genes CASP8, FAS and BIK  and the tumor 
suppressor gene RRAD, was detected at each time point consolidating their early 
involvement in essential gene pathways to apoptosis in Rb. Most interestingly, the 
expression of other pro-apoptotic genes involved on the intracellular signaling at 
mitochondrial level, such as BAX and  BCL_XL (also known as BCL2L1) expression was 
significantly up regulated only at the latest time point. On the other hand, BIRC5 (also 
known as Survivin) underwent an early down-regulation, favoring cell apoptosis. Similar, 
but opposite, gene expression fluctuations were detected for TRAP2 and CASP6 (T-test 
*P<0.05). 
 
Fig. 4.4: qPCR analysis. Fold change (log2 transformed) of gene expression in DAC-treated samples 
relative to the controls at 48, 72 and 96 hrs., reported as Mean ± SD (T-Test *P<0.05). 
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Methylation status of selected genes after DAC on Weri-Rb1  
 
A DNA methylation analysis was then performed on CASP8, FAS and BIK as they 
resulted to be the most up regulated genes in treated Weri-Rb1 after qPCR validation. 
Changing in methylation status of these genes provides a unique insight into the role of 
epigenetics in gene regulation, which is reflected by the proportion of methylated DNA. 
Therefore, any potential alteration of the methylation levels compared with control would 
indicate the drug effect on the epigenetic regulation of gene expression. 
 
More specifically, DNA methylation patterns in the CpG islands of FAS, CASP8 and BIK 
were assessed because of the sequence differences between the DNA status after sodium 
bisulfite modification. CASP8 and BIK showed a distinct methylation profile when 
comparing treated and control cells. Methylation profile changes for both CASP8 and 
BIK after DAC epigenetic treatment: control (CTRL) presented the methylated (silenced) 
form of both genes, whereas DAC-treated cells showed unmethylated (reactivated) form 
of CASP8 and BIK. On the contrary, using primer for the methylated sequence, FAS 
either did not appear amplified in CTRL or treated samples, and this suggested an 
indirect activity of DAC on FAS gene regulation (Fig. 4.5). 
 
Fig. 4.5: Methylation analysis. Agarose gel of PCR products after methylation analysis of CASP8, FAS 
and BIK genes using sodium-bisulfite convension kit.  
 
Through methylation study, direct and indirect regulatory mechanism of action of DAC 
treatment it has been described on the selected gene expression profiles at 48 hrs. We can 
assume that an epigenetic treatment directly affects CASP8 and BIK genes thought 
DNMT inhibition of their promoter. FAS, encoding for FAS trans-membrane protein, 
instead results unmethylated and its regulation is dependent on the extracellular stress 
signal and on the binding of DAC on the FAS death receptor.   
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Preclinical evaluation of DAC anti-tumoral effect 
 
We described both anti-proliferative and apoptotic features of DAC on retinoblastoma 
cells in vitro. For a complete characterization of the epigenetic therapy, an in vivo 
evaluation of the anticancer effect is necessary. A preclinical study was set using a 
xenograft animal model, developed in our laboratory to test the therapeutic DAC effect 
on tumor growth. A three-week treatment of therapeutic DAC was administered by I.V. 
injection and its effect was evaluated after the latest injection. Tumor mass volume was 
measured using both digital caliper and the ultrasound system. A representative image of 
the off-line 3D reconstruction (left) of the tumor mass acquired by ultrasound system 
VEVO2100 (right) is shown (Fig. 4.6). The mass volume measurements are coherent 
with those acquired by digital caliper (Fig. 4.7). For ethical reasons, only initial and final 
measurement sections were acquired by VEVO2100 as animals needed to be anesthetized 
















Fig. 4.6: Weri-Rb1 xenografts. 3D ultrasound imaging of CTRL and DAC-treated xenografts. 
 
Our results indicated that a significant reduction was obtained with DAC compared to 
untreated control, demonstrating for the first time an anti-tumoral activity of this 
demethylating agent on retinoblastoma (Fig. 4.7). (CTRL 1434.19±193.44 vs DAC 75μg 
150.58±32.40). One-way ANOVA RM (*P<0.05) was used to demonstrate that the two 
treatments induced significantly different growth rate.  
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Fig. 4.7: Weri-Rb1 xenografts. Normalized tumor mass (mm3) after I.V. biweekly DAC treatments. 
Mean values ± SEM. *P<0.05.  
 
Ex vivo validation of gene expression after DAC treatment 
 
Pro-survival and apoptotic gene expressions were monitored in collected samples of 
Weri-Rb1 xenografts after treatment with DAC to evaluate the occurrence of gene 
pathway changes and to confirm the previous in vitro gene profile. In particular, the 
expression of the same relevant genes analyzed in vitro was evaluated using qPCR. This 
analysis confirmed the pivotal role of the pro-apoptotic genes CASP8, FAS and BIK , as 
they appeared over-expressed following the administration of the DNA demethylating 
agent. Most relevantly to our purposes and similarly to in vitro results, the oncogene 
BIRC5(Survivin) expression was found to be down regulated at the end of the treatment 
(Fig. 4.8).  
 
Fig. 4.8: qPCR analysis. Fold change (log2 transformed) of gene expression in DAC-treated xenografts 
relative to the controls after sample collection, reported as Mean ± SD. 
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Development and epigenetic treatment of a retinoblastoma orthotopic model 
 
One of the purposes of our investigation was to study Rb in its natural site. This will 
allow investigating the influence of the environment and of the spatial/localization of the 
tumor lesion on the effect of the therapy. To strengthen our preclinical investigation, an 
orthotopic model of retinoblastoma was also developed. Weri-Rb1 cells were injected in 
retro-orbital space of the eye. For this model, the growth was detected by ultrasound 
system: in fact, orthotopic Rb is an internal cancer detectable only by 3D ultrasound 
imaging techniques. For this reasons, animals were anesthetized only once a week during 
measurement sections. To treat this orthotopic tumor, therapeutic dose of DAC was 
administered by I.V injection and compared to untreated control. The preliminary results 
indicated a trend of anti-proliferative effect induced by DAC treatment when compare 
with controls (Fig. 4.9) (CTRL 4.7±0.3 vs DAC 75μg 1.3±0.5). Moreover, we verified 
the correct localization of the orthotopic tumor through morphological investigation. The 
tumor mass can be traced as a dark mass inside the ocular globe  that  appeared clear in 










Fig. 4.9: Orthotopic tumor of Weri-Rb1. Normalized tumor mass (mm3) after I.V. biweekly DAC 
treatments. Mean values ± SEM. *P<0.05.  
 
Fig. 4.10: Contrast phase microscopic imaging of naive (left) and tumor (right) mouse eye. 
Magnification at 20x. 
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Effect of HDAC inhibitors on Weri-Rb1: a comparative study and combined 
treatment 
 
Our results demonstrated that methylation of genes can contribute to Rb tumorigenesis. 
However, methylation is only one of the most prominent epigenetic mechanisms for gene 
regulation expression.  
To investigate other potential epigenetic regulatory mechanisms on Rb cell survival, I 
treated Weri-Rb1 with scalar doses of free TSA (75 - 150 - 300ng) and compared to 
control. TSA is an inhibitor of HDAC enzymes that regulates histone deacetylation.   
Both the cell cycle profile and apoptosis were measured by FACS analysis at 24, 48 and 
72 hrs. and a dose-dependent effect of TSA was detected. In particular, TSA 300ng 
induced an enrichment of sub G1 cell phase comparing to untreated cells, reaching 
statistical significance at the latest time-point (Fig. 4.11a) (CTRL 4.1±0.8 vs TSA 300ng 
60.2±5.9) (ANOVA *P<0.05).  
 
Fig. 4.11a: FACS analysis. Cell cycle in Weri-Rb1, using propidium iodide at 24, 48 and 72 hrs. after 
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To assess if TSA treatment could induce apoptosis in Weri-Rb1 cells, Annexin V test 
was also performed. The analysis indicated that only the highest dose of HDAC inhibitor 
exerted a pro-apoptotic effect in retinoblastoma cells (Fig. 4.11b). In particular, the 
epigenetic treatment induced a reduction of alive cells and, as a consequence, an 
enrichment in late apoptosis at 72 hours after treatment, reaching statistical significance 
if compared to control (CTRL 59.4±1.6 vs TSA 300ng 20.5±7.5) (ANOVA *P<0.05). 
 
Fig. 4.11b: FACS analysis. Apoptosis in Weri-Rb1, using Annexin V-FITC at 24, 48 and 72 hrs. after 
different doses of TSA treatment.  Mean ± SD. *P<0.05. 
 
Our results indicated that both the demethylating agent DAC and the inhibitor of HDAC 
TSA induce apoptosis in Weri-Rb1 cell. A synergistic effect of both epigenetic drugs 
administered together has never been tested in Rb before. Previous non-shown results of 
combined treatment with these two molecules would indicate that the best apoptotic 
effect could be obtained administering therapeutic DAC 24 hours in advance. These 
preliminary results were obtained in different cancer cell lines.  
Here I administered DAC to the cells 24 hrs. before than TSA treatment in Weri-Rb1. 
Moreover, scale-doses of TSA were used to describe TSA effect. I measured a significant 
variation of cell cycle: after this combined treatment results reached statistical 
significance at 48 only after using the highest dose of TSA (CTRL 4.2±1.3 vs DAC 
1.7µg + TSA 300ng (24h) 64.1±1.6); this effect remained consistently significant up to 
72 hours (CTRL 3.3±1.3 vs DAC 1.7µg + TSA 300ng (24h) 82.9±2.5) (ANOVA 
*P<0.05) (Fig. 4.12a). 
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Fig. 4.12a: FACS analysis. Cell cycle in Weri-Rb1, using propidium iodide at 48 and 72 hrs. after 




In order to assess if the combined treatment could increase the apoptotic response in 
Weri-Rb1 cells, Annexin V test was also performed. Accordingly with the cell cycle 
analysis, combined epigenetic treatments with the highest dose of TSA (300ng) induced 
anti-tumoral effect at 72 hrs. after treatment. In particular, a reduction of alive cells and, 
as a consequence, enrichment in late apoptosis was shown after 24 hrs., reaching 
statistical significance if compared to control (CTRL 59.4±1.4 vs DAC 1.7µg + TSA 
300ng (24h) 22.1±1.9) (ANOVA *P<0.05) (Fig. 4.12b). 
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Fig. 4.12b: FACS analysis. Apoptosis in Weri-Rb1, using Annexin V-FITC at 24, 48 and 72 hrs. after 
different doses of TSA treatment.  Mean ± SD. *P<0.05. 
 
 
Effect of deacetylation inhibition in vivo: epigenetic therapy failure  
 
Following the encouraging results obtaining using HDAC inhibitor in vitro, I studied the 
effect of TSA on xenograft animal model. I had previously performed preliminary studies 
using scale-doses of single TSA to set an effective dose-response (range 15 - 45μg per 
injection, data not shown).  
For the main body of the experiment, animals were treated with high TSA (45μg) alone 
or in combination with therapeutic DAC (75μg) given 24 hrs. before. These experiments 
showed that at the end of the treatments, TSA alone did not exert any significant effect in 
term of reduction of tumor size, when compared with controls (CTRL 1434.19±193.44 vs 
TSA 45μg 698.1±173.09). On the contrary, I could detect a trend of anti-tumoral effect 
using the combined treatment DAC/TSA if compared to control. However, this combined 
treatment failed to reach significance thought-out all the length of the experiment (CTRL 
1434.19±193.44 vs DAC 75µg - TSA 45µg (24h) 285.19±64.64) (ANOVA *P<0.05). 
When compared with previously shown results (Fig. 4.7), significant reduction in term of 

















Fig. 4.13: Weri-Rb1 xenografts. Normalized tumor mass (mm3) after I.V. DAC, TSA and combined 
DAC/TSA biweekly treatments. Mean values ± SEM. *P<0.05.  
 
 
New formulation for DAC epigenetic treatment: the use of EMHVs DDS in vitro 
 
My results indicated that DAC used free represents a very effective epigenetic treatment 
for both in vitro and in vivo experiment. Combination with TSA did not improve 
significance when administered in preclinical models. For my further experiment on the 
characterization of a newly formulated epigenetic therapy inside a drug delivery system, I 
therefore selected DAC. My project was in fact focused on the possibility of improving 
DAC anti-tumoral effect, in order to reduce its numerous toxic side effects. To achieve 
this aim, I used a modified erythrocyte-based drug delivery system that is CNR patented. 
EMHVs are normally produced in the laboratory and their content of DAC has been 
standardized (2x109 erythrocytes contain 10μg DAC). DAC-loaded EMHVs were then 
tested both in vitro and in vivo on Weri-Rb1 cells.  
 
For our experiment, we aimed at comparing similar dose of DAC either administered free 
or loaded into the EMHVs. However, technical impediments related to in the use of 
FACS analysis of the treated cells in the presence of EMHVs allowed us to use the 
maximum dose of 2x108 loaded EMHVs per sample containing 1μg of DAC. For the 
same reason, apoptosis investigation using Annexin V was not performed as EMHVs 
were detected as false negative.   
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The in vitro efficacy of DAC-loaded EMHVs was tested and the cell cycle profile was 
measured by FACS analysis at 24 up to 72 hours. DAC contained inside the engineered 
DDS was used at the dose of 1μg and was found to induce induced a significant 
enrichment in sub G1 phase comparing to untreated cells (Fig. 4.14) at 72 hours (CTRL 
9.2±2.3 vs DAC 1.7μg 32.8±2.2 or DAC 1μg - EMHV 52.1±7.1) (ANOVA *P<0.05).  
 
Fig. 4.14: FACS analysis. Cell cycle in Weri-Rb1, using propidium iodide at 24, 48 and 72 hrs. after free 
therapeutic DAC or DAC-loaded EMHVs. Mean ± SD. *P<0.05. 
 
These results indicated that a lower dose of DAC carried by EMHVs would induce a 
stronger effect than a high dosage of free DAC. This would highlight the importance of 
the use of a localizing carrier, that also act as a bioreactor, activating DAC into its 
phosphorylated active forms before reaching intracellular targets[463]. 
 
 
DAC-loaded EMHVs as an anti-tumoral therapy in vivo 
 
Following our encouraging results in vitro, I decided to evaluate the anticancer effect of 
this new therapeutic formulation of DAC using the xenograft model of Weri-Rb1. In this 
experiment, free therapeutic drug (75μg) was compared to an EMHV loaded dose of 
10μg. This loaded dose was selected considering the murine hemochrome: an optimal 
dose volume of 300μl, containing 2x109 erythrocytes, was given by I.V injection so that 
animals did not show any signs of distress (AWB guidelines). To carry this experiment, 
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the group of EMHV-treated animals was also administered with two external magnetic 
fields (52N) positioned on the site of tumor for thirty minutes. This treatment allowed 
EMHV localization and fusion to target cells.  
At the end of the treatment with EMHVs, a comparable to free DAC anti-tumoral effect 
was detected in the animals (Fig. 4.15) (DAC 75μg 150.58±32.40 vs DAC 10μg - 
EMHV - MF 175.99±38.12). Noticeably, the dose included into EMHVs was 7.5 times 
lower that the free dose. We demonstrated that the use of EMHVs localized by a 














Fig. 4.15: Weri-Rb1 xenografts. Normalized tumor mass (mm3) after I.V. free DAC and DAC-loaded 
EMHVs biweekly treatments. Mean values ± SEM. *P<0.05.  
 
 
The results of my investigation indicated that it is possible to treat Rb with DAC to 
epigenetically reprogramming gene expression among which BAX, CASP8, FAS and BIK, 
to revert the cancer associated cell proliferation and induce apoptotic phenotype. 
Moreover, we confirmed that the use of EMHVs carrier as DDS could be exploited to 
convey anticancer molecules to tumor lesions, increasing bioavailability and reducing 
dosage. I therefore tested the anti-proliferative potential of a biodrug, namely molecular 
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A biodrug-based treatment for retinoblastoma to target pro-survival gene 
 
EMHVs are a versatile carrier and can host molecules of different nature, such as 
antibodies and nucleotides. Our validation studies on DGE stressed the importance of the 
gene that encodes for Survivin, that largely varies its expression after DAC treatment and 
it is known to be involved in cell survival pathways. More specifically in Weri-Rb1, a 
reduction of BIRC5 gene expression is associated with the apoptotic response. I decided 
to use the molecular beacons against Survivin-mRNA (SURV-MB) to impede its 
translation and reduce protein level inside the cells. MB holds the property to emit 
fluorescence signal once it reaches specific target inside the cells. For this, MB can be 
considered theranostics, able to reveal target presence and to modify its activity by 
inhibiting protein's synthesis.  
 
In the first instance, we verified the targeting of SURV-MB inside Weri-Rb1 cells. We 
demonstrated that free MB could internalize into the cell after lipofectamin treatment and 
could reached their specific intra-cellular target (Fig. 4.16a) causing fluorescence 
emission in the cytoplasm. 
 
To test their therapeutic effect, I loaded SURV-MB into EMHVs. This required the 
characterization of the new therapeutic formulation. For formulation characterization, a 
study to verify loading was carried out: to visualize the internalization of MB inside 
EMHVs, I used modified SURV-MB without the quencher that constantly emits 
fluorescence light. Confocal microscopy view of a general population of EMHV loaded 
with de-quenched SURV-MB confirmed that the majority of the EMHV produced ad hoc, 
contained the nucleotides sequence (Fig. 4.16b). Similar loading is likely to be obtained 
with active therapeutic SURV-MB that does not constantly emit fluorescence but exerts it 
























Fig. 4.16: CLSM imaging. a: Weri-Rb1 cells and free fluorescent MB for Survivin; b: EMHVs loaded 
with fluorescent MB for Survivin; c: Weri-Rb1 cells and EMHVs loaded with fluorescent MB for Survivin; 
d: naive Weri-Rb1 cells. MB (red), nuclei (blue, DAPI staining). 
 
 
When EMHVs loaded with the active fluorescent SURV-MB are administered to Weri-
Rb1 cells, they fuse to the cell membrane and release the contains inside the cells. As 
shown in Fig. 4.16c, the released active SURV-MB can reach its mRNA target, 
generating a red fluorescent signal. DAPI (blue) fluorescent signal indicated the presence 
of the cell nuclei, as in control cells (Fig. 4.16d).   
 
 
The effect of EMHV loaded active SURV-MB on Weri-Rb1 cells was detected at 6 hours 
and 12 hours after treatment. In comparison with control value, the treatment induced a 
cell cycle variation in the cell population with an enrichment of cells in sub G1 phase 
(Fig. 4.17). This would indicate that SURV-MB induced an inhibition on Survivin-
mRNA translation altering cell survival pathways.   
These preliminary results in vitro suggest the possibility of using SURV-MB as a 
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Fig. 4.17: FACS analysis. Cell cycle in Weri-Rb1, using propidium iodide (PI) at 6 and 24 hours after 
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5 DISCUSSION  
 
 
Searching for the magic bullet  
 
The principal objective for pharmaceutical concerns the discovery and the development 
of medicines that satisfy requirement of patients for better therapeutics or diagnostics. 
This will lead not only to offer new therapies for currently untreated diseases, but also to 
improve options for safer, more efficacious and more cost-effective treatments, 
including, for example, generic drugs or more recently developed biosimilar antibodies. 
This field of research and development (R&D) more often includes the optimization of 
novel tailored nanodevices for medical purposes.  
Meanwhile, the discovery and development of new therapeutic molecules for the 
treatment of cancer have undergone many changes. One of the most prominent is a 
conceptual change from one-size-fits-all approach that relies on the cytotoxicity action of 
well-known chemotherapeutics to a more personalized medicine approach: the latter 
often focuses on the optimization and implementation of target-tailored drugs that exploit 
a particular genetic dowry of the cells to cause vulnerability to cancer.   
Drug repositioning is another aspect of utilizing clinical approved drugs for disorders 
other than the diseases that they are approved for. As the Nobelist James Black 
commented that "The most fruitful basis of the discovery of a new drug is to start with an 
old drug". Indeed, one of the challenges of the drug discovery market is to convey 
investments into the development of new strategies that would encourage the scientific 
community to test approved drugs for different diseases. For example, FDA 
(www.cancer.gov)[773] and EMEA originally approved DAC for the treatment of 
myelodysplastic syndromes, however it has been proposed and trialed for human solid 
metastatic tumors such as colorectal and ovarian cancer (www.clinicaltrials.gov)[584]. 
Here, we demonstrated that it would be possible to implement its use outside these 
boundaries and to candidate DAC as a possible epigenetic treatment in Rb. Indeed, a 
careful evaluation of dosing using carrier-mediated delivery indicated the possibility of 
using DAC at effective concentration lower that those required for clinical use in other 
solid tumor.  
 
Another strategy that we investigated in this thesis is to identify of new therapeutic tools 
for cancer thought a in-depth insights on its biological systems that can be obtained with 
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advancement in the field of high throughput genomics, using technologies such as cDNA 
microarrays and RNA Seq. Growing information on common molecular pathways 
identified in different malignancies focuses the screening of safe-drug libraries and 
shortens R&D processes, resulting in an economic cost-effective management.  In the 
last ten years, DNA microarrays has emerged as a powerful approach to study the 
transcriptome of individual cancers and allows identifying characteristic patterns of gene 
expression and led to an explosion of studies of the molecular pathogenesis of tumors. 
NGS and other high-throughput genome-wide techniques have revealed in fact 
extraordinary genome complexities, conferming heterogeneity, not only between 
different tumors but also within an individual cancer histotype[774-775]. In this study we 
have taken a "high-resolution" view of specific epigenetic variation in Rb to open the 
door to understanding of cancer development and progression. We also provided an 
insight into molecular mechanisms of Rb to find novel cancer biomarkers (treatable 
biomarkers). Starting from microarray analysis and using public available data from 
different individuals and different experiments it was possible to identification of key 
driver genes that could be epigenetically regulated. This was fundamental for studying 
and targeting those mechanisms that regulate Rb cancer phenotype and allowed us 
matching drug therapies to reverse malignant cell fate. 
 
Although others as well as our success has led to the identification of novel molecular 
targets that become markers for therapies (feasible), these need to be translated into 
druggable target, followed by therapeutic effect validation. The importance of 
understanding the difference between biologically active molecules and drugs is well 
established in the drug discovery industry. In general, after a potential novel therapeutic 
target has been identified, there can be significant scientific and technical hurdles to 
discovering a novel and effective drug. It is crucial to link the proposed target to the 
clinical disease but also to demonstrate quantitative consequences of target modulation 
that are sufficient to deliver a therapeutically meaningful biological effect. Finally, 
translating efficacy determined in drug discovery phase to clinical relevance could be a 
hard challenge: the drug target interaction must be then revealed in relevant in vitro and 
preclinical models. This in turn would also impinge on the choice of physic-chemical 
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Fig. 5.1: epi/genomic biomarker diagram I (before investigation) 
 
 
The foggy landscape of retinoblastoma 
 
When we embarked in the study of retimoblastoma we realized how, notwithstanding the 
clinical, psycho-social and economic relevance of Rb, few studies have taken a 
comprehensive look at differential gene expression patterns in retinoblastomas[776]. The 
information of gene methylation profile of retina cells is also seldom reported[777], often 
in comparison to the altered profile described for Weri-Rb1 and Y79 cells[778]. Only 
recently a panel of differential methylated genes in Rb was compiled[779] showing the vast 
majority of those to be hypermethylated, with only few genes that showed low 
methylation status. For example, hypermethylation was shown for RB1 that regulates cell 
cycle and acts as tumor suppressor as well as for TP53 that regulates cell division and 
RASSF1A that concur to inhibit cyclin D1 accumulation. Proto-oncogene SYK, for 
example belongs to the hypomethylated gene group. In this panorama, only Nalini and 
coworkers[780]  investigated a cDNA microarray of pre- and post-chemotherapy Rb tumor 
threated with etoposide, vincristine and carboplatin. Among the differential expressed 
genes, they identify twenty-one key gene categories, pathways, biomarkers and 
phenotype that undergo altered regulation after chemioterapeutic treatment including 
RB1, SYK, BIRC5. Nalini's work indicated that a global regulation of gene expression is 
induced by a harsh treatment resulting into a wide broad spectrum activity. 
In this scenario our  an ongoing research investigates the fine regulation on differential 
gene expression of Rb after treatment with a well-known demethylating agent, such as 
DAC. A thorough microarray-based computational investigation on the effect of 
therapeutic dose of DAC on Weri-Rb1 cells identified a panel of epigenetically up or 
down regulated genes and their time course gene expression[195]. Gene-gene co-
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expression networks at different time points are used to identify context-driven marker 
association of transcription factor regulated proteins that belong to master regulatory 
paths. We applied computational analysis to describing DAC-driven regulatory 
connectivity patterns as network biology provides valuable prototype to understand 
complexity of cellular system and generate hypotheses for treatable biomarkers.  On the 
same line of thought our group[419] identified signature genes that could be further 
exploited as epigenetic markers for retinoblastoma and are shared with the DGE 
landscape of non-ocular associated cancer osteosarcoma with inference on possible 
biological processes. The identified evidences were partially validated using 
experimental methods demonstrating a strong biological correlation.  
 
The aim of this work has been to characterize and develop an innovative strategy for the 
local delivery of new therapies to treat retinoblastoma. The research initiated to 
consolidate previously acquired data, targeting the reversible epigenetic gene silencing 
that sustains cancer development using DAC in Weri-Rb1 cells in vitro and in vivo. We 
have shown how analysis of both cell cycle variation and apoptosis emphasized to role of 
therapeutic DAC as an anti-proliferative agent in Rb. Particularly, it was interesting to 
follow the time-dependent variations of the percentage of cells in sub G1 phase as well as 
the decrease of alive cells at the latest time point of treatment. It is likely that these 
effects were mediated by the modulation of specific gene expression already described 
by our in house computational studies. I investigated the role of a higher number of all 
those genes that have been shown to be differentially expressed in epigenetic-drug 
treated Weri-Rb1 in order to identify new feasible genetic markers. Among these 
hundreds of genes, we selected relevant genes that are showing high differential 
expression equal or greater than log2 across all time points and are involved in pathways 
related to different cancers, such as pro-apoptotic pathways. The selected genes were 
involved in various pathways, namely: extrinsic apoptosis pathway (CASP8, FAS, 
DAP3), intrinsic apoptotic pathway (BIK, BCL2L1, BAX), TFN signaling pathway 
(TRAP2, TRAF2). Moreover, genes encoding for ubiquitous transcription factors (RELA, 
HSF1, TOLLIP) were selected for their involvement in several biological processes. 
BIRC5 was selected as it is known to be a member of the inhibitor of apoptosis (IAP) 
gene family and it is high expressed in several tumors. P73, a p53 family member, 
encodes for transcription factors related to stress response. CASP6 product is a 
downstream effector of Caspase cascade, likely to be regulated by apoptotic treatment. 
RRAD was selected as it holds a role in regulating metabolic processes in cancer. It is 
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interesting that the interaction network analysis showed that several of these selected 
genes are involved in a common pathway centered on CASP8 and correlating extrinsic 
apoptosis pathway effectors (FAS) and downstream intrinsic (mitochondrial) apoptosis 
pathway genes (BIK, BCL2L1, BAX).   
Once the cancer target genes were identified, validation of computational analysis data 
became inevitable. qPCR is considered as a reference method to measure the selected 
gene expression. In this work, I validated the expression of the selected genes. In vitro I 
was able to verify the trend of expression fold-change after treatment at different time 
points that correlate with the presence of early and late apoptosis expression. In fact, both 
FAS and CASP8 that mediate extracellular early apoptosis appeared over-expressed at 48 
hours after treatment. On the other hand, after cell damage, BAX and BCL2L1 are over-
expressed at latest time points. Their protein products are known to be involved in the 
cytochrome C release from mitochondrion to the cytosol and are indirectly responsible 
for the formation of "apoptosome" that activates the downstream Caspase cascade[781]. 
BIRC5, also known as Survivin, is a small member of the IAPs family, predominantly 
expressed in tumor versus normal tissues. It is considered a prime cancer-specific drug 
target and its down-regulation has been reported to sensitize cancer cells to various 
chemotherapeutic agents[782]. Tumor cell lines in vitro culture are frequently used as the 
first line of study the effect of any treatment on cell proliferation, apoptosis and other 
cellular endpoints, that can easily be measured using different high-throughput methods. 
There are, however, some caveats with regard to the use of cancer cells overriding the 
signals that tell them to self-destruct and that may result in substantial phenotypic, 
genetic, and epigenetic alterations induced by environment[783]. 
Therefore, we corroborated our in vitro results with ex vivo validation from tumor 
samples obtained by explants from mice treated with therapeutic DAC after three weeks 
treatment. The treatment induced a significant anti-tumoral effect using a therapeutic 
dose scaled from clinical reports and tested on human xenografted derived cells. To best 
of our knowledge, we have reported, for the first time, the systemic use of DAC effect 
tested on ocular tumor.   
Our results showed a similar landscape of gene expression variation ex vivo with the 
most relevant genes, namely FAS, BIK and CASP8, showing upregulation at the end of 
treatment. BIRC5 instead appeared down regulated, confirming its role as a major 
effector in cell survival. The biological effect on tumor mass reduction and in differential 
gene expression regulation in Rb suggested the possibility of repurposing DAC for 
retinoblastoma therapy.  
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DAC is a DMNT inhibitor that irreversibly anneals the methylating activity of the 
enzyme, however it might exert a more general dose-dependent cytotoxic effect[784]. For 
these reasons, we explored the methylation patterns of those selected genes that showed a 
more prominent differential expression variation in Rb and the possibility to deliver DAC 
at the site of action so that reducing its cytotoxic effect. 
Several previous investigations described the methylation profile of CASP8 on 
retinoblastoma cells[191]. Our result confirmed this finding, suggesting that CASP8 profile 
could be referred as a positive internal control of our experiment. However, beyond 
CASP8 methylation, we were able, for the first time, to demonstrate that also BIK, 
implicated in the intrinsic apoptotic pathway, is methylated in Rb and that DAC 
treatment is able to demethylate both genes, so increasing their expression in treated 
cells.  
Their upregulation exerts a down-stream regulatory effect in the FAS-dependent 
apoptotic signaling thus inducing the block tumor cells growth. On the other hand, 
methylation analysis of FAS demonstrates its demethylated status, suggesting that in Rb 
the lack of apoptotic response and the consequent tumor growth are not dependent from 
the down regulation of cell surface stress signaling receptors, but from the silencing of 
down-stream CASP8 and BIK apoptotic effectors.   
 
Interestingly, FAS is a member of the TNF-receptor superfamily, and its product 
mediates the extrinsic apoptosis pathway and it has been implicated in pathogenesis of 
several diseases. It is known that FAS-dependent apoptosis pathway is activated by 
extracellular stress signals of different nature (chemical, physical, metabolic).  
 
Experimental oncology research and drug development both substantially require 
specific, clinically relevant in vitro and in vivo tumor models. For these, biomarkers 
identified through basic research need to be validated using a preclinical discovery phase. 
Once a target candidate has been identified, sufficient preliminary data need to be 
generated to support clinical trials.  
Preclinical models need to take into account both of the molecular nature of the target 
and behavior of the chemical compound. The use of different models will be required for 
a detailed investigation of compounds targeting epi/genetic markers that might be 
sensitive to environmental characteristics. In this work, we have intensively used tumor 
xenografts to exhibit the relevant molecular characteristics of the corresponding human 
cancers. However, human tumor xenografts might encompass some limitations, as they 
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do not replicate human stromal cell interactions as are not implanted at their native site. 
Despite these limitations, xenografts will retain their role as workhorses in drug 
discovery, however a higher degree of accuracy should be used. For this, we developed 
an orthotopic model in order to investigate the influence of environment and spatial 
localization of tumor lesions on the effect of the therapy. The morphological appearance 
of the tumor lesion obtained inside the engrafted animal eyes confirmed that we achieved 
optimization of the model with the correct localization in correspondence of the retinal 
tissue. Similarly, to our previous preclinical investigation, in this orthotopic model it was 
possible to evaluate the activity of systemic therapeutic dose of DAC. In this case, free 
DAC reached ocular department exerting a tumorstatic activity. The preliminary results 
of our studies are encouraging and need a deeper investigation for confirmation and 
refinement. Immunohistochemistry investigation is likely to verify the reduction of 
DNMT activities, as this enzyme family represents the direct target of DAC. In depth 
studies are needed to find the expected reduction in Ki67 signal, as already shown in our 
previous work on DAC activity on other tumors[645]. A thorough analysis of the 




Exploring combinatory therapies (might disappoint you) 
 
In therapeutic development, a major hurdle is translating efficacy determined in drug 
discovery phase to practical application in clinics, as there are often discrepancies 
between drug efficacy in vitro and in vivo experimental models and final efficacy, in 
patients.  
 
In the scope of this thesis, we learnt that not all the agents that exert a significantly high 
anti-cancer effect in vitro could maintain their promises when translated in vivo. The 
prominent example that we found of anti-cancerous effects in vitro and have lesser or no 
effect in vivo is that of HDAC inhibitor TSA in the treatment of Rb. In fact, based on the 
epigenetic pathogenesis of Rb, an increasing dose (75 - 150 - 300ng) of TSA was tested 
on Weri-Rb1 cells, obtaining striking anti-proliferative time-dependent effect in vitro at 
the highest dose suggesting that also the removal of histone acetylation is relevant in 
inhibiting tumor cells survival. Unexpectedly, the same results have not been obtained in 
in vivo experiments where the I.V. administration of TSA alone did not exert any 
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significant anti-tumoral effect.  
 
We can also hypothesize that the fine-tuned dose-dependent regulation of gene 
expression by DAC in Rb could lead to overcoming potential anti-tumoral drug 
resistance as investigated in other solid tumors[785-786]. DAC hypomethylation activity 
might for example, unblock silenced genes involved in drug-efflux inactivation 
pathways. Clinical trials are instructed to verify the possibility of increasing 
chemotherapics' effect used in combination with low doses of DAC (NCT00925132; 
NCT01876641). However, in Rb the effect of combination of DAC and chemotherapics 
has not been tested so far. Further experimental evidence is needed. 
 
These evidences also demonstrated a time-regulation in activity of TSA with the highest 
effect that was measured at time point of 72 hours. These positive results led us to test 
the possibility of administering a combined epigenetic treatment to maximize the anti-
proliferative effect on Weri-Rb1. DAC was then administered 24 hours before TSA  (75 - 
150 - 300ng) obtaining an earlier anti-proliferative response at 48 hours. This indicated 
towards the inhibition of histone deacetylation by TSA in Weri-Rb1 could be facilitated 
by the effect of previous administration of DAC. Unexpectedly, the administration of 
TSA alone did not exert any significant anti-tumoral effect in vivo. The association of the 
two epigenetic treatments equaled the efficacy of the DAC alone, indicating that 
probably the effect ascribed to the combined treatment is only due to the DAC activity.  
Also as regard, the administration of the combined epigenetic treatments (demethylation 
and acetylation), in order to maximize the anti-proliferative effect on Weri-Rb1 cells, has 
given rice to discordant results in vitro and in vivo. In fact, the administration of DAC 24 
hours before TSA (75 - 150 - 300ng) obtained an earlier anti-proliferative response in Rb 
cells in vitro comparing DAC treatment alone, suggesting that the inhibition of both 
DNA methylation and histone deacetylation is more efficient than each single treatment 
in removing epigenetic gene silencing. On the other hand, the association of the two 
epigenetic treatments in vivo equaled the efficacy of the DAC 5 2alone, indicating that 
probably the effect ascribed to the combined treatment was only due to the DAC activity 
or because it has been known that hydroxamate-based HDAC inhibitors, although their 
promising anticancer activities, lead to poor in vivo results due to their metabolic 
instability and poor pharmacokinetics[787].  
In literature it is reported that use of HDACi as anticancer drug in retinoblastoma[788]. 
Authors were able to demonstrate TSA effect in vitro, however there are no reports of in 
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vivo Rb anticancer activity. It is interesting however that also in clinical trials, TSA failed 
to produce the expected effect in patients. "There is much to be said for failure. It is 
much more interesting than success", as quoted the British humorist Max Beerbohm in 
1946 in his "Mainly on the air"[789].  
 
It would be interesting to find out if, in an orthotopic model, a significant anticancer 
effect can be obtained by using a drug delivery system that protect HADC inhibitor by 
degradation and improve its pharmacokinetics. The use of a more sophisticated model 
may also provide indication of the HDAC inhibitor effect on its specific target (histone 
deacetylases), when investigated a full screening of AMDE processing of TSA will also 





One of the major pharmacological challenges is to achieve drug effectiveness using dose 
levels below thresholds associated with off-target effects and cytotoxicity. To reach this 
goal, several strategies can be implemented: to delivery drug in combination with other 
therapeutic agents for generating a synergistic effect and/or to modify the chemical 
nature of the molecule both for strengthen its resistance to metabolic agents and/or to 
phantom it from RES action. However, in the past few years, the most commonly used 
approach to this issue has been to associate drugs to suitable drug delivery systems.  
 
Toxicity of DAC as a single agent has been evaluated extensively to support oncology 
clinical trials. Cytotoxicity, non-specific targeting, structural instability, catabolism and 
poor bioavailability restrict the DAC broader clinical application. As already mentioned 
in introduction, toxicological effects of DAC are mainly characterized as hematological 
(leukopenia, anemia and thrombocytopenia)[450], myeloid (bone marrow hypoplasia), 
lymphoid (thymic/testicular atrophy[790]. These effects are very much consistent with its 
cytotoxic biologic action at high drug concentrations. It has been reported that low doses 
of DAC can deplete DNMTs  causing less significant DNA damage or cytotoxicity 
(www.dacogen.com)[791]. Indeed, dosage is a critical determinant for this epigenetic 
agent, characterized by a narrow therapeutic window. To overcome the issues associated 
with inefficient bioavailability, whilst facilitating the administration to enhance efficacy, 
several DDS-based strategy have been developed. In time, poly (lactic-co-glycolic acid) 
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(PLGA) and poly(ethylene glycol) (PEG) based nanoparticles[792], gelatinases-stimuli 
responding smart material nanoparticles[793] and lipid-based nanocarrier systems were 
implemented for the potential delivery of decitabine improving formulation design and 
characterization for in vivo  assessment[794]. Nanoparticle-based drug delivery systems 
still have some limitations. Once administered in the blood stream, they must overcome 
the biological barriers and obstacles such as mucosa and the cellular and humoral arms of 
the immune system. Moreover, they can be sequestered by serum proteins and undergo 
opsonization. These nanocomplexes generally undergo rapid clearance. Furthermore, 
limitations can arise from the intricate tumor microenvironment and higher interstitial 
fluid pressure found in solid tumor tissue that could prevent diffusion of nanoparticles. 
Considering these drawbacks, a cellular carrier might represent a better choice of 
delivery system. Among them, erythrocytes stand out to be the most appealing in order to 
improve the pharmacokinetics, biodistribution and pharmacodynamics of therapeutics or 
diagnostics. Erythrocyte technology to develop a drug delivery system has been long 
explored as blood and its components represent the natural biological carrier for drug 
delivery in the whole body.  
 
Despite the apparent simplicity and obviousness of this strategy, RBC-based drug 
delivery is a highly challenging task. In general, many aspects of production, storage and 
regulatory affairs complicate industrial and clinical translation of natural biological 
carriers. Furthermore, the negative impact of transfusion-transmitted infectious diseases 
in the eighties almost decimated RBC drug delivery research. Nowadays, RBC carriers 
seem to be back of fashion, with growing recent literature available to witness new 
scientific interest[795-797]. Indeed, there are some companies exploring preclinical studies 
of RBC drug delivery[584,798]. However, very few original works are detailed, where 
RBCs are being explored for delivery of therapeutics, including nanoparticles and other 
novel nanomaterials.  
 
In this scenario, our research has a prominent place. In this work, we showed that DAC 
effect and bioavailability could be improved by a drug delivery system based on the use 
of engineered erythrocytes (EMHVs).  
Ongoing research activity in our laboratory led to characterize the EMHVs delivery 
system both in vitro and in vivo. EMHVs accommodate paramagnetic nanoparticles that 
are instrumental for selective localization to specific tissue and site of actions. These 
FDA approved NPs are commercially available and used in low concentration to avoid 
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accumulation in target organs. Furthermore, to facilitate anchoring and subsequent 
membrane fusion of EMHVs to host cells, filamentous hemaglutinin was inserted during 
resealing procedure. These both are the ciphers that make EMHVs standing out against 
the field of drug delivery. In addition, we proved that EMHVs are a versatile carrier that 
could accommodate high quantity of molecule of different nature. For different studies, 
EMHVs were prepared with chemotherapics (doxorubicine, cisplatin), antibodies 
(patented antibody against colon cancer), oligonucleotides (decoys against NFkB, HFS1), 
radioactives for nuclear medicine and fluorescent nanoparticles and dyes for diagnostics.  
 
Recently, we developed an innovative formulation for DAC loaded inside EMHVs, and 
we have standardized the loading procedure to obtain constant yield of DAC 
inclusion[639]. This formulation was successfully used for the treatment of prostate cancer. 
Interestingly, in preclinical model, not only we were able to obtain a significant response 
in androgen-sensitive prostate cancer, but also we explored the possibility of treating also 
non-responsive, hormone-refractory tumor. Due to their remarkable long life span in 
circulation, they act as potential reservoirs for a slow, controlled and sustained release of 
their cargoes. Furthermore, EMHVs act as active bioreactors due to the enzymatic 
phosphorylases that they possess. Indeed, DAC is a pro-drug that will be modified inside 
the EMHVs and presented to its target in the active phosphorylated form at time of intra-
cellular release[463].  
Here, for the first time, it was demonstrated that DAC has therapeutic effect in Rb and 
that its bioavailability and pharmacokinetic is improved using EMHVs delivery system. 
EMHVs loaded with DAC were able to exert a significant anti-tumoral effect in Rb 
xenograft model similar to that obtained with free DAC treatment even if the dose 
administered by EMHVs is 7.5 times lower.  
Therapy localization by magnetic exposure and increased FHA-mediated membrane 
fusion, as well as carrier protection and bioreactor activity of EMHVs enhanced DAC 
bioavailability and its therapeutic efficacy.   
 
 
More to the point  
 
Briefly, we can conclude that EMHV delivery system has documented advantages: they 
can accommodate fragile biologics, which should circulate as long as possible preserving 
their properties and preventing loss of function; they can act as circulating reservoirs as 
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slow-drug delivery systems where a prodrug is converted by red cell resident enzymes 
into its active form; EMHVs preventing opsonization and fast removal by the 
mononuclear phagocyte system, especially in the liver and spleen. Finally, one of the 
most interesting EMHVs feature, is the possibility of being localized in specific tissues 
by magnetic forces. For this, we will extend our research focusing on the possibility of 
using EMHVs in an orthotopic model of Rb reaching thought the blood-stream the retro-
ocular compartment, often invaded by resident cancer. To date, in fact, ocular drug 
delivery with conventional systems, such as drops, hydrogel and other disposals, suffer 
from lack of control in targeting of therapy and poor drug bioavailability. On the other 
hand, more localized ocular injections are hardly accepted by patients. To reduce these 
drawbacks, a systemic EMHV therapy could be enriched at the site of cancer by a 
biocompatible magnetic field exposure that would likely be tolerated by patients. 
In our experiment with magnetic exposure, we achieved EMHVs and drug localization 
both in superficial district (flank xenograft tumor mass[645] and in deep tissues (lung, 
unpublished). Ongoing experiment also indicated that EMHVs could enrich in the CNS 
(motor cortex) once injected I.V. overcoming the blood brain barrier. These acquired 
experiences would lead us to develop the optimal localization strategy to reach the ocular 
compartment. To accomplish this task, the magnetic source will have a pivotal role. A 
cylindrical heart magnet is normally used in our studies, however, a collaboration with 
the department of robotics of the Scuola Superiore Sant'Anna (Pontedera, Pisa), will 
provide us with a customized tunable source of magnetic field, able to focus magnetic 
forces toward selected tissue. This devise will be instrumental for the optimization of 
EMHV-loaded drug delivery to the Rb lesion in the eye.  
 
 
Shedding light on Beacons (MB) 
 
Development of sensitive, specific molecular probes is one of the central challenges in 
bioimaging. In fact, the last two decades have witnessed the implementation of MBs in a 
variety of fields, including target analysis and molecular and cellular imaging. MBs have 
become an effective molecular tool able to enhance gene expression or inhibit the 
production of deleterious proteins, thus serving as excellent candidates for gene therapy. 
With the use of MB, the synthesis, transport, and distribution of mRNA in living cells 
can be monitored with good spatial-temporal resolution to provide important information 
for functional genomics. In this work, we tested the possibility of using SURV-MB 
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against Survivin-mRNA, as a theranostic agent for Rb.  
Survivin is the product of BIRC5, which is known to be over-expressed in several tumors 
including retinoblastoma and that we demonstrated to be down regulated in Rb after 
DAC treatment. Many evidences suggested that targeting Survinin expression with the 
use of drug delivery system can be considered an effective anticancer strategy and 
several clinical trials using inhibitors such as YM155 have been instructed, however with 
limited success[798]. Inefficient in vivo delivery and poor bioavailability are suspected to 
be two of the culprits responsible for the poor translation. This would leave ample room 
of maneuver for continuing innovation to realize the potential of targeting Survivin, 
ranging from better understanding of mechanistic the action of Survivin to more rational 
design of nanocarriers to deliver therapeutic cargoes in a targeted manner.  
 
Few original research works have been carried out using MB targeting Survinin-mRNA 
in solid tumors and up to recently, only for diagnostic development[799-800]. Moreover, 
there is only another report of the use on molecular beacon in Rb cells to induce photo-
dynamic-mediated cell killing[801]. 
We characterized SURV-MB as a diagnostic tool in Rb by detecting a significant burst of 
fluorescence enhancement upon target binding. The results demonstrated that delivery of 
MB targeting Survivin-mRNAs produced a strong signal, confirming the diagnostic 
potentials of SURV-MB. For this first step, we used lipofectamine as internalizing 
adjuvant, given the hydrophilic nature of MB. In fact, as for all the oligonucleotide 
therapeutics, such as siRNA, miRNA, aptamers and decoys, MBs would be more 
efficiently reaching their target if associated with drug delivery systems, such as 
fusogenic peptides, pH-sensitive lipoplex or liposomes. Most frequently, gold-NPs are 
used as an effective vector for MB intra-cellular bioimaging[802-804].  
 
To develop an optimal therapeutic formulation, we used EMHVs to deliver SURV-MB 
into Rb. Contextually, we verified that this carrier, with enhanced fusion and release 
properties, could efficiently deliver the biodrug into the cytoplasm of targeted cells. 
Upon reaching intracellular target, we were able to track SURV-MB internalized amount, 
as well as its distribution. Finally, SURV-MB loaded inside EMHV exerted an anti-
proliferative effect in Rb suggesting the possibility of using this new biodrug-based 
EMHVs formulation for theranostic purposes. Cell cycle analysis would suggest that 
with the investigated treatment protocol, the increased amount of sub G1 was a major 
contribution to the cell death. The data suggested that the designed molecular beacon 
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might provide a potential alternative for Rb therapy and secure the ground for future 
investigation. 
To refine and confirm these preliminary results, it would be necessary to deeply 
investigate the effect of SURV-MB-loaded EMHVs in vivo, especially in orthotopic 
model. From these experiments, we could verify the benefit of using EMHVs in reducing 
effective dosage in comparison to freely administered SURV-MB, and the ability of a 
novel tunable magnetic source to efficiently localize EMHV-loaded therapy at eye level. 
Furthermore, we could obtain strong indications about the theranostic nature of SURV-
MB in Rb and move to design a translatable protocol for personalized medicine. The 
efficient design, versatility of features and functionalities, reproducible chemical 
synthesis and modification, target binding selectivity and affinity together with relatively 
rapid tissue penetration, low immunogenicity and rapid systemic clearance are often 
considered exploitable features that would make MBs the ideal recognition elements for 
use as therapeutics. 
 
Testing the effect of SURV-MB-loaded EMHV new formulation, we suggested that 
SURV-MB could be a good theranostic tool9 for the targeting of BIRC5(Surviviv)-
mRNA. After high-resolution investigation of epigenetically regulated gene networks, we 
selected BIRC5 among feasible targets for cancer treatment in Rb and we are confident 
that it could "run for" the role of druggable candidate.  
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6 CONCLUSIONS & FUTURE PRESPECTIVES 
 
 
In conclusion, we provided preclinical evidence of a successful new formulation of a 
localized epigenetic treatment of retinoblastoma. Contextually the basis for investigating 
the potential of repositioning DAC as an epigenetic drug to treat the ocular cancer was 
established. After an integrative bioinformatics analysis, we validated selected gene 
candidates to become feasible targets for developing a high-precision medicine treatment 
and we proved the druggability of Survivin gene as a possible therapeutic target in 
retinoblastoma, characterizing the theranostic potential of a DNA-based biodrug, 
Molecular Beacon against Survivin-mRNA. Moreover, the use of the in house-developed 
EMHVs carrier allowed localized tissue and cell-specific drug delivery to cancer cells 
together with a lowering of dosage and reduction of off target effect.  
This work has a place in the field of preclinical investigation for retinoblastoma cancer 
therapy. Indeed the study of retinoblastoma has revealed guideline principle for 
epigenetically regulated initiation and progression. We proposed an integrative 
bioinformatics approach that revealed expected gene network and interaction of relevant 
pathways involved in apoptosis, however most interesting also unveiled unexpected 
causal relationships emerged because of DGE investigation. We widen the concept of 
precision medicine opening two fronts of access: 1) we optimized the potential of the 
commonly re-known as "ideal" natural biocarrier erythrocytes creating novel EMHV 
formulations. Being aware of the many hurdles, intrinsic to R&D of erythrocyte 
technology, such as safety, stability, toxicity, as well as production, large scalability and 
regulatory issues, I am confident that researches like mine will lead the path toward the 
autologous use of erythrocyte in clinics envisaging customized production for each 
patient; 2) the introduction of a treatment based on the use of a biodrug such as SURV-
MB not only suggests the need for further preclinical investigation of the EMHV loaded 
formulation in relevant orthotopic or humanized models, but also indicates the possibility 
of implementing a theranostic approach for specific gene targets in retinoblastoma. One 
of the future research challenge could be, via an integrate approach that merges wet-
lab/NGS investigation and high-resolution genomic and proteomic technology, to 
identify early players in the genetic landscape of Rb. A therapy based on EMHV-loaded 
MB against those targets could result in highly reliable tool for early diagnosis and cure 
of Rb and MB might change its meaning from Molecular Beacons to Magic Bullets. 
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